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SUMMARY
The mechanism o f induction of peroxisome p ro life ra tion  by xenobiotics was 
investigated. F irs tly , the evidence fo r a soluble cytosolic receptor was evaluated. 
No specific  displaceable binding o f P h ] -nafenopin or -c ip ro fib ra te  to ra t
live r subcellular fractions was observed. It was concluded tha t there is no evidence 
fo r a cytosolic receptor fo r the xenobiotic peroxisome p ro life ra to rs .
The tim e course of induction of several parameters were determined at the 
m olecular, protein and enzyme a c tiv ity  levels, fo llow ing a single i.p. dose o f sodium 
c lo fib ra te . Cytochrom e P-450 IVA1 and lau ric  acid hydroxylase a c tiv ity  showed a 
biphasic response to  sodium c lo fib ra te , w ith the major peak occurring between 18 
and 24 hours post dose. The m inor peak occurred a fte r 30 minutes post dose and the 
ac tiv itie s  returned to basal level a fte r 2 hours. Peroxisomal 6 -oxida tion, and the 
levels of b ifunctional protein, responded in a monophasic manner, peaking 
approxim ately 24 hours post dose. Cytochrome P-450 IVA1 and lauric  acid
hydroxylase were therefore induced before peroxisomal 6 -oxidation and bifunctional 
protein.
The e ffe c t of cyclohexim ide on the induction of peroxisome p ro life ra tion  by 
c lo fib ra te  was investigated. The p rio r adm in istration of cyclohexim ide ablated the 
induction of cytochrome P-450 IVA1 prote in , lau ric  acid hydroxylase, peroxisomal 6 - 
oxidation and acyl-CoA mRNA, although the induction of cytochrome P-450 IVA1 
mRNA was not a ffected . The adm in istration of c lo fib ra te  p rio r to cyclohexim ide 
was tox ic , resulting in the death of 5 out of 6 rats.
The data, taken co llec tive ly , is not inconsistent w ith  a cascade type 
mechanism of induction which postulates tha t the induction of peroxisomal 6 - 
oxidation is dependent upon the p rio r induction of cytochrom e P-450 IV A l.
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PBSBT phosphate buffered saline containing BSA and T riton  X-100
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PMSF phenymethysulphonyl fluoride
PPbP peroxisome p ro life ra to r binding protein
RNA ribonucle ic acid
RSA ra t serum albumin
SDS PAGE sodium dodecylsulphate polyacrylam ide gel electrophoresis
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CHAPTER 1 
INTRODUCTION
Since the ir discovery in the mid-1950s, a considerable amount of data has 
been generated on the morphology, enzymology, and pathological e ffec ts  associated 
w ith  the subcellular organelle, the peroxisome. I t  has been noted tha t many 
s truc tu ra lly  dissim ilar drugs and industria l chemicals cause a s ign ificant 
hepatomegaly and p ro life ra tion  o f peroxisomes in rats and m ice (Cohen and Grasso, 
1981; Reddy and Lalwani, 1983). These chemicals have been classified together 
under the term  "peroxisome p ro life ra to rs", and many have been shown to possess 
hypolipidaemic properties, tha t is they reduce the levels o f serum lipids (S to tt, 
1988). Many o f the xenobiotics which cause peroxisome p ro life ra tion  in rats are 
drugs tha t are used to tre a t hyperlipidaemia, a lip id  disorder which is characterized 
by elevated levels of lipoproteins and/or lip ids in the blood. Another major group of 
peroxisome pro life ra tors  is the phthalate ester p lastic izers, such as d i-(2 - 
ethylhexyl)phthalate (DEHP), which are used extensively in medicinal and food 
packaging (S to tt, 1988).
In addition to xenobiotic chemicals, i t  has been observed tha t several 
nu tritiona l and physiological states can also cause peroxisome p ro life ra tion  in the 
ra t liver. These include high fa t diets, v itam in  E defic iency, diabetes, s tarvation 
and cold adaptation (Hawkins et a l., 1987).
In recent years concern has grown regarding the possible e ffec ts  on human 
health o f long term  exposure to hypolipidaemic drugs, through therapeutic use, and 
industria l plasticizers, as a result o f leaching from  plastic packaging. This concern 
is largely based on the evidence tha t compounds th a t cause peroxisome p ro life ra tio n  
also induce hepatocellular carcinomas in rats and m ice (Reddy et a l., 1980a).
l j  HEPATIC RESPONSES TO THE ADMINISTRATION OF
PEROXISOME PROLIFERATORS 
The adm in istration of c lo fib ra te  and other peroxisome p ro life ra to rs  to  rats 
results in several characteris tic  hepatic responses. The induced hepatic responses 
have been extensively studied and can be subdivided into:
1 ) Hepatomegaly
2) P ro life ra tion  o f smooth endoplasmic re ticu lum  and a modulation o f the 
cytochrome P-450 isozyme pro file .
3) P ro life ra tion  o f peroxisomes and associated changes in enzyme composition.
4) A lte ra tio n  in m itochondrial number and structure, w ith  associated increases 
in certa in enzyme levels.
5) Modulation o f the levels o f certa in  cytosolic enzymes.
The compounds tha t cause peroxisome p ro life ra tion  have been divided in to 
two general groups, c lo fib ra te  and its  s truc tu ra l analogues, and compounds 
s truc tu ra lly  unrelated to c lo fib ra te  (Reddy and Lalwani, 1983). Some of the vast 
range of known xenobiotic peroxisome p ro life ra to rs  are shown in Figs. 1 .1 .-and 1.2. 
Table 1.1. shows the uses o f some of these compounds.
I t  has been suggested that a ll compounds tha t cause peroxisome p ro life ra tion  
in rats also show hypolipidaemic a c tiv ity  but not vice-versa (Cohen and Grasso, 
1981). This corre lation is shown in Table 1.2. and may im p lica te  the phenomenon of 
peroxisome pro life ra tion  in the mechanism of hypolipidaemic action of these 
compounds.
1 .1.1  Hepatomegaly
Hepatomegaly is live r enlargement, measured as an increase in the liv e r  to 
body weight ra tio , and appears to be a characteris tic  response in laboratory animals 
exposed to a varie ty  o f xenobiotics (Schulte-Hermann, 1979). I t  has been established 
that the hepatomegaly induced by peroxisome p ro life ra to rs  is the resu lt o f both 
hyperplasia and hypertrophy, i.e. an increase in ce ll number and size (Beckett, 1972). 
The hypertrophy is associated w ith  a marked p ro life ra tion  of the smooth
Fig. 1.1 Xenobiotic Peroxisome P ro life ra to rs : C lo fib ra te  and its s tructura l 
analogues
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Table 1.1 Use of Compounds tha t are Peroxisome P ro life ra to rs
Peroxisome
P ro life ra to r
Use Reference
Drugs
C lo fib ra te
C ip ro fib ra te
Bezafibrate
Aspirin
POCA
Chlorpromazine 
LY  171883 
Valproic acid 
1 -benzylim idazole 
OKY-1581
Industria l Chemicals
Isooctane 
T richloroethylene 
Prudhoe Bay 
crude oil 
Perfluorinated 
fa tty  acids
Pesticides
Tridipane
2,4-D
2,4,5-T
Lactofen
D im ethrin
Miscellaneous
)
) hypolipidaem ic 
)
anti-in flam m atory
hypoglycaemic
tran qu illize r
leukotriene antagonist 
an ti-ep ilep tic  
anti-funga l agent 
TxA 9 synthetase inh ib ito r
industria l solvent 
crude petroleum m ixture
surfactants, flame 
retardants
herbicide
insecticide
Hawkins et al., 1988
Oesch & Schladt, 1987 
Bone et al., 1982 
Vamecq et al., 1987 
Eacho et al., 1986 
Horie & Suga, 1983 
Oesch & Schladt, 1987 
Watanabe et al., 1986
Lock et al., 1987 
Goldsworthy & Popp, 1987 
Khan et al., .1989
Ikeda et al., 1986
Moody and Hammock, 1987 
Lungren et al., 1987a 
B u tle r et al., 1988a
Hruban et al., 1974a
DEHP
DEHA
C itra l
p lastic izers
Food flavouring, cosmetic 
fragrence
Hawkins et al., 1988 
Jackson et al., 1987
Table 1.2 C orre la tion between hepatic peroxisome p ro life ra tion  
and hypolipidaem ic a c tiv ity  in ra ts or mice
Compound Peroxisome8
P ro life ra tion
Hypolip idaem ic^
A c t iv ity
Reference
C ip ro fib ra te + + Lalwani et al., 1983b
C lo fib ra te + + Schladt et al., 1987
Fenofibrate + + Schladt et al., 1987
Bezafibrate + + Reddy, 1980a
Wy-14643 + + Reddy e t al., 1979
Tiadenol + + Schladt et al., 1987
Aspirin + + Schladt e t al., 1987
1-Benzlim idazole + + Schladt et al., 1987
Prudhoe Bay Crude O il + + Khan et al., 1989
POCA + + Bone et al., 1982
Phytol + + Van den Branden et al.,
Valproic acid + +
1986
Horie & Suga, 1983
2,4-D/2,4,5-T + + Kawashima et al., 1984b
Ly 171883 + + Eacho e t al., 1986
DEHP + + Reddy et al., 1976
Medica 16 + + H ertz et al., 1988
D im ethrin + + Hruban et al., 1974a
Heptam ethyl nonane + + Ikeda et al., 1988
N ico tin ic  acid - + Cayen et al., 1979
Probucol - + Fournel et al., 1983
Boxidine - + Hruban et al., 1974b
Haloperidol - + Hruban et al., 1974b
DMP - + Locci-Cubeddu & Bergamini
Acipim ox _ +
1983
Locci-Cubeddu &  Bergamini
Benfluorex +
1983
Van Veldhoven et al.,
Ammonium +
1984
Pastoor et al., 1987
perflurooctanoate 
Hexanoic acid Moody &  Reddy, 1978b
Wy-14,643 analogues - - Reddy et al., 1977
9as measured by e ithe r an increase in peroxisomal 8 -oxidation or peroxisomal volume 
^as measured by a s ign ifican t decrease in serum trig lyce ride  and/or cholesterol levels
endoplasmic re ticu lum , peroxisomes and, to  a lesser extent, m itochondria (Hess et 
al., 1963; Reddy e t _al., 1973X The live r enlargement is also associated w ith  a 
m idzonal and periporta l accumulation o f lip id  droplets and an increase in 
phospholipid and to ta l protein levels (A zarno ff J2t_al., 1965; Mannjet_al., 1985). The 
hyperplastic response of ra t live r to peroxisome pro life ra to rs  may be due to the 
m itogenic properties o f these xenobiotics (B ieri, _et_al., 1984; Elcombe _et_al., 1985; 
Reddy _et_aL, 1979). The observed increase in DNA synthesis occurs in the absence 
o f cy to tox ic ity /hepa toce llu la r necrosis, and therefore  represents a rep lica tive  event 
and not reparative hyperplasia (Levine jet _al., 1977; Reddy et a l., 1979). Peroxisome 
pro life ra tor-induced hepatomegaly is generally regarded, at least in its  in it ia l 
stages, as an adaptive response of the liv e r to the administered compound rather 
than necessarily a pathological change (S to tt, 1988).
1.1.2 Smooth endoplasmic reticulum (SER) changes and modulation of the
the cytochrome P-450 isozyme profile
P ro life ra tion  of the S.E.R. in the hepatocytes o f rats treated w ith  peroxisome 
p ro life ra to rs  is associated w ith  a concom itant increase in certa in  microsomal 
enzymes, in particu la r cytochrome P-450. The p ro life ra tion  of the S.E.R. is 
apparent as early as the th ird  day o f c lo fib ra te  trea tm ent and is m aintained as long 
as the inducer is present (P la tt and Thorp, 1966; Svoboda and A za rno ff, 1966).
1.1.2.1 Cytochrome P-450 and Cytochrome P-452
Cytochrome P-450 is the term ina l component of the monooxygenase system, 
which is found in animals, plants and microorganisms. The major enzymic reaction 
o f cytochrome P-450 is hydroxylation as has been shown in the metabolism of a 
range of endogenous substrates, including steroids, eicosanoids, fa tty  acids and bile 
acids (Hansson and W ikvall, 1980; Kupfer, 1980). Xenobiotics, including drugs, 
insecticides and chemical carcinogens are also metabolized by cytochrom e P-450 
(Gelboin, 1980). In addition to hydroxylation, cytochrome P-450 can also catalyze 
dehydrogenation, epoxidation and reductive reactions. The cytochrome P-450
m ultisubstrate monooxygenase system represents a super-genefamily consisting o f 
over tw enty individual isozymes (Adesnik and Atchison, 1986; Guengerich, 1987; 
N ebert j^ ja l . ,  1987). Each P-450 isozyme has a d iffe re n t substrate sp e c ific ity  but, 
unlike the situation w ith  most enzymes, the substrate spec ific ity  o f a particu la r 
isozyme may be quite broad. The P-450 system is highly inducible by both 
xenobiotics and endogenous hormones (Nebert and Gonzalez, 1987).
I t  has been reported tha t the chronic adm in istration of the peroxisome 
p ro life ra to rs  c lobuzarit and m ethyl clofenapate to male rats resulted in an induction 
o f the cytochrome P-450 dependent hydroxylation of lauric  acid in live r microsomes 
(Parker and Orton, 1980). Subsequently, an isozyme of cytochrome P-450 was 
purified to homogeneity from  the live r of male rats treated w ith  c lo fib ra te  
(Tamburini j 3t_al., 1984). This isozyme was in it ia lly  term ed cytochrome P-452 based 
on the wavelength absorption maximum of the ferrous-carbon monoxide adduct o f 
the haemoprotein. The pure protein has a molecular weight of 51,500 daltons and 
possesses an extrem ely high substrate spec ific ity , the p re fe ren tia l substrate being 
lauric  acid. Lauric acid is metabolized by cytochrome P-452 to OJ -hydroxylauric  
acid, w ith  trace amounts of the (6J-1) hydroxylauric acid being formed. Cytochrome 
P-452 shows no re a c tiv ity  towards testosterone. Comparison w ith  other purified  
isozymes of cytochrome P-450 by peptide mapping and im m unological analysis 
indicates tha t cytochrome P-452 is a novel isozyme.
Hardwick et al., (1987) have also reported the pu rifica tion  o f an isozyme of 
cytochrome P-450 from  the live r of male rats treated w ith  c lo fib ra te  and named i t  
P-450 L A w on the basis of its substrate spec ific ity . This isozyme possesses an 
identica l substrate spec ific ity , and m olecular weight, to  tha t o f cytochrome P-452. 
The nucleotide sequences of the cDNAs coding fo r cytochromes P-452 and P- 
450 L A w have been shown to be v ir tu a lly  identica l (Hardw ick jet_al., 1987; Earnshaw 
et_al., 1988). I t  is now accepted tha t these two preparations represent the same 
isozyme of cytochrome P-450 which shares less than 25% sequence homology w ith  
other isozymes (Nelson and Strobel, 1987). Thus i t  was decided tha t cytochrome P-
450 LA  /P-452 represents a member o f a new P-450 gene fam ily . Recently, an
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isozyme termed cytochrome P-450^ ^  w ^h  a substrate sp e c ific ity  fo r the CJ -
hydroxylation of prostaglandin A^, has been isolated from  rabb it lung and shown to
share a 75% deduced amino acid sequence homology w ith  P-450 L A W (Matsubara j 3t
al., 1987). This suggests tha t cytochrome P-450 „  and P-450 LA  /P-452 belong to —  p-z w
the same gene fam ily .
The nomenclature o f the cytochrome P-450 isozymes is extrem ely 
id iosyncratic and in order to rationalise this problem Nebert e t a l., (1987) proposed a 
systematic nomenclature based on the assignment o f the isozymes to gene fam ilies 
and subfamilies. This system is based on evolution and the recommendations include 
Roman numerals fo r d is tin c t gene fam ilies, cap ita l le tte rs  fo r subfamilies and 
Arabic numerals fo r individual genes. Using this nomenclature, the peroxisome- 
p ro life ra to r inducible isozyme was assigned to the P-450IV gene fam ily  containing 
one subfam ily. Under this new nomenclature cytochromes P-452 and P-450 LA ■ 
were renamed cytochrome P-450 IVA1. Recently, an updated nomenclature system 
fo r the genes coding fo r cytochrome P-450 isozymes has been proposed (Nebert et 
al., 1989). This nomenclature includes the roo t symbol "CYP", denoting 
"Cytochrome P-450". For a chromosomal locus, the root symbol is followed by an 
Arabic numeral designating the P-450 fam ily , a le tte r  indicating the sub-fam ily, and 
an Arabic numeral representing the individual gene w ith in  the fam ily  or sub-fam ily. 
Under this nomenclature system the gene coding fo r cytochrome P-450 IVA1 has 
been termed CYP 4A1.
A phylogenetic tree fo r the cytochrome P-450 isozymes has been proposed 
and places cytochrome P-450 IVA1 as one of the most ancient of the mammalian 
m icrosomal cytochrome P-450 isozymes, having diverged from  other isozymes by 
gene duplication approxim ately 1,250 m illion  years ago. However, i t  is not possible 
to ascertain whether cytochrome P-450 IVA1 is a bacteria l re lic  or a more recent 
branch from  the cholestero l-re la ted P-450s.
I t  has been suggested, based on southern b lo t analysis, tha t the cytochrome
P-450 IVA1 gene fam ily  consists of two or more members (Hardwick J3t_ai.» 1987). 
Analysis o f the inh ib ition of lauric acid hydroxylation by specific inh ib itors has led 
to  the proposal tha t there are at least three' isozymes that contribute to the overall 
a c tiv ity  in ra t live r (O rtiz  de Montellano and Reich, 1984), and at least two lauric  
acid hydroxylases in the rabbit lung (M uerhoff e t al., 1989). The cytochrome P- 
450 IV fam ily  has been proposed to consist o f two subfamilies, A and B, which 
contain between 2 and 7, and 2 or 3 isozymes respectively (Nebert et a l., 1989). A 
model fo r the positioning o f lauric acid in the active s ite o f cytochrome P-450 IVA1 
has been proposed (CaJacob et a l., 1988) and is shown in Figure 1.3.
—I—
Figure 1.3.
Schematic representation of the active  site of 
lauric acid AJ-hydroxylase.
I t  has been suggested tha t the active site of lauric  ac idD  -hydroxylase is highly 
structured and s te rica lly  suppresses ( c j- 1) hydroxylation in order to de liver the 
oxygen to the therm odynam ically disfavoured te rm ina l carbon.
Cytochrome P-450 IV A 1 has been shown to be induced by a range o f 
xenobiotics (Sharma, 1988a). I t  has been estim ated tha t cytochrome P-450 IVA1 
constitutes approxim ately 2-5% o f to ta l P-450 in contro l male ra t live r, and up to
50% in induced male ra t liv e r (Sharma et a l., 1988a, Makowska, 1988).
1.1.2.2. Non-cytochrom e P-450 changes
O ther changes in microsomal enzyme levels have been noted. C lo fib ra te  has 
been shown to cause an induction o f pa lm itoy l-C oA  synthetase (Berge j 3t  _al., 1988b) 
and m icrosomal carboxylesterase in the ra t live r (Mentlein j2t  al., 1986; Ashour et 
al., 1987). I t  has also been shown tha t the adm in istration o f c lo fib ric  acid causes an 
increase in some of the enzymes o f lip id  synthesis, including stearoyl-CoA 
desaturase, pa lm itoy l-C oA  chain elongation, 1 -acyl-GPC acyltransferase and 1- 
acylglycerophosphate acyltransferase (Kawashima and Kozuka, 1982, 1985;
Kawashima et a l., 1983b, 1984a,b; Hirose j 3t_al., 1987). Dihydroxyacetonephosphate 
(DHAP) acyltransferase and sn-glycerol-3-phosphate acyltransferase a c tiv itie s  are 
enhanced by c lo fib ra te  feeding (Burke and Hajra, 1980; Pollard and Brindley, 1982). 
The m icrosomal chain elongation system responsible fo r the hepatic synthesis of 
saturated and unsaturated fa tty  acids w ith  a chain length higher than C^g has been 
reported to be markedly reduced by c lo fib ra te  (Landriscina _et _al., 1975). The 
adm in istration of DEHP to rats has been shown to enhance the hepatic synthesis o f 
phospholipids (Yanagita _et_al., 1987). Associated w ith  these changes in some of the 
enzymes o f lip id  biosynthesis there is also a marked a lte ra tion  in ra t liv e r o f the 
fa tty  acyl composition o f the glycerolipids, especially an increase in the proportion 
of octadecenoic acid (Kawashima _etjal., 1985b, 1986; Hirose _et_al., 1987; Nakagawa 
et a l., 1986). Dose dependent decreases in benzphetamine-N-demethylase and 
ethoxyresorufin-O-demethylase ac tiv itie s  have been observed in ra t live r fo llow ing 
trea tm ent w ith  a range of xenobiotic peroxisome p ro life ra to rs  (Makowska, 1988).
NADPH-cytochrome c reductase has been shown to be induced by peroxisome 
pro life ra to rs  (Facino and Carin i, 1981; Ganning and Dallner, 1981). An induction of 
a specific conjugation enzyme, b ilirub in  UDP-glucuronyltransferase, has been 
observed in rats dosed w ith  a range of peroxisome p ro life ra to rs  (Fournel e t a l.,
1987).
1 J..3. Peroxisome p ro life ra tion  and associated changes in enzyme composition 
1J.3 .1 . S tructure and function o f the peroxisome.
The peroxisome is a subcellular organelle present in many tissues and cells of 
animals and plants, including unice llu lar eukaryotes (Beevers, 1979; Tolbert, 1981). 
The iden tifica tion , and descriptions of the morphology, o f peroxisomes is usually 
based upon the cytochem ical detection o f catalase, which is regarded as a 
peroxisomal m arker enzyme (N ov iko ff and Goldfisher, 1969). Peroxisomes are 
usually spherical or s ligh tly  e llip tic a l in shape and possess a single membrane, a 
fine ly  granular m atrix  and, in some species, a dense paracrysta lline core. This core, 
in the ra t liver, consists o f urate oxidase (Angerm uller and Fahim i, 1986). In ra t 
liv e r peroxisomes have a mean diameter of 0.6 to 0.7 pm, number between 370 and 
620 per parenchymal ce ll, and occupy about 1.5 to  2% of the parenchymal ce ll 
volume (Loud, 1968; Weibel _et_al., 1969). The average peroxisome is one-fourth to 
one-sixth of the volume of the average m itochondrion, and are four to two times 
less numerous than m itochondria in contro l ra t live r (Lazarow, 1982b).
Peroxisomes tend to occur in clusters w ith in  the ce ll and occasionally appear 
to be interconnected, form ing a "peroxisomal re ticu lum " (Legg and Wood, 1970; 
Reddy and Svoboda, 1971; Yamamoto and Fahim i, 1987b). Peroxisomes often occur 
in close association w ith  elements of the endoplasmic re ticu lum  (Zaar _et_al., 1987) 
and i t  was orig ina lly believed tha t peroxisomes were formed by budding from  the 
endoplasmic re ticu lum  (DeDuve and Baudhuin, 1966). However, the polypeptide 
composition of the peroxisomal membrane and the endoplasmic re ticu lum  have been 
shown to be markedly dissim ilar (Fu jik i _et _al., 1982). The curren t model o f 
peroxisome biogenesis suggests tha t peroxisomes form  by fission from  pre-existing 
organelles (Fu jik i e tjaL , 1984; Yamamoto and Fahim i, 1987a). I t  has been suggested 
tha t the ra t live r peroxisomal proteins have s im ila r ha lf lives, approxim ate ly 1.5 
days (Poole et al., 1969). There is no evidence to suggest tha t small peroxisomes 
gradually grow to become large peroxisomes, instead i t  has been proposed tha t 
peroxisomes exchange the ir contents and are destroyed randomly (Poole e t al.,
1970).
Peroxisomal proteins, including in tegra l membrane proteins, are synthesized 
on free polyribosomes and are imported post-transla tiona lly  in to pre-existing 
peroxisomes (Lazarow and F u jik i, 1985). In this respect peroxisomal biogenesis 
resembles tha t of m itochondria and chloroplasts. However, in the case of 
m itochondria l and chloroplast (as well as secretory) proteins, the newly synthesized 
polypeptides generally contain an extra sequence of amino acid residues at the ir 
amino terminus. This sequence is essential fo r targeting and is removed 
enzym atica lly during, or a fte r, translocation in to  the organelle (W alter _et_al., 1984; 
H u rt and Van Loon, 1986; Schmidt and Mishkind, 1986). In contrast, the m a jo rity  of 
peroxisomal proteins lack cleavable topogenic sequences and are therefore 
synthesized at the ir mature size (Lazarow and F u jik i, 1985; Borst, 1986). Only 3- 
ketoacyl-CoA thiolase makes an exception, being synthesized in a fo rm  3000 dalton 
larger than its  mature subunit (Fu jik i _et _al., 1985; Heinrich, 1982). Recently, 
peroxisomal targeting signals, located at or near the carboxy term inus o f the prote in 
have been iden tified  fo r human catalase, ra t b ifunctiona l protein, pig D-amino acid 
oxidase and ra t acyl-CoA oxidase (Gould et a l., 1988; Small et a l., 1988).
The peroxisomal membrane is permeable to low molecular weight solutes, 
including sucrose and the cofactors fo r fa tty  acid oxidation, NAD+, CoA, ATP and 
carn itine (Van Veldhoven _et _al., 1987). The non-specific perm eability  of the 
peroxisomal membrane to small solutes has been explained by the presence o f a 
pore-form ing prote in (Labarca et a l., 1986; Van Veldhoven, et a l., 1987).
Peroxisomal enzymes, in general, represent a lterna te  routes of m etabolic 
pathways already in existence in other subcellular compartments. Numerous 
enzymes including oxidases, dehydrogenases, acyltransferases, aminotransferases, 
reductases, hydrolases, catalase, and a number of the enzymes of the fa tty  acid 
oxidation and g lycolate cycle have been iden tified  in peroxisomes isolated from  a 
varie ty  of p lant and animal tissues. Unlike the enzym atic complement o f many 
other organelles, the enzymology of the peroxisome may vary considerably from
tissue and between species. Some of the enzymes found in ra t live r peroxisomes are 
shown in Table 1.3.
Many o f the biochem ical reactions o f peroxisomes are oxidative, functioning 
in catabolic pathways. Some, however, are anabolic reactions, and some end 
products o f peroxisomal reactions serve as precursors fo r anabolic reactions 
elsewhere in the cell.
The respiratory pathway of peroxisomes, discovered and characterized by de 
Duve and coworkers is illus tra ted  in Figure 1.4.
The respiratory pathway of peroxisomes consists of a group of oxidases tha t 
u tilize  molecular oxygen to d irec tly  oxidize a varie ty  of substrates, and produce 
hydrogen peroxide (H^O^), together w ith  catalase which decomposes the The
substrates fo r the oxidases include lacta te , g lycola te, and other a-hydroxyacids, 
urate, D-amino acids, acyl-CoAs, and polyamines, such as spermine (Lazarow, 
1982b). The decomposition of by catalase can occur by two mechanisms: the
ca ta la tic  reaction shown in Fig. 1.4., or the peroxidative reaction shown below it .  
Substrates fo r peroxidation include alcohols, form ate, n itr ite  and quinones. Ethanol 
can be metabolized by this peroxidative reaction of catalase (Lazarow, 1982a). I t  
has been shown tha t voluntary alcohol consumption of rats can be increased by 
simultaneous trea tm ent w ith  c lo fib ra te , possibly due to the increased 
production associated w ith  peroxisome p ro life ra tion  (Handler and Thurman, 1987; 
Schlicht, 1987). The peroxidative reaction is favoured by the conditions existing 
inside peroxisomes, namely, a high catalase concentration and a low, steady 
form ation of ^ 2 ^ 2  *S Pr °b ably destroyed peroxida tica lly  to the extent tha t
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Fig. 1.4. The respiratory pathway of peroxisomes (derived from  deDuve 
and Baudhuin, 1966).
Table 1.3 Rat L ive r Peroxisomal Enzymes
Enzyme Reference
Catalase
Oxidases
)
) Masters and Holmes, 1977
) Leighton et al. 1968
D-amino acid oxidase
L-a-hydroxyacid oxidase )
Polyamine oxidase Beard et al., 1983
F a tty  acyl-CoA oxidase
J
Osumi and Hashimoto, 1978a
Deh>/roqenases
3 -hydroxyacyl-CoA-dehydrogenase Osumi and Hashimoto, 1979
(b ifunctional protein)
G lycerol phosphate dehydrogenase Murphy et al., 1979
Aldehyde dehydrogenase Turtle taub and Murphy, 1987
Isoc itra te  dehydrogenase Leighton et al., 1968
G lyoxylate reductase Masters and Holmes, 1977
Glucose-6 -phosphate dehydrogenase Panchenko and Antonenkov, 1984
Acyl/a lkyl-d ihydroxyacetone Hajra and Bishop, 1982
phosphate reductase
Transferases
Carnitine-acetyltransferase Moody and Reddy, 1974
C arn itine -acy ltransf erase M arkwell e t al., 1976
A ce ty l-C oA -ace ty ltrans f erase Miyazawa et al., 1980b
(thiolase)
C arn itine-octanoiy transferase M arkwell e t al., .1976
Dihydroxyacetone phosphate-acyl Declercq e t al., 1984
transferase
Gly oxylate-am inotransferase Hsieh and To lbert, 1976
Serine: pyruvate aminotransferase Noguchi and Takada, 1978
Other enzymes and activ ities
NADH-cytochrom e c-reductase Donaldson et a ir,.1972
Allantoinase Nogushi et al., 1979
Enoylhydratase (b ifunctional Osumi and Hashimoto, 1979
protein)
A cyl-C oA  synthetase Mannaerts et al., 1982
2,4-dienoyl CoA reductase Dommes et al., 1981
HMG-CoA reductase K e lle r e t al., 1985
B ile  acid synthesis Krisans e t al., 1985
Thompson and Krisans, 1985
Bjbrkhem et al., 1985
B ile  acid conjugation Kase et al., 1986
3-Hydroxyacyl-CoA epimerase Chu and Schulz, 1985
suitable peroxidatic substrates are available; excess would be destroyed
ca ta la tica lly . Peroxisomal respiration d iffe rs  from  m itochondrial respiration in 
several respects. The energy of peroxisomal oxidations is not conserved by the 
form ation o f ATP but instead is dissipated as heat, contribu ting to thermogenesis. 
Peroxisomal consumption is not blocked by cyanide and is insensitive to 
respiratory contro l. The physiological a c tiv ity  o f peroxisomal respiration has been 
estimated to account fo r roughly 2 0 % of the oxygen consumption of the live r (de 
Duve and Baudhuin, 1966; Oshino j 3t  _al., 1975). Catalase may also function to 
p ro tec t thiolase and its  substrate, 3-ketoacyl-C oA, both of which may be modified 
by ^ 2 ^ 2  ( ^ ash imoto anc* Hayashi, 1987).
O ther peroxisomal ac tiv itie s  include the 8 -oxidation o f both mono-and 
d icarboxylic fa tty  acids, bile acid synthesis, ether g lycero lip id biosynthesis and 
purine catabolism (Lazarow, 1982b). The peroxisomal fa tty  acid 8 -oxida tion system 
consists of four enzyme ac tiv ities : acyl-CoA oxidase, enoyl-CoA hydratase, 3- 
hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-C oA thiolase (Lazarow, 1982b). 
The second and th ird  enzyme ac tiv ities  are properties o f the same prote in, termed 
b ifunctiona l prote in or peroxisome p ro life ra to r associated protein 80,000 daltons 
(PPA-80) (Osumi and Hashimoto, 1979; Reddy e t  _al., 1980b). Peroxisomal 8 - 
oxidation is discussed in section 1 .6 .2 .
1.1.3.2. Peroxisomal changes
The adm in istration of peroxisome p ro life ra to rs  to rats results in an increase 
in both peroxisome numbers and volume. The peroxisome may account fo r up to 
25% of the hepatocyte cytoplasm ic volume in the livers  of rats and mice treated 
w ith  potent peroxisome pro life ra to rs  such as Wy-14643, m ethylclofenapate and 
c ip ro fib ra te  (Rao and Reddy, 1987). This represents a 10-20 fold increase. A 
sim ilar, i f  not greater, induction is seen in the enzymes o f peroxisomal 8 -oxidation 
(Reddy _et_al., 1986; Osumi and Hashimoto, 1978b) and m icrosomal lauric  ac id& 7 - 
hydroxylase (Sharma _et_al., 1988a). The a c tiv ity  o f catalase is also inducible, but
th is increase is not usually greater than 2-fo ld . U rate oxidase, D-amino acid oxidase 
and L-a-hydroxyacid oxidase are even less inducible (Cohen and Grasso, 1981). 
Peroxisomal dihydroxyacetone phosphate a c tiv ity  is doubled, and aldehyde oxidase 
a c tiv ity  increased four-fo ld , by peroxisome p ro life ra to rs  (Pollard and Brindley, 1982; 
Antonenkov et al., 1983). The a c tiv ity  of carn itine  acetyltransferase, a peroxisomal 
enzyme which is also located in the m itochondrial membrane, may be induced to a 
much greater degree (often several hundred-fold) than tha t o f peroxisomal 8 - 
oxidation under s im ilar experimental conditions (S to tt, 1988). Carn itine 
octanoyltransferase, a purely peroxisomal enzyme, can be induced 40-fo ld by DEHP 
(Miyazawa et a l., 1983).
C lo fib ra te  has been shown to cause changes in the phospholipid composition 
of the peroxisomal membranes in mouse live r, mainly an increase in 
lysophosphatidylcholine content and a decrease in phosphatidylcholine content 
(Crane and Masters, 1986). This increase in the level o f a natural detergent, w h ils t 
not great enough to cause lysis in vivo, may lead to a decreased struc tu ra l s ta b ility  
and increased perm eability of the membrane (W eltzein, 1979). This may account fo r 
the altered properties of the peroxisomal membrane in c lo fib ra te  treated rats 
(Crane _et_al., 1985; Hayashi e t al., 1987, 1988). DEHP feeding has been shown to 
increase the phospholipid content of ra t live r peroxisomes (Edlund et al., 1986).
1.1.4 Mitochondrial changes
Treatm ent o f rats w ith  peroxisome p ro life ra to rs  results in several observable 
changes in hepatic m itochondria, which include p ro life ra tion , s truc tu ra l changes, 
enlargement and the induction o f certa in  enzymes (Svoboda and A zarno ff, 1966; 
Reddy _et_al., 1969; Kurup j 3t_al., 1970). P re trea tm ent o f rats w ith  c lo fib ra te  has 
been demonstrated to elevate the ac tiv ities  o f cytochrom e oxidase and g lyce ro l-1 - 
phosphate dehydrogenase (Hess j 3t_al., 1965; W esterfeld _et_al., 1968). Increases in 
the a c tiv ity  o f acyl-CoA synthesis, carn itine  acetyltransferase, carn itine  
palm itoyltransferase and acyl-CoA hydrolase have been observed in hepatic
m itochondria isolated from  rats treated w ith  peroxisome pro life ra to rs  (Krisans _et 
a l., 1980; Leighton _et_al., 1982; Solberg j 3t_al., 1972; B e rge ^t_a l., 1983). A slight 
induction in the m itochondria l B-oxidation o f short chain acylcarnitines has been 
observed in c lo fib ra te  trea ted rats (Christiansen et a l., 1978). DEHP has been shown 
to increase the a c tiv ity  of acetyl-CoA dependent hepatic fa tty  acid elongation (Nagi 
et a l., 1986).
Decreases in the specific ac tiv itie s  of monoamine oxidase, kyuramine 
hydroxylase and rotenone-insensitive NADH-cytochrom e c reductase have been 
observed (Gear j 5t  ja l., 1974). Chronic c lo fib ra te  trea tm en t resulted in a decrease in 
O2 consumption and CO2 production associated w ith  the oxidation of fa tty  acids, 
ind ica tive  of im paired oxidation w ith  a reduction o f ketone body production 
(Cederbaum js tja l., 1976). C lo fib ra te  has also been shown to in h ib it branched-chain 
amino acid metabolism in the m itochondria (Wagenmakers e t a l., 1985).
1.1.5 Cytosolic changes
The e ffe c t of peroxisome p ro life ra to rs  on cytosolic enzymes is not well 
documented. Inh ib ition o f glutathione peroxidase, glutathione transferase and 
superoxide dismutase has been observed when rats have been treated w ith  
peroxisome p ro life ra to rs  fo r period o f 30 days or more (C irio io  jet_al., 1982, 1984; 
Lake _et_al., 1987, 1989; Antonenkov _et_al., 1987). These enzymes are associated 
w ith  the detoxication o f peroxides. G lutathione peroxidase, a selenium containing 
protein, converts glutathione to g lutathione disulphide during hydroperoxide 
metabolism and u tilizes H 2 O2 , lip id  and steroid peroxides as substrates (Wendel, 
1980; H a lliw e ll and Gutteridge, 1985). G lutath ione transferase also possesses 
g lutathione peroxidase a c tiv ity . Superoxide dismutase catalyses the conversion o f 
superoxide radicals in to  oxygen and hydrogen peroxide.
The adm in istration o f peroxisome p ro life ra to rs  to rats has been shown to 
induce certa in  cytosolic proteins, namely pa lm itoy l-C oA  hydrolase, cytosolic 
epoxide hydrolase and fa tty  acid binding pro te in  (Berge J3t_al., 1987a; Kawashima et
al., 1983a; Moody _et_al., 1983; Paulussen_et_al., 1986). Cytosolic epoxide hydrolase 
has been im plicated in the hydrolysis of fa tty  acid epoxides which have been formed 
by the action of cytochrome P-450 (Moody _etjal., 1985; Lundgren jst_al., 1987a,b; 
Oesch and Schladt, 1987) and lip id  peroxidation (G ill and Hammock, 1979; Sevanian 
e t al., 1980). F a tty  acid binding protein (FABP) is a low molecular weight (14-15 
kilodalton) cytosolic protein tha t is believed to play an im portant role in the 
in trace llu la r translocation and metabolism of long chain fa tty  acids (Kawashima et 
al., 1983a, Spener et al., 1989). FABP has been shown to be involved in the 
regulation o f peroxisomal 8 -oxida tion (Appelkvist and Dallner, 1980; Kawashima eit 
a l., 1983a). FABP has been shown to be identica l to a cytoplasm ic 14,000 dalton 
polypeptide (p l4 ) tha t is associated w ith  m itosis (Bassuk £ t al., 1987).
The proportion o f catalase in ra t live r cytosol is increased fo llow ing the 
adm in istra tion of peroxisome p ro life ra to rs  (K lucis et al., 1985; Crane et al., 1985). 
This may re fle c t an altered f lu id ity  o f the peroxisomal membrane.
1.1.6. Other changes
The adm in istration of peroxisome pro life ra to rs  to rats has been reported to 
increase the levels of free CoASH, long-chain acyl-CoA, carn itine and acylcarn itine
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in ra t live r (Halvorsen, 1983; Kahonen, 1979; Miyazawa et al., 1975; Skrede and 
Halvorsen, 1979; Savaloinen e t  _al., 1977). A trans ito ry  increase in the levels of 
orn ith ine decarboxylase (ODC) has been observed a fte r the adm in istra tion of 
peroxisome p ro life ra to rs  (Izumi et a l., 1981; Osmundsen and Eliassen, 1986). ODC is 
a rate lim itin g  enzyme in the polyam ine-biosynthetic pathway which appears to play 
an im portant role in the regulation o f cell p ro life ra tion  and growth. Peroxisome 
p ro life ra to rs  have also been shown to a lte r the levels of certa in  serum enzymes. A 
s ign ifican t increase in serum cholinesterase, and a decrease in serum arylesterase, 
a c tiv ity  levels have been observed fo llow ing the adm in istration of nafenopin or 
c lo fib ra te  (Butler _et_al., 1988c). C lo fib ra te  has been shown to lower plasma insulin 
levels in the ra t (Paul and Adib i, 1979).
1.2 N ON-XEN OBI OTIC INDUCED PEROXISOME PROLIFERATION
In addition to the w ell documented peroxisome p ro life ra tion  evoked by 
certa in  xenobiotics, th is phenomenon has been observed fo llow ing dietary 
manipulation and in several physiological conditions. The induction o f peroxisomal 
8 -oxidation in ra t live r by high fa t diets, especially those rich in C^g and C22  fa tty  
acids (e.g. pa rtia lly  hydrogenated fish oils and rape seed oil), has been w ell 
documented (Ishii _et_al., 1980a; Thomassen _et_al., 1982; F latm ark _et_al., 1983). A 
s tim ula tion o f the microsomal Ca) -oxidation o f fa tty  acids has been observed in rats 
fed high fa t diets (Nilsson _et _al., 1986). C arn itine acetyltransferase, acyl-CoA 
hydrolase and fa tty  acid binding prote in have also been shown to be induced by such 
d ietary manipulations (Ishii _et _al., 1980a; Ul-Haq and Shrago, 1983; Berge et a l., 
1987b). High fa t diets have been shown to lower plasma triacy lg lyce ro l levels in 
rats. In these animals no inh ib ition of g lutath ione peroxidase or glutathione 
transferase ac tiv itie s  was observed which is in contrast to the e ffe c t seen in rats 
fed w ith  xenobiotic peroxisome p ro life ra to rs  (Yamazaki _et_al., 1987). I t  appears 
tha t the geometry of the d ietary fa tty  acids (ie. whether i t  is predom inantly cis or 
trans) has only a marginal e ffe c t in modulating the induction of peroxisomal 8 - 
oxidation ( Id e ^ t  al., 1987). Peroxisomal 8 -oxidation and lauric  acid CJ -hydroxylase 
ac tiv itie s  have also been shown to be inducible in ra t hepatocyte cu lture systems by 
long chain fa tty  acids (Hertz e t _al., 1983). Induction of microsomal UJ -and 
peroxisomal 8 -oxidation may represent an adaptive response to the presence of fa t 
in the d ie t (Bremer and Norum, 1982).
O ther d ie tary manipulations, such as a choline de fic ien t d ie t or a v itam in  E 
de fic ien t d ie t, have also been shown to induce peroxisomal 8 -oxida tion (Berge et a l., 
1988c; Reddy _et_al., 1981). Berge et al., (1984a) suggested tha t a high glucose d ie t 
may decrease the level o f peroxisomal 8 -oxidation in ra t live r.
The e ffe c t o f starvation (or fasting) on the peroxisomal 8 -oxidation system in 
ra t live r is equivocal. Several groups have reported an induction of this a c tiv ity
upon fasting (Ishii e t a l., 1980b; Bremer e t a l., 1981; Mortensen and Gregersen, 1982; 
Thomassen e t _ai., 1982; H ertz  and Bar-Tana, 1987), although other groups have 
fa iled to report such an increase (Mannaerts j 3t  _al., 1979; Saulter and Yamazaki, 
1984; Locci-Cubeddu e t _al., 1983; Veerkamp and Van Moerkerk, 1986). The 
microsomal <*3 -hydroxyla tion of fa tty  acids has been reported to  be induced by 
starvation (Bjorkhem, 1973, 1976; Lu j 3t_al., 1979; Hasumura ^ t_ a l., 1983; Hardwick 
j 3t_al., 1987), as has acyl-CoA hydrolase and fa tty  acid binding protein (Berge et a l., 
1984a,b; Paulussen j 3t_al., 1986). Free CoASH and long-chain acyl-CoA levels are 
also increased (Berge et a l., 1984a).
Diabetes, induced by the adm in istration of streptozotocin, has been shown to 
cause an induction o f both lauric  acid 0J -hydroxylase and peroxisomal 8 -oxidation 
(Horie _et_al., 1984; Sharma, 1988; Mortensen and Gregersen, 1982). The magnitude 
of induction o f peroxisomal 8 -oxidation in the fasted, diabetic or fa t-fe d  ra t is 
usually only 2-3 fo ld  which is s ign ifican tly  less than the 2-20 fo ld  induction seen in 
rats treated w ith  xenobiotic peroxisome p ro life ra to rs  (Reddy and Lalwani, 1983; 
S to tt, 1988). This re la tive ly  low induction may be accounted fo r  by the fast 
m etabolic e lim ination of the natural long chain fa tty  acids, as compared to the 
sustained presence of the xenobiotic peroxisome p ro life ra to rs  (H ertz and Bar-Tana,
1987). I t  is believed tha t the induction of peroxisomal 8 -oxidation seen in response 
to fasting and diabetes is due to the increased libe ra tion  of monocarboxylic fa tty  
acids from  fa t deposits (Pettersen, 1972; Mortensen and Gregersen, 1981, 1982). 
During starvation and diabetes the markedly increased hepatic fa tty  acid oxidation 
is accompanied by a decrease in the level of FABP (Sweetser et al., 1987).
Prolonged exposure of rats to cold has been shown to cause an increase in 
brown fa t peroxisomal 8 -oxidation (Nedergaard _et_al., 1980). Here, the essentially 
energy wasteful nature of peroxisomal 8 -oxidation is used in its e lf fo r a purpose, 
namely thermogenesis.
There appears to be several hormonal m odifications o f peroxisome 
p ro life ra tion . M ild hyperthyroidism has been shown to cause an increase in ra t live r
peroxisomal volume and 8 -oxidation (Fringes and Reith, 1982; Just and H a rtl, 1983; 
H a rtl and Just, 1987). In the hypothyroid ra t the inductive e ffe c t o f c lo fib ra te  on 
both hepatomegaly and peroxisomal 8 -oxidation was depressed (Kawashima et a l., 
1983c). I t  has been shown tha t the hepatomegaly seen upon adm in istration of 
xenobiotic peroxisome p ro life ra to rs  is reduced in adrenalectom ized rats, w ith  this 
e ffe c t being reversed by the concom itant adm in istra tion o f dexamethasone. No 
such e ffe c t on peroxisomal 8 -oxidation a c tiv ity , however, was observed (Kawashima 
et a l., 1983c). S im ila rly , the hepatomegaly induced by c lo fib ra te  is ablated in 
hypophysectomized, thyroidectom ized and adrenalectom ized rats. The induction o f 
peroxisomal 8 -oxidation was not a ffected  in these animals (Elissen and Osmundsen, 
1984). Presently, i t  is not known what role the thyro id and adrenal hormones play in 
the regulation of peroxisome pro life ra tion . Glucagon has been shown to increase 
peroxisomal 8 -oxidation in perfused ra t live r (Saggerson e t al., 1981).
I t  has been observed tha t the hepatic hepoxisomal 8 -oxidation a c tiv ity  is 
elevated approxim ately threefo ld in obese (ob/ob) m ice, re la tive  to the ir lean 
controls mates (Lazarow, 1982a; Imesch and Giacobino, 1986). This may im ply a 
role fo r peroxisomal 8 -oxidation in the e lim ina tion  of excessive levels of 
trig lycerides.
1.3 IN  VITRO INDUCTION OF PEROXISOME PROLIFERATION
I t  is w e ll documented tha t many, i f  not a ll, o f the compounds tha t have been 
shown to be peroxisome pro life ra tors  jn  vivo also produce s im ila r responses in ra t 
hepatocyte ce ll culture systems. This in v itro  approach has been used to investigate 
closely the phenomenon of peroxisome pro life ra tion , in particu la r the mechanism of 
induction and the s tru c tu re -a c tiv ity  relationships o f groups o f chemicals (Elcombe 
and M itche ll, 1986; Fe lle r _et_al., 1987; Foxworthy and Eacho, 1986; Gray et a l., 
1983a; H ertz et al., 1983; Kocarek and Fe ller, 1987; K ryv i j 3t_al., 1986; Lake et a l., 
1984b, 1986b; Muakkassah-Kelly J2t_al., 1988). A decline in enzyme ac tiv ities , such 
as peroxisomal 8 -oxidation and lauric acid U )-hydroxylase, is a common phenomenon
seen in contro l ra t hepatocyte ce ll cultures (Lake et a l., 1983; M itche ll e t a l., 1984). 
Peroxisome p ro life ra to rs , such as c lo fib ric  acid and MEHP, produce a dram atic 
induction of peroxisomal 8 -oxidation which fa r exceeds the a c tiv ity  in freshly 
isolated hepatocytes. The a b ility  o f a compound to e lic it  peroxisome p ro life ra tion  
in cu lture is markedly enhanced by the presence o f hydrocortisone in the medium. 
Hydrocortisone may be replaced by other natura lly occurring or synthetic 
corticostero ids, the extent of induction increasing w ith  increasing glucocorticoid 
potency. The presence o f corticostero ids in the cu lture medium does not appear to 
be essential to merely maintain the v ia b ility  o f the hepatocyte. The p ro life ra tion  of 
the S.E.R. and the induction o f cytochrome(s) P-450 on cultured ra t hepatocytes are 
unaffected by supplementation o f the medium w ith  corticostero ids (M itche ll et a l.,
1984). Cell culture studies have shown tha t ethanol can induce lauric acid 
hydroxylase a c tiv ity  e ither alone or in synergism w ith  c lo fib ra te  (Pazo and Para fita ,
1988).
Cell cu lture  systems can be used to study the e ffe c t of xenobiotics on most 
o f the parameters o f peroxisome p ro life ra tion . However, i t  should be noted tha t the 
e ffe c t o n  hepatomegaly cannot by m im icked, nor can the e ffe c t of starvation, 
diabetes or cold adaptation be studied.
1.4 PEROXISOMES IN  EXTRAHEPATIC TISSUES
Peroxisomes have been detected in a range of extrahepatic tissues as shown 
in Table 1.4. However, the induc ib ility  of peroxisome p ro life ra tion  and peroxisomal 
8 -oxidation in these tissues is equivocal. Nemali _et_al., (1988) reported a s light 
increase in peroxisomal 8 -oxidation in kidney, heart and small in testine, but not in 
pancreas, adrenal, lung, spleen, testis, brain, skeletal muscle and salivary gland, 
fo llow ing the adm in istration of c ip ro fib ra te . A cy l-C oA  oxidase a c tiv ity  has been 
reported to be induced in a range o f ra t tissues fo llow ing trea tm ent w ith  nafenopin 
(Leighton and Lazo, 1982). The induction was most pronounced in kidney, ileum,
Table 1.4 Mammalian tissues in which peroxisomes have been found
Tissue C ell Type
L ive r Hepatocyte
Sinus-lining
Kidney Epithelium  of proxim al and distal tubules
Lung Clara, alveolar
Glandular
Adrenal C o rtica l
Pancreas Acinar
Lacrim al
Parotid
Thyroid E p ithe lia l
Harder's Sebaceous
Meibomian
Preputia l
Muscular
H eart
Skeletal
Smooth (aorta)
Nervous System
Cerebrum C ortica l
Cerebellum C ortica l
Retina Epithelium , pigment
Ganglion Neuron, Schwann
Others
T estes Leydig
Ovary Stromal, lu tea l
Placenta Decidua
Intestine Epithelium
Fat Brown fa t cells
Reproduced from  S to tt (1988)
thymus, and muscle. I t  appears tha t the most responsive organ, a fte r the live r, is 
the kidney (Nemali _et_al., 1988). The peroxisome p ro life ra tion  in the kidney is most 
pronounced in the epithelium  of the proxim al convoluted tubule (Reddy e_t al 1975; 
Lalwani _et _al. 5 1981b; Le H ir and Dubach, 1982). C lobuzarit has been shown to 
cause a 2-3 fold induction in renal microsomal lauric  acid hydroxylase a c tiv ity  
(Parker and Orton, 1980).
However, i t  should be noted tha t in studies tha t have investigated the tissue 
d istribu tion  o f the peroxisome p ro life ra to rs  DEHP and c ip ro fib ra te  there appears to 
be a good corre lation between the tissue d is tribu tion  of the compound and the 
induc ib ility  o f peroxisomal 8 -oxidation in those tissues (Daniel and B ra tt, 1974; 
Waddell ^ t_a l., 1989). Uptake of c ip ro fib ra te  in to  ra t live r and kidney is comparable 
although these tissues show d iffe ring  responses to this compound (Makowska, 
personal communication).
1.5 ENZYfvE INDUCTION BY PEROXISOME PROLIFERATORS
1.5.1 The Peroxisome P ro life ra to r Domain
I t  has been noted tha t the induction of maxim al peroxisome p ro life ra tion  in 
liv e r cells o f rats and mice is accompanied by predictable, but variable, increases in 
the ac tiv ities  of several hepatic enzymes (Reddy and Lalwani, 1983; Lalwani e t a l., 
1983b). These proteins have been classified as belong to a d is tinc t set, termed the 
"peroxisome p ro life ra to r domain" (Watanabe _et_al., 1985). Some o f these proteins 
are listed in Table 1.5. The e ffe c t o f individual inducers on some of the enzymes o f 
the peroxisome p ro life ra to r domain are presented in Table 1.6.
1.5.2 Potency o f the Peroxisome P ro life ra to rs
Typical of most classes of pharm acologically active chemicals, the potency 
o f the compounds which cause peroxisome p ro life ra tion  covers a broad spectrum 
(S to tt, 1988). Thus m ethyl clofenapate, c ip ro fib ra te  , bezafibrate, gem fib roz il, 
nafenopin and fenofibra te  have been shown to be several orders of magnitude more
Table 1.5 Some enzymes of the peroxisome p ro life ra to r domain
Enzyme Reference
Cytochrome P-450 IVA1 
Peroxisomal 8 -oxidation pathway 
Catalase
Cytosolic epoxide hydrolase 
B ilirub in  UDP-glucuronyltransferase 
C arn itine acetyl-CoA transferase 
C arn itine pa lm itoy l-C oA  transferase 
M icrosomal carboxylesterase 
Acyl-C oA  hydrolase 
Aldehyde dehydrogenase 
A lcohol dehydrogenase 
F a tty  acid binding protein
Hardw ick et al., 1987 
Reddy and Lalwani, 1983 
Reddy and Lalwani, 1983 
Oesch and Schladt, 1987 
Fournel et al., 1986 
M arkwell £ t  al., 1977 
Sharma et al., 1988a 
Ashour et al., 1987 
Berge and Thomassen, 1985 
Kram ar and Kremser, 1984 
Lamboeuf and Blanquat, 1980 
Kawashima et al., 1985b
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potent than the prototype compound c lo fib ra te  under sim ilar experimental 
conditions (Reddy j 3t  _al., 1982b; Lalwani j 5t  _al., 1983b; Sharma et al., 1988a). 
Ingestion of a d iet containing 0.5% c lo fib ra te  results in a peroxisome pro life ra tion  
s im ila r to tha t observed in rats fed a d ie t containing 0.05% c ip ro fib ra te  (Lalwani et 
jal., 1983b,c; Reddy and Kumar, 1977, 1979). In contrast, ace ty lsa licy lic  acid and 
phthalate esters are considered to be only very weak peroxisome pro life ra to rs , 
requiring 1 to 2% concentrations in the d ie t to induce p ro life ra tion  (Hruban et a l., 
1974a; Ishii and Suga, 1979; Moody and Reddy, 1978b; Reddy _etjal., 1976). A single 
dose (50 mg/kg, i.p.) o f perfluorodecanoic acid (PFDA) causes a 20-40 fo ld  increase 
in ra t live r peroxisomal 8 -oxidation tha t persists fo r as long as 50 days post dose 
(Harrison et al., 1988). This may represent the most potent peroxisome p ro life ra to r 
yet reported. The re la tive  potencies of some of the peroxisome p ro life ra to rs  are 
shown in Table 1.7. The re la tive  potencies of the peroxisome p ro life ra to rs  are 
s im ila r fo r the ir e ffe c t on both peroxisomal 8 -oxidation and lauric  acid 6J - 
hydroxylase (Sharma _et _al., 1988a). A lthough d iffe ring  absorption, metabolism, 
d is tribu tion  and excretion k inetics may play a role in determ ining the varying 
potencies o f the peroxisome pro life ra to rs  in vivo, com parative data obtained in v itro  
has also demonstrated s ign ifican t differences in the potency of these compounds 
(Foxworthy and Eacho, 1986; Gray et a l., 1983a; H ertz , et a l., 1985). This suggests a 
basic d ifference in the ir a c tiv ity  at the m olecular level. The extent o f peroxisome 
p ro life ra tion  seen in response to certa in  nu tritiona l factors, such as high fa t diets, 
diabetes and starvation, is in general considerably less than tha t obtained w ith  
xenobiotic peroxisome p ro life ra to rs  (Ishii e t a l., 1980a,b; Thomassen et a l., 1982).
Several compounds, including an ti- in flam m ato ry  drugs such as to lm e tin , 
fenbufen, aminopyrine and m epirizole, have been shown to cause a s ligh t (< 2  fo ld) 
but s ign ifican t induction o f peroxisomal 8 -oxidation in rats when adm inistered a t 
high concentrations (Watanabe and Suga, 1985). O ther compounds which induce a 
s im ila r response include ethionine and 12-0-te tradecanoyl-phorbo l-13-aceta te  (TPA) 
(Aarsaether _et _al., 1988; Lillehaug and Berge, 1986). The c lass ifica tion  o f these
Table 1.7 Ranking o f som ePeroxisom ePro life ra to rsbyP a lm itoy l-C oA  oxidase 
values (male rat)
Compound A c t iv ity *
Fenofibrate 304
C lobuzarit 302
C ipro fib ra te 66
T ib ric  Acid 44
Wy 14643 44
M ethyl Clofenapate 37
C lo fib ra te 29
DEHP 15
DEMA 5
Aspirin 1
*  (nmoles/m in/mg)/(y moles/kg/day) x 10  ^
Reproduced from  Barber et al. 1987
compounds as peroxisome pro life ra tors is tenuous. Weak peroxisome pro life ra tors 
can be detected by th e ir adm in istration to starved ra ts, which results in a 
potentia ted response to  the p ro life ra to r (Hertz and Bar-Tana, 1987).
1.5.3 Chronology o f induction and reve rs ib ility
Induction of peroxisome p ro life ra tion  may occur re la tive ly  rap id ly . W ithin 24 
hours of adm in istra tion of an e ffec tive  dose of c lo fib ra te  to rats, increases in the 
number of hepatocellular peroxisomes and the a c tiv itie s  of peroxisomal enzymes 
have been recorded (Hess _et _al., 1965; Svoboda and A za rno ff, 1966; Price et al., 
1986). This was subsequently fo llowed by a measurable increase in  liv e r  weight 
w ith in  a few days. An increase in the ra te  of transcrip tion of several of the genes 
of the peroxisome p ro life ra to r domain has been observed w ith in  a few  hours of the 
adm in istration of inducer (Hardwick et al., 1987; Osumi _et _aL, 1985; Reddy et al., 
1986). M axim al induction is achieved a fte r about 7-14 days of continuous dosing, 
a fte r which the ac tiv ities  may rem ain constant or drop o ff  to about one-half 
maximum a fte r 90 days of continuous dosing (Kawashima _et_al., 1985b; M itche ll et 
a l., 1985c; Price et al., 1986; Reddy and Lawani, 1983).
The e ffec ts  of the peroxisome p ro life ra to rs  on live r parameters are rapid ly 
reversible fo llow ing the term ination  of dosing (Moody and Reddy, 1976). W ith in a 
few  weeks of the cessation o f trea tm ent peroxisomal numbers, liv e r  weights and 
enzyme ac tiv ities  have returned to  control values (Chatterjee et a l., 1983; Eacho et 
a l., 1986; M iyazawa et_al., 1980a; Reddy _et_al., 1978). This indicates the absolute 
requirement of the continued presence of the peroxisome p ro life ra to r fo r  the 
maintence of elevated numbers of peroxisomes, enhanced ac tiv itie s  of peroxisomal 
enzymes, and the generation of the ir m etabolic by products (S tott, 1988).
1.5.4 D ifferences in the response to  peroxisome pro life ra tors
Species, sex and stra in differences in the response to  peroxisome 
pro life ra tors  have been observed.
1.5.4.1. Species D ifferences
A pronounced species d ifference in the xenobiotic induced peroxisome 
p ro life ra tion  has been observed and are summarised in  Table 1.8. I t  is clear from  
th is data tha t higher mammalian species are considerably less sensitive than rats, or 
to ta lly  insensitive, to the e ffe c t of the known peroxisome p ro life ra tive  agents at 
to lerated or therapeutic doses. Thus, compounds such as gem fibrozil, fenofib ra te , 
LY  171883 and c lobuzarit, which cause as much as a 10- to 20-fold increase in 
peroxisomal 8 -oxidation in rats, cause only slight increases, or no change, in dogs 
and nonhuman primates at much higher dose levels. S im ilar differences between 
rats, mice and higher mammalian species have also been reported fo r  trich lo roace tic  
acid and DEHP (Osumi and Hashimoto, 1978b; Elcombe _et_al., 1985; Elcombe 1985; 
Elcombe and M itche ll, 1986). The species difference in the response to DEHP is 
seen in both peroxisomal 8 -oxidation and lau ric  acid CO -hydroxylase ac tiv ities  
(Lhuguenot, 1988).
The s trik ing  species difference in the response to peroxisome pro life ra tors 
has led to the suggestion th a t the ra t live r response should be considered as a 
unique, a typ ica l phenomenon re lated to  the biology o f the peroxisome in  th is species 
(de la  Iglesia et. _al., 1981). However, the very potent peroxisome p ro life ra to r, 
c ip ro fib ra te , has been observed to  induce substantial (though s t i l l  lower than in rats) 
increases in peroxisomal numbers and enzyme a c t iv ity  in cynomolgus and rhesus 
monkeys. This was only accomplished fo llow ing adm in istra tion of a 5- to 1 0 -fo ld  
higher dose level than tha t which resulted in a much greater response in the ra t 
(Reddy _et _al., 1984b). S im ilar, DL-040 has been shown to induce peroxisome 
p ro life ra tion  at dose levels tha t greatly exceed the therapeutic dose (Lalwani e t a l.,
1985). W ith other compounds, such as L Y  171883 and DEHP, no peroxisome 
p ro life ra tion  was seen at the maximum to lerated dose (Eacho est_al., 1986; Rhodes et 
al., 1986).
I t  should be noted that many reviews state that rodents are sensitive to 
peroxisome pro life ra tors  (Rodricks and Turnbull, 1987; S to tt, 1988), This however,
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is not s tr ic t ly  true. Guinea pigs, which are non-responsive, belong to the order 
rodentia, sub-order hystricomorpha. Rats and m ice, which are both extrem ely 
sensitive to the e ffects  of peroxisome pro life ra tors , belong to the order rodentia, 
sub-order myomorpha, sub muridae. Hamsters, which are weak responders,
belong to  the order rodentia, sub-order myomorpha, sub-fam ily critidae. 
Accordingly, care must be taken not to  use the term  rodent to include a ll sub­
orders.
The only substantiated report of a chem ically induced increased in the 
number of peroxisomes in humans has been made by Hanefeld je tja l. ,  (1983). A 
morphological analysis of live r biopsy tissue obtained from  hyperlip idaem ic patients 
receiving a therapeutic dose level of c lo fib ra te  (20-40 m g/kg/day) revealed a 1.3- 
fo ld  increase in the number, and a 23% increase in the volume density, of 
hepatocellular peroxisomes. In contrast, no increase in the number of hepatocellular
CSperoxisomes in hyp lidaem ic patients receiving therapeutic dose levels of 
gem fibrozil or fenofib ra te  have been reported, even though these were only roughly
ii
one-half those causing pronounced e ffects  in rats (Blane and P inaroli, 1980; Blumke 
et al., 1983; G ario t js tja l., 1983, 1987; de la  Iglesia _et_al., 1981, 1982).
I t  has been suggested that the phylogenetic differences in the response of 
animals to xenobiotic peroxisome pro life ra to rs  are simply due to  interspecies 
differences in the pharmacokinetics of these compounds (Berge et al., 1984b). 
However, the interspecies differences, in the response to peroxisome pro life ra to rs , 
seen in vivo are reproducible in v itro  using hepatocyte cultures. Thus ra t and mouse 
hepatocyte cultures were found to respond to peroxisome p ro life ra to rs , whereas 
guinea pig, marmoset monkey, cynomologus monkey and human hepatocyte cultures 
were not responsive (Elcombe, 1983; M itche ll _et_al., 1985; A llen  _et_al., 1987; H ertz 
et _aL, 1987). In general, the sensitiv ity  o f species to peroxisome pro life ra to rs  
fo llows the trend: rats, mice »  hamster > guinea pig > rabb it > dog, prim ates.
1.5.4.2. Strain differences
There have been reports of slight s tra in  differences in the response to 
peroxisome pro life ra to rs . MEHP, DEHP and c lo fib ra te  have been shown to  increase 
live r weight and peroxisomal B-oxidation to a greater extent in Chinese hamsters 
than in Syrian hamsters (Lake _et_al., 1986a,b). This d iffe rence in the induc ib ility  of 
peroxisomal B-oxidation is seen both in  vivo and in  v itro .
Dw ivedi e t aL, (1988) did not detect any s ign ifican t differences in the 
induction of peroxisomal B-oxidation in  9 strains of mice fed c ip ro fib ra te . Recently 
i t  has been demonstrated th a t C37 and C3H inbred strains o f m ice d iffe r  
s ign ifican tly  from  one another and th e ir  hybrid in  both th e ir  basal and nafenopin- 
induced peroxisomal B-oxidation a c tiv ity . The C57 stra in displayed the highest 
a c tiv ity , whereas the C3H had the lowest and the hybrid possessed an a c tiv ity  
tha t was in term ediate between th a t o f its  two parental strains. D is tin c t differences 
in glutathione peroxidase a c tiv ity  exists between the strains in both control and 
treated animals (Butler_et_al., 1988b). A d iffe rence in the magnitude o f induction o f 
peroxisomal B-oxidation in several strains of male rats, in  response to c ip ro fib ra te , 
has been observed (Makowska, 1988).
1.5.4.3. The e ffe c t of age and sex on peroxisome p ro life ra tion
Increases in liv e r weight, peroxisome number and peroxisomal B-oxidation 
have been reported to  occur in foe ta l and neonatal rats fo llow ing the adm in istra tion 
o f DEHP, nafenopin or Wy-14,643 to pregnant and/or nursing dams (Bell j3t_al*5 1979; 
Fahl et al., 1983a). When pregnant rats were trea ted w ith  c lo fib ra te  peroxisomal B- 
oxidation was elevated in the live rs  of both the foetus and the mother (C ibe lli e t al.,
1988). L iver weight increases in aged rats (25 weeks old) have been reported as 
being approxim ately one-half of the increase seen in adolescent rats (5 weeks old) 
w ith  no differences in the induction of peroxisomal B-oxidation (Kawashima et a l., 
1985b).
A significant sex d iffe rence in the response of rats to many, but not a ll,
peroxisome p ro life ra to rs  has been reported (Svoboda et al., 1967; Moody and Reddy, 
1974). The p ro life ra tive  response obtained in male ra ts  fed a diet containing 0.25% 
(w /w) c lo fib ra te  has been observed to  be s im ilar to that obtained in  fem ale rats fed 
a diet containing 2% (w/w) c lo fib ra te  (Reddy and Kumar, 1979; Svoboda et al., 
1967). In contrast, no sex-related differences in peroxisome p ro life ra tion  in rats 
have been reported fo r  nafenopin or RM I 14,514 (Reddy et_al., 1974; Svoboda, 1979). 
The adm in itra tion  of bezafibrate to  rats showed tha t, at the same dose leve l, males 
were 6 x more sensitive than females. No such sex d ifference was observed in mice 
(Watanabe et a l., 1989).
1.5.5 Mechanism of Induction of Peroxisome Proliferation
The exact ce llu la r mechanism responsible fo r the induction of peroxisome 
p ro life ra tion , and associated enzyme a c tiv itie s , remains to be ascertained. Two 
theories have been proposed to explain the induction, namely 1) a cytosolic receptor 
fo r the xenobiotic peroxisome pro life ra tors  and 2) a "substrate overload" 
mechanism.
1.5.5.1. Receptor mediated induction of peroxisome p ro life ra tion
The existence of a receptor fo r the xenobiotic peroxisome p ro life ra to rs  was 
f irs t  suggested by Lalwani _et _aL5 (1983a) fo llow ing  the discovery o f a nafenopin- 
binding prote in in ra t live r cytosol. The binding of nafenopin to ra t liv e r  cytosol was 
found to be com petitive ly  inh ib ited by c lo fib ra te  and c ip ro fib ra te , suggesting a 
common binding site fo r these compounds. Phenobarbital and the hypolipidaem ic 
peroxisome pro life ra tors BR-931 and W y-14643 did not compete w ith  the specific  
binding of nafenopin. The binding characteristics of nafenopin to ra t liv e r  cytosol 
produced an equilibrium  dissociation constant (K ^ )o f  0.53 pM and a to ta l number of 
binding sites (n) of 2.73 pmol/mg cytosolic protein. Recently, a peroxisome 
p ro life ra to r binding prote in (PPbP) was purified from  ra t live r cytosol by a f f in ity  
chromotography and ion-exchange chromatography (Lalwani at _al., 1987).
Nafenopin, c lo fib ric  acid and c ip ro fib ra te  were covalently attached through the - 
COOH group of the ligands to the -N b ^  group o f the Sepharose beads. A pro te in  of 
70,000 dalton estimated m olecular weight, was purified  in all three cases. The PPbP 
appears to be a dimer w ith  a subunit M r of 70,000. However, the purified PPbP did 
not show any specific  binding of nafenopin (Lalwani ,et_al*> 1986). The existence of 
the PPbP is anticipated to  be the basis fo r the observed species, tissue and sex 
differences in the response to the peroxisome p ro life ra to rs , and the d ifference in 
the potency o f these compounds. Reported s truc tu re  a c tiv ity  re lationship have been 
cited as c ircum stantia l evidence fo r  the existence of a specific  receptor fo r the 
xenobiotic peroxisome pro life ra tors  (Fournel _et _al., 1985; Lundgren _et _al., 1987c, 
1988a,b).
To account fo r the structura l d ivers ity  of the xenobiotic peroxisome
pro life ra tors  i t  has been suggested tha t there is e ither more than one type of
receptor, o r one receptor w ith  more than one binding s ite  (Reddy and Rao, 1986), as
shown in Fig. 1.5. I t  has been suggested th a t the PPbP acts in a s im ilar manner to
os
that proposed fo r the Ah receptor (Nebert, 1979) illus tra ted  in F ig . 1.6. I t  is
postulated th a t the peroxisome pro life ra tors  (PP) enter the cell by passive d iffusion 
through the plasma membrane and then bind to  the receptor (R) inside the ce ll. The 
binding of the ligand activates the receptor and th is  ligand-receptor complex (PPR) 
then binds w ith  increased a ff in ity  to  select site(s) in  ce llu lar DNA, trigge ring  the 
transcrip tion of the genes of the peroxisome p ro life ra to r domain.
However, i t  has recently been reported that no such binding prote in was 
found in ra t liv e r cytosol, using nafenopin and c ip ro fib ra te  as ligands, despite these 
animals being sensitive to the peroxisome p ro life ra ting  e ffects  of these compounds 
(Milton_et_al., 1988). S im ilarly, Siest et al., (1988) were also unable to  id e n tify  such 
a cytosolic receptor.
Fig. 1.5 Proposed model(s) of the peroxisome pro iife ra to r-b ind ing  protein
One type: 
single receptor 
site
One type: 
two or more 
sites
Two or more types: 
single receptor 
site
Fig. 1.6 A proposed mechanism for the xenobiotic mediated induction of 
peroxisome p ro life ra tion
P P
C oordinate
TranscriptionP P .R
PP Dom ain
Nucleus
m R N A
Translation
Hepatocyte
Both figure  are derived from  Reddy and Rao (1986)
I.5 .4.2. "Substrate overload" mechanism o f induction
Support fo r a "substrate overload" mechanism of induction of peroxisome 
p ro life ra tion  has come from  the observation of peroxisome p ro life ra tion  in rats fed 
high-fa t diets (Neat et ah, 1980; Ishii et al., 1980a; Osmundsen, 1982; Nilsson et al.,
1984). S tarvation, diabetes and cold adaptation, which are all conditions th a t result 
in an increased ra te  of lipolysis, have also been shown to cause peroxisome 
pro life ra tion  (Ishii et al., 1980b; Nedergaard _et _al., 1980; Horie e t _al., 1984). 
Transient lip id  accumulation is observed shortly  a fte r the adm in istra tion of 
peroxisome p ro life ra ting  agents to rats (Mann _et _al., 1985; M itche ll _et_al*> 1985c; 
Price _et_al., 1986). L ip id  droplets appear w ith in  the f ir s t  24 hrs of trea tm ent, and 
the rea fte r disappear from  the centrilobu lar zone where peroxisomes are 
concentrated. This has lead Sharma _et _al., (1988a) to  propose a cascade type 
mechanism fo r the induction of lauric  acid Co -hydroxylase and peroxisomal 8 - 
oxidation. This scheme is shown in  F ig. 1.7.
An a lterna tive  "substrate overload" mechanism of induction has been 
proposed. I t  has been proposed th a t the induction is mediated by increased levels of 
long-chain acyl-CoAs which have been shown to occur in  the livers of fa t-fe d  and 
c lo fib ra te  treated rats (Nilsson jet _al., 1984; Berge and Aarsland, 1985). A good 
corre lation has been shown to  exist between the level of long-chain acyl-CoA and 
peroxisomal 8 -oxida tion a c tiv ity  a fte r the adm in istra tion of various doses of 
c lo fib ra te  fo r  10 days (Berge and Aarsland, 1985). However, i t  has since been shown 
th a t the increase in the level o f long-chain acyl-CoA followed the increase in 
peroxisomal 8 -oxidation (Fukami et aL, 1986).
1.6 THE OXIDATION OF FA TTY ACIDS
F a tty  acids have been shown to be oxidized in several d is tinct ways, p rim arily  
at the a, 8, (fcJ-1) and c j -carbon atoms (Bremer and Osmundsen, 1984). 8 -O xidation 
has been found in both m itochondria and peroxisomes, and involves the shortening o f 
a fa t ty  acids by two carbon units, producing acetyl-CoA. M onocarboxylic fa t ty
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acids can also be oxidized at the t J  or (CJ-1) carbon atoms producing dicarboxylic 
and ketoacids respective ly. The a-oxidation of fa tty  acids results in the shortening 
of fa tty  acids by one carbon unit.
1.6.1 The oJ-oxidation of fa tty  acids
Monocarboxylic fa t ty  acids are hydroxylated predom inantly by e ither of two 
microsomal pathways:CJ -  or (cJ-1) hydroxylation, both of which have been shown to 
be cytochrome P-450 dependent activ ities  (E llin  _et _al., 1972, 1973; E llin  and 
Orrenius, 1973; Lu and Coon, 1968, Lu ^ t  _al., 1969). These ac tiv itie s  are 
constitu tive and the CJ -hydroxyla tion of monocarboxylic fa t ty  acids is greatly 
enhanced by the adm in istration of peroxisome p ro life ra to rs  such as c lo fib ra te  (Orton 
and Parker, 1982). Recently, an isozyme of cytochrome P-450, term ed cytochrome 
P-450 IV A l, has been purified  from  the live r of c lo fib ra te  treated rats (Tam burini et 
al., 1984). This isozyme shows a high sp e c ific ity  fo r  the CJ -hydroxyla tion of lauric 
acid and has l i t t le ,  if  any, (l j - 1 ) hydroxylase a c tiv ity . Cytochrom e P-450 IV A l is 
discussed in section 1.1.2.1. The (cj-1) hydroxylation of fa tty  acids is not inducible 
to any great extent by c lo fib ra te  but is inducible by phenobarbital (Okita and 
Masters, 1979). An isozyme of cytochrome P-450 which shows high (cJ-1) 
hydroxylase a c tiv ity , and no CJ -hydroxylase a c tiv ity , has also been purified (Imai,
1988). The ra t live r has been shown to contain two or possibly three cytochrome P- 
450 isozymes which function  in CJ and (41-1) hydroxylation (O rtiz  de Montellano and 
Reich, 1984).
The LO -hydroxyla tion of monocarboxylic fa t ty  acids produces prim ary 
alcohols whoch are subsequently oxidized by cytoso lic  alcohol and aldehyde 
dehydrogenases to form  dicarboxylic fa tty  acids (Bjorkhem 1972, 1973). The (cJ-1) 
hydroxylation of monocarboxylic fa tty  acids produces secondary alcohols, which are 
converted by cytosol or microsomal dehydrogenase to  form  ( tJ -1) keto fa t ty  acids 
(Bjorkhem and Hamberg, 1971, 1972). These pathways are shown in F ig. 1.8.
The tissue and species d istribu tion of fa tty  acid CJ-hydroxylase has been
Figure 1.8.
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reviewed by Mortensen (1984). Rat renal microsomes have been shown to Co- 
hydroxylate lau ric  acid at a ra te  fa r greater than th a t seen in ra t liv e r, but th is 
a c tiv ity  is far less inducible than its  hepatic counterpart (Sharma, 1988). Indeed, 
the m ajor form  of cytochrome P-450 in control ra t kidney has been shown to possess 
high lau ric  acid hydroxylase a c t iv ity  (Imaoka and Funae, 1986).
The CJ-ox ida tion pathway has been calculated to be responsible fo r 
approxim ately 10% o f the in it ia l oxidation of monocarboxylic fa t ty  acids in rat live r 
(Bjorkhem, 1978; K a m js tja l. ,  1978). The d icarboxylic fa tty  acids produced by th is 
pathway are substrates fo r peroxisomal 8 -oxidation (Vamecq and Draye, 1987).
Cytochrom e P-450 can m etabolize fa tty  acids other than medium chain 
saturated fa t ty  acids such as lau ric , m yris tic  and p a lm itic  acids. Unsaturated fa tty  
acids, such as oleic, lino le ic  and lino len ic  acids, have been shown to be oxidized by 
ra t live r microsomes (O liw, 1983; Capdevila et al., 1985). Other substrates include 
arachidonic acid, prostaglandins, leukotrienes and xenobiotics (Kupfer, 1980).
The metabolism of arachidonic acid by ra t hepatic and renal microsomes to 
U) and { U - l )  hydroxylated products has been shown to be cytochrom e P-450 
dependent (Capdevila, et al., 1981; O liw  and Oates, 1981). Other cytochrom e P-450 
dependent arachidonic acid m etabolites include epoxy acids, epoxides, 
hydroxyeicosatetraenoic acids (HETEs) and epoxyeicosatetraenoic acids (EETs) 
(Capdevila e l _al., 1982; Chacos _et _al., 1982, 1983; O liw  _et _al., 1982). These 
activ ities  have been shown to occur in a range of tissues including kidney, 
polymorphonuclear leukocytes, lung, blood vessels and the eye (P into _et_al., 1987; 
M cG iff and C arro l, 1987; Schwartzman et al., 1987; Carrol et al., 1988; Hatzlemann 
and U llr ich , 1988) and often results in the fo rm ation  of pharmacologically active  
metabolites. The CJ and (CJ-1) hydroxylation of arachidonic acid has been shown to 
be increased by the adm in istration o f peroxisome pro life ra tors  (Bains j 5t_al., 1985; 
Capdevila et al., 1985) and by deoxycorticosterone acetate (Lapuerta et a l., 1988). 
The CJ -hydroxyla tion o f HETEs has also been reported and this pathway is generally 
regarded an an inactiva tion  mechanism for arachidonic acid m etabolites (Wong et
a l., 1984; O 'Flaherty j 3t_al., 1986; O k ita  e t al., 1987). The CJ-hydroxylation of 12- 
HETE has been shown to be inh ib ited by LTB^, possibly ind ica ting tha t these two 
compounds are m etabolized by the same isozyme of cytochrome P-450 (Marcus et 
al., 1987). S im ilarly, the CJ -hydroxyla tion of 15-HETE is inhib ited by prostaglandin 
E, and the antibody to cytochrom e P-450 prostaglandin C J -hydroxylase, thereby 
suggesting tha t the CJ -hydroxyla tion of 15-HETE is catalyzed by th is  isozyme (Okita 
e t al., 1987). The metabolism  of docosahexanoic acid, an essential fa tty  acid, also 
shows sim ilar cytochrome P-450 dependent metabolism (van Rollins et a l., 1984).
Prostaglandins have been shown to be metabolized to  CJ and (CJ-1) hydroxy 
products, by cytochrome P-450, in  a range of tissues (Kupfer and Navarro, 1976). 
These tissues include live r, in tes tina l mucosa, colon, lung, vesicular glands and 
placenta (Kusunose _et _ah, 1984; O liw  and Hamberg, 1986; Yamamoto jet _al., 1986; 
M uerhoff et al., 1987; Kupfe r _et _al., 1988). Several prostaglandins can be 
metabolized by CJ -hydroxyla tion, namely PGE^, PGE2 J PGA^, and PGF2 a . 
C lo fib ra te  and DEHP have been shown to cause an increase in PGACJ -hydroxylase 
a c tiv ity  in  rabb it liv e r  (Yamamoto _et _aL, 1986a). Pregnancy and progesterone 
trea tm ent have been shown to  induce these a c t iv ity  in rabb it lung and an isozyme of 
cytochrome P-450, term ed cytochrome bas been isolated from  this
tissue (W illiams _et _al., 1984; Yamamoto et_al., 1984). This isozyme is extrem ely 
active towards PG£^ and pa lm ita te , but not lau ric  acid, and has been shown to be 
d is tinct from  cytochrome P-450 IV A l (Matsubara _et _al., 1987). I t  has been 
suggested that the CJ and ( c j - 1 )  hydroxylation of prostaglandins may not just be a 
prim ing step fo r the ir u ltim ate  8 -oxidation but may also represent the generation of 
pharmacologically active m etabolites (O liw  and Hamberg, 1986).
Leukotrienes B^, E^ and C^ have been shown to be substrates fo r  cytochrome 
P-450 dependent CJ-hydroxyla tion. The CJ-hydroxylation of leukotriene B^ has been 
observed in human polymorphonuclear leukocytes, and in ra t hepatic microsomes 
(Hansson et al., 1981; Newton _et_al., 1985; Shak and Goldstein, 1985; Sumimoto et 
al., 1988). I t  is not presently known whether the isozyme of cytochrom e P-450
responsible fo r  th is a c t iv ity  is identical to, or d iffe ren t from , those that catalyze 
the CJ -hydroxyla tion of prostaglandins and fa tty  acids. The main function  of the CJ- 
h y d ro x y la tio n  of LTB4 is detoxication although CJ -  OH LTB4 s t i l l  retains some 
pharmacological a c tiv ity  (Clancy eT _al., 1984; Lawson ^ t  _al., 1986). The CJ - 
hydroxylation of leukotriene E^, N -acetylleukotriene E^ and leukotriene C4 by ra t 
liv e r microsomes has been reported (Orning, 1987a,b; Orning ^ t  _al., 1988). 
C lo fib ra te  trea tm ent appears to decrease both the 6J and (cj-1) hydroxylation of 
LTB^ (Sharma, 1988).
Xenobiotics can also be metabolized by CJ-hydroxylation. Compounds that 
are subject to  th is  type o f metabolism include MEHP, prop analol and N-(4- 
chlorophenyl)propanamide, possibly due to the ir s im ila r ity  to  fa tty  acids (Albro et 
a l., 1984; Apostolescu and Leuk, 1981; Shetty and Nelson, 1986).
1.6.2 Peroxisomal 8-oxidation
The 8 -oxidation of fa tty  acids has been detected in  two d is tinc t subcellular 
organelles, the peroxisome and the m itochondrion. The enzymes of peroxisomal 8 - 
oxidation d iffe r from  th e ir m itochondrial counterparts in terms of the ir ca ta ly tic  
and molecular properties. The peroxisomal 8 -oxidation system is not coupled to a 
phosphorylating system or d irec tly  linked to the m itochondrial e lectron transfer 
chain and is there fo re  insensitive to  CN and actinom ycin (Lazarow and DeDuve, 
1976; Mannaerts _et _al., 1979). Peroxisomal 8 -oxidation is also carn itine
independent, unlike m itochondrial 8 -oxidation (Lazarow, 1982b). The peroxisomal 
and m itochondria l 8 -oxidation pathways are depicted in  F ig. 1.9.
A long-chain acyl-CoA synthetase is located on the external face o f the 
peroxisomal membrane and the long-chain acyl-CoAs form ed enter the peroxisome 
by passive d iffusion (Krisans ^ t  _al., 1980; Shindo and Hashimoto, 1978). The 
oxidation of fa tty  acyl-CoA esters in peroxisomes is catalyzed by fa t ty  acyl-CoA 
oxidase (a purely peroxisomal enzyme) yielding ^ 0 2  (Hashimoto, 1982). In 
peroxisomes the ac tiv ities  of enoyl-CoA hydratase and 3 -hydroxyacyl-CoA
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Fig. 1.9 F a tty  acid 6 -oxida tion pathway in peroxisomes and m itochondria
(1) F a tty  acyl-CoA synthetase; (2) A cy l-C oA  oxidase; (3) B ifunctiona l enoylACoA 
hydratase/3-hydroxyacyl-CoA dehydrogenase; (A) 8 -ketothiolase; (3) F a tty  acyl- 
CoA dehydrogenase (6 ) Enoyl-CoA hydratase; (7) 3 -hydroxyacyl-C oA 
dehydrogenase; (8 ) B-ketothiolase
dehydrogenase have been shown to  copurify on one single polypeptide (the 
bifunctional protein; PPA 80) whereas in m itochondria the enzyme activ ities  reside 
on separate proteins (Bremer and Osmundsen, 1984). Peroxisomal thiolase is 
im m unologically d is tinct from its m itochondrial counterpart (Lazarow, 1982b; 
Bremer and Osmundsen, 1984). The products of peroxisomal 6 -oxidation, namely 
acetyl-CoA and acyl-CoA, are removed by carn itine acyl transferases (Lazarow, 
1982b). I t  has been suggested tha t fa tty  acid binding prote in may be involved in the 
regulation of peroxisomal 8 -oxidation (Appelkvist and Dallner, 1980; Fournier and 
Rahim, 1983). The peroxisomal and m itochondria l 8 -oxidation systems show great 
differences in the ir chain length specific ities . These differences are shown in  Table 
1.9.
Peroxisomal 8 -oxidation does not proceed to completion as does 
m itochondrial 8 -oxidation. The chain length sp e c ific ity  of the peroxisomal system 
means that the 6 -oxidation cannot proceed past C^-Cg mono- and d icarboxylic fa tty  
acids, and can stop at any tim e up to this point (Cerdan et_al., 1988; Kolvraa and 
Gregersen, 1986; Mortensen and Gregerson, 1982; Suzuki et al., 1989).
In term s of capacity to generate acetyl groups, the capacity of peroxisomes 
is re la tive ly  low, being around 10% of the m itochondria l capacity in  the live r of rats 
treated w ith  c lo fib ra te  or fed on a partia lly  hydrogenated marine oil diet (Mannaerts 
jet _al., 1979; Neat _et _aL, 1980; Osmundsen, 1982). However, the peroxisomal 
capacity to chain shorten a ^22*1 ^a t ty ac^  may as much as 100-300% of the 
m itochondrial capacity to  oxidize this fa tty  acid (Bremer and Osmundsen, 1984). 
Peroxisomal 8 -oxida tion is most im portant when the liv e r  is required to m etabolize 
a sustained high in flux  o f very long chain fa t ty  acids*
The function of the peroxisome appears to be to shorten fa tty  acids tha t are 
poorly oxidized by the m itochondria (e.g. long chain fa tty  acids, long chain 
d icarboxylic fa tty  acids and trans fa tty  acids) in to  fragm ents tha t can be oxidized 
by the m itochondria (Osmundsen et al., 1982; Singh je tja l., 1987; Vamecq and Draye, 
1987). Indeed, many polyunsaturated fa tty  acids (PUFAs) are inh ib ito rs  o f
Table 1.9 Comparison of m itochondrial and peroxisomal 8-oxidation
M itochondria l
6 -oxidation
Peroxisomal
8 -oxidation
Contribution to to ta l Major M inor
fa tty  acid oxidation (>90%) (<1 0 %)
S pecific ity :
a c tiv ity  towards acyl-CoAs
short chain (<C^) +++ 0
medium chain (C ^ -C ^ ) +++ +
long chain ^ 2 2 " ^ 2 2 ^ +++ ++
very long chain ( ^ 2 2 ) 0 +++
Oxidation o f bile acid
precursors 0 +++
prostaglandins +(?) +++
w-hydroxyacids +++ ++
dicarboxylic acids +(?) +++
Table adapted from  Vamecq et al., 1988
m itochondrial 8 -oxidation (Osmundsen and Bjornstad, 1983) and long chain 
d icarboxylic acids have been shown to  cause m itochondria l swelling (Tonsgard and 
Getz, 1983; K imura, 1986). Peroxisomes have been shown to possess the isomerases 
necessary fo r the 6 -oxidation of unsaturated fa tty  acids (Chu and Schulz, 1985; 
Dommes _ e t _ 1981; Karki _et _aL, 1987) and have been shown to be more active 
towards long-chain monounsaturated fa tty  acids as compared w ith the corresponding 
saturated fa t ty  acids (Osmundsen _et _al., 1979; Neat _et _al., 1981; Alexson and 
Cannon, 1984).
Peroxisomes have been shown to be involved in the 6 -oxidation of 
prostaglandins E^ and F^ot’ e^cosaPentaeno c^ ac^  anc* arachidonic acid (Christensen 
_et_al., 1986; D iezfalusy and Alexson, 1988; Diezfausy et al., 1987; H iltunen et al., 
1986; H orvik and Osmundsen, 1987; Kubo_et_al., 1988). The peroxisomal 8 -oxidation 
pathway may contribute to the metabolism of xenobiotic acyl compounds such as 
r f iH P  andO -phenyl fa tty  acids (Albro_et_al., 1987; Yam ada^t_al., 1987).
Microsomal CJ -hydroxylation, peroxisomal 6 -oxidation and m itochondria l 6 - 
oxidation are inextricab ly  linked, as shown in F ig. 1.10, which may explain the ir 
close physical interrelationships w ith in  the ce ll (Zaar et ah, 1987).
1.7 PEROXISOME PROLFERATOR INDUCED HEPATOCARCINOGENESIS
Long-term  adm in istration of peroxisome p ro life ra to rs  to ra ts and m ice is 
associated w ith  increased incidences of hepatocellular carcinomas (Reddy et al., 
1980a; Rao and Reddy, 1987). The adm in istration of c lo fib ra te  in the d iet, at a 
concentration of 0.5% (w/w), to  male F344 ra ts  resulted in the development of 
hepatocellular carcinomas in 91% of the trea ted animals sacrificed between 24 and 
28 months (Reddy and Qureshi, 1979). Between 18 and 25 months, hepatocellu lar 
carcinomas developed in 73% of nafenopin trea ted male F344 rats (Reddy and Rao, 
1977). S im ilarly, Wy-14643, t ib r ic  acid, BR-931, gem fib roz il, bezafibrate , 
c ip ro fib ra te  and m ethyl cl of ena pate have also been shown to  cause hepatocellu lar 
carcinomas in the rat (F itzgerald et al., 1981; H artig  et al., 1982; Lalwani et al.,
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1981a; Rao et aL, 1984; Reddy et al., 1980a, 1982a). To date, a ll peroxisome 
p ro life ra to rs  tha t have been tested have been shown to produce hepatic tumours in 
rats and m ice.
Generally, peroxisome pro life ra tors  are not considered to  be mutagenic. The 
hypolipidaem ic agents Wy-14643, nafenopin, BR-931, c lo fib ra te , m ethyl clofenapate, 
gem fibrozil, bezafibra te  and c ip ro fib ra te  are devoid of mutagenic a c tiv ity  in the 
Ames Salmonella typhim urium  reversion assay, as was the p lastic izer DEHP (Warren 
et al., 1980, 1982; F itzgera ld et al., 1981; Reddy et al., 1982a). No induction of 
unscheduled DNA synthesis could be detected fo llow ing in vivo trea tm en t of rats 
w ith  nafenopin or DEPP (Bentley et al., 1988; B u tte rw orth  et al., 1984; C a ttley  et 
al_., 1986). S im ila rly , attem pts to demonstrate the form ation of DNA adducts by 
peroxisome pro life ra tors have fa iled  (Von Daniken et al., 1981; Goel et al., 1985). 
This lack of m utagenic ity  has lead to the peroxisome pro life ra tors being classed as a 
novel group of carcinogens, called epigenetic, or non-mutagenic, carcinogens 
(Reddy et ah, 1980a).
I t  has been proposed that the compounds may induce ind irect DNA damage 
(Reddy et ah, 1980a). The increase in peroxisomal 13-oxidation a c tiv ity  induced by 
peroxisome pro life ra tors  results in an increase in ^ 2 ^ 2  Pro duction (Tomaszewski et 
al., 1986). I t  has been proposed tha t the increased production is linked w ith
the observed he pat ocarci nogenesis (Rao and Reddy, 1987). Increases in the amount 
of lip id  peroxidation and lipofuscin fo rm ation  fo llow ing trea tm ent of animals w ith  
peroxisome p ro life ra to rs  have been taken as an ind ica tion of an increased production 
of an active oxygen species (Reddy et ah, 1982a). However, no increase in lip id  
peroxidation has been reported in short-term  studies of up to  28 days duration 
(E llio tt  and Elcombe, 1987; Nakagawa et al., 1987; Tomaszewski et al., 1986). 
Indeed, over a 14 day period lip id  peroxidation was seen to be decreased in  both 
male F344 and female B6C3F^ mice trea ted w ith  DEHA, DEHP or nafenopin 
(Tomaszewski et al., 1986). Peroxisome p ro life ra to r induced hepatocarcinogenesis 
has been reported to be inh ib ited by the antioxidants ethoxyquin and BHA (Rao e t
al., 1984). Studies w ith  isolated hepatocytes have shown that H ^O ^ roay diffuse 
from  the peroxisome in to  the surrounding cytoplasm, where i t  is inactiva ted  by the 
glutathione peroxidases (Jones et al., 1981; Poole, 1975). These enzymes provide a 
back-up defence system should catalase prove unable to  cope w ith the amount of 
H2 O2 produced. Treatment of rats w ith  peroxisome pro life ra tors has been shown to 
reduce glutathione peroxidase a c tiv ity  (C irio lo  ^ t_ a l., 1982; Furukawa et_al., 1985; 
Lake _et_aL, 1987, 1989). Such an inh ib ition  may potentia te the harm ful e ffects  of 
the Treatm ent of ra ts  w ith  nafenopin has been shown to deplete hepatic
v itam in  E content and to elevate plasma oxidized glutathione levels (Lake et al.,
1989). These changes are ind ica tive  of ox idative  stress. I t  should be noted tha t 
oxidative stress can occur w ithout necessarily resulting in increased lip id  
peroxidation (H a lliw e ll, 1987). I t  has been reported th a t long-term  adm in istra tion 
(29 weeks) o f bezafibrate to male rats resulted in  a 10-fold increase in peroxisomal 
8 -oxidation but the increase in hepatic content o f was less than 1.5 fo ld
(Watanabe jet _al., 1989). From these studies i t  is apparent that the steady-state
concentration is controlled by a complex in terre la tionsh ip  o f several d iffe re n t 
enzyme ac tiv ities  which are d iffe re n tia lly  a ffected by the trea tm ent of rats w ith  
peroxisome pro life ra tors .
DNA damage, o f the type induced by activa ted oxygen, can be detected by an 
increase in the ra te  of alkaline e lution of the ce llu la r DNA. Bentley e t al., 1987) 
showed that trea tm ent of animals w ith  nafenopin was associated w ith  a slight 
increase in the alkaline elution ra te  of hepatic nuclear DNA from  polycarbonate 
f ilte rs . However, e lu tion rates were not fu rthe r increased fo llow ing  additional 
trea tm ent o f the animals to in h ib it catalase a c tiv ity  or to s tim u la te  H2 O2 
production. These findings suggest that excess H 2 O2 production does not induce 
oxidative damage of the DNA. S im ila rly , other groups have found no evidence o f 
DNA damage or lip id  peroxidation in rat liv e r fo llow ing trea tm ent w ith  peroxisome 
pro life ra tors (B utte rw orth  et _al., 1984; E llio t and Elcombe, 1987; Gupta, e t al.,
1985).
A strong s ta tis tica l corre lation has been reported between the a b ility  o f 
compounds to  induce peroxisome pro life ra tion  in ra t liv e r  and the ir 
hepatocarcinogenicity upon chronic adm in istration (S tott, 1988). In general, the 
dose-response fo r peroxisome p ro life ra tion  and the induction of peroxisomal 
enzymes appears to  be s im ilar to that fo r  tum origen ic ity . I t  has been reported tha t 
dose levels o f feno fib ra te  tha t do not cause peroxisome p ro life ra tion  are not 
tum origenic (Fahimi_et_al., 1982; H artig  _et_al., 1982). Other data that supports this 
association includes:
(1) The trend of hepatocarcinogenic potency in rodents re flects  the peroxisomal
p ro life ra tive  potency of the compounds ( tib ric  acid = BR931 = Wy 14,643 > 
c lo fib ra te  > DEHP = trich loroe thylene) (Reddy _et_aL> 1980a; Elcombe et a l., 
1983).
(2) The sex dependency of both the tumorigenic and peroxisome p ro life ra tive
properties where applicable (S to tt, 1988).
(3) The species dependency o f the tum origen ic ity  o f trich loroethylene in  rats and
mice in which there is a corre lation between tum origen ic ity , and the a b ility  
of mice to  metabolize this compound to  the proxim ate peroxisome 
p ro life ra to r, trich lo roace tic  acid (Elcombe et_al., 1983; Prout et_al., 1983).
However, in  a study by Marsman _et _aT, (1988), i t  has been shown that the 
degree of peroxisome p ro life ra tion  corre lates poorly w ith the re la tive  
hepatocarcinogenicity o f DEHP and Wy-14643. Male Fischer 344 ra ts  that were fed 
diets containing 0.1% (w/w) DEHP or Wy-14643 fo r up to 365 days showed a 4-6 fo ld  
increase in peroxisomal volume and a 6 and 8 fo ld  increase in peroxisomal 3- 
oxidation a c tiv ity  respectively. However, there was a 100% tum or incidence in the 
Wy-14643 trea ted rats and a 0% incidence in the DEHP treated rats. However, a 
strong corre lation was observed between the re la tive  hepatocarcinogenicity of 
DEHP and Wy-14643 and the a b ility  to  induce a persistent increase in rep lica tive  
DNA synthesis. This has been in terpre ted as implying the im portance of ce ll
rep lica tion  in the mechanism o f peroxisome p ro life ra to r induced 
hepatocarcinogenesis (Marsman _et _al., 1988). I t  has been shown that ammonium 
perfluorooctanoate (APFO), which is a potent peroxisome p ro life ra to r, did not 
increase the incidence of hepatocellular carcinoma in  rats fed fo r 2 years on a diet 
containing 300 ppm APFO (Pastoor e t ah, 1987).
Although rat hepatocarcinogenesis has been shown not to be corre lated w ith  
the exten t of peroxisome p ro life ra tion , i t  has been shown to  corre la te  closely w ith  
the extent o f lipofuscin deposition, induction o f lysosomal enzymes and conjugated 
diene accumulation (Conway et al., 1989).
There appears to be equivocal evidence fo r  the tum or prom oting properties of 
the peroxisome pro life ra tors . A prerequisite fo r a compound to a c t as a tum or 
promoter is the a b ility  to  include DNA synthesis in  hepatocytes. I t  is well known 
tha t peroxisome p ro life ra to rs  induce rep lica tive  DNA synthesis, both m vivo and in 
prim ary cell cultures of adult ra t hepatocytes (B ieri _et _al., 1984). The m itogenic 
potency of a varie ty  of peroxisome p ro life ra to rs  is well corre lated w ith  th e ir  
carcinogencity (Bieri _et_aL, 1986). I t  should be noted tha t FABP is identica l to the 
mitosis-associated polypeptide (p l4 ) of ra t liv e r  cytosol (Bassuk e t al., 1987), 
although its  ro le, i f  any, in peroxisome p ro life ra to r induced hepatocarcinogenesis is 
unknown. Peroxisome p ro life ra to rs  such as c lo fib ra te , DEHP and nafenopin have 
been shown to in h ib it the development of y-g lu tam yl transpeptidase foc i in two- 
stage models fo r hepatocarcinogenesis (Numoto _et _al., 1984; Staubli e t _al., 1984; 
Popp_et_al., 1985). However, DEHP has been shown to s tim u la te  the fo rm ation  of 
foci of hyperplasia and hepatic neoplasms in d ie thyln itrosam ine-pre treated B6C3F^ 
mice (Ward _et _al., 1984). Despite the in a b ility  o f nafenopin to  s tim ula te  y -  
glutamyltranspeptidase positive foc i in ra t liv e r the compound has been shown to  
enhance cell p ro life ra tion  in such putative preneoplastic foc i (Schulte-Hermann et 
a l., 1981), and promotional a c tiv ity  of Wy-14643 and c lo fib ra te  has been 
demonstrated using other histochem ical markers (G lauert et al, 1986). An increased 
production o f active oxygen species as a consequence of the peroxisome
pro life ra tion  could contribu te  to th is promotional a c tiv ity  (C eru tti , 1985). No 
in itia tin g  a c tiv ity  has been found fo r  DEHP when administered in a single oral dose 
(lO g /kg ) or a fte r feeding at a d ie ta ry concentration of 1 . 2% when each was 
followed by a prom otional regimen (Garvey et a l., 1987). S im ila rly , c ip ro fib ra te  has 
been shown to lack in it ia tin g  a c tiv ity  in two-stage hepatocarcinogenesis (Glauert 
and C lark, 1989).
The evidence fo r the role of peroxisome pro life ra tion-m ed ia ted oxidative 
stress as a possible in it ia tio n  and promotion mechanism fo r hepatocarcinogenesis has 
been summarized by Rao and Reddy (1987) and includes:
(i) consistent association between the induction o f peroxisome p ro life ra tion  and 
hepatocarcinogenesis.
(ii) sustained and specific  induction of ^ 0 2  producing 8 -oxidation enzymes.
( iii)  increased in trace llu la r levels of ^ 0 2  in rats treated w ith  peroxisome 
pro life ra tors .
(iv) increases in hepatic lipofuscin and increased levels of diene conjugates, 
ind ica tive  of oxidative stress, in rats chronica lly treated w ith  peroxisome 
pro life ra to rs .
(v) Marked inh ib ition  of peroxisome pro life ra tor-induced hepatocarcinogenesis by 
antioxidants..
I t  has been noted that certa in  proto-oncogenes, namely c-ras, c-fos and c-H - 
ras, were induced w ith in  24 hours of exposure of the ra t to nafenopin and appeared 
to remain elevated fo r  the duration of the trea tm ent (28 days). In contrast, 
increased expression of c-myc was not observed at anytime during nafenopin 
treatm ent (Bentley _et_ah, 1988). An in teresting feature  of this response was its 
duration, which was much more pronounced in the case of c-fos and c-H-ras then 
fo llow ing partia l hepatectomy. This finding is consistent w ith  a continual 
stim ulation of cell growth during prolonged nafenopin trea tm ent. BR931 and DEHP 
have both been shown to in h ib it the binding o f epidermal growth fa c to r (EGF) to  ra t
live r cells. I t  has been shown in various other instances that other agents inh ib iting 
EGF binding promote the p ro life ra ting  a b ility  o f EGF, possibly by increasing the 
sensitiv ity  o f this growth fa c to r (Gupta et al., 1988).
The signals which trigge r hepatocyte rep lica tion  are not understood but are 
thought to be the same as those which trigge r short term changes, the d ifference 
being in the way th a t the signal is presented (Berridge, 1987). For short-te rm  
changes the stimulus is presented fo r short periods at low  levels, w h ils t prolonged 
hyperstim ulation is required to  induce cell division. Bentley j 3t_al., (1988) suggest 
that nafenopin trea tm ent provides the necessary hyperstim ulation fo r extended 
periods. In th is  respect the reve rs ib ility  of the response to peroxisome pro life ra to rs  
is of in terest. I t  has been shown that nodule form ation by c lo fib ra te  was to ta lly  
reversible a fte r up to 95 weeks of trea tm ent, when animals were m aintained fo r a 
fu rther 16-18 weeks on a contro l diet before being k illed  (Greaves et a l., 1986). This 
implies th a t the development of autocrine growth is a very la te  event in the course 
of carcinogenesis caused by such compounds and that continuous exposure over 
prolonged periods is necessary to  induce neoplasia. I t  has been shown recently  th a t 
acyl-CoA thioesters of hypolipidaem ic drugs such as nafenopin and c ip ro fib ra te , can 
potentia te d iacy lg lycero l-activa ted  protein kinase C (pKC) (Bronfman et al., 1989). 
Protein kinase C has been im plica ted in turnorigenesis (Nishizuka, 1984) and i t  has 
been postulated tha t the carcinogenic effects of hypolipidaemic drugs such as 
c lo fib ra te  may be related to m odifications in the a c tiv ity  of pKC. A scheme 
showing the possible mechanisms of tum or induction by peroxisome p ro life ra to rs  is 
shown in  F ig . 1.11.
1.8 INHERITED DISORDERS OF FATTY A C ID  OXIDATION.
Inherited disorders of peroxisomal and m itochondrial B-oxidation and 
microsomal A l-ox ida tion  are well documented in humans. These disorders are most 
commonly associated w ith  in fants and have very poor prognoses.
F ig .1.11 Probable mechanisms of tumor induction by peroxisome p ro life ra to rs
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1.8.1 Peroxisomal disorders
Peroxisomopathies are a new class o f human diseases that are characterized 
by e ither the absence or the abnorm ality of peroxisomes. These disorders have been 
extensively reviewed (Gordon, 1987; Kaiser and Kram er, 1988; Moser, 1987, 1988;
Reinecke, 1988; Schutgens et_al., 1986). The peroxisomal disorders can be dividied
inot three groups (Moser, 1986) as outlined in  Table 1.10.
The group 1 disorders are l i fe  threatening and lead to death in early
childhood. They all show elevated levels of very long-chain fa t ty  acids,
hyperpipicolinem ia, accumulation of bile acid interm ediates, defective plasmalogen 
synthesis, a loss of phytanic acid oxidation and d icarboxylicaciduria (Bjorkhem _et 
a l., 1984; Kaiser and Kram ar, 1988; Vamecq et_al., 1986).
The defects in peroxisomal 8 -oxidation seen in Zellweger syndrome, which is 
the most widely studied of the peroxisomopathies, are pronounced not only in the 
liver, but also in  the brain where an accumulation of - C^g polyenoic fa t ty  acids 
has been observed (Poulos at _al., 1986). This observation, coupled w ith the
decreased plasmalogen biosynthesis seen w ith  some disorders, may explain the 
observed demyelination of nerves (Moser, 1988; Stephenson, 1988). No e ffe c tive  
trea tm ent is known fo r the Zellweger syndrome, in fa n tile  Refsum disease or 
hyperpipecolic acidaemia (Schutgens a t _al., 1986). C lo fib ra te  trea tm en t o f 
Zellweger syndrome patients fa iled to improve the condition as assessed 
biochem ically, m orphologically, and c lin ica lly  (Lazarow at_al., 1985).
1.8.2 Defects in mitochondrial 8-oxidation
There are several classes o f m itochondrial 8 -oxidation defect. One of note is 
medium-chain acyl-CoA dehydrogenase (MCAD) defic iency (D ivry a t _al., 1983; 
Rhead _et _al., 1983; Stanley _et_al., 1983). This disorder frequently masquerades as 
Reyes syndrome or sudden in fan t death syndrome (Roe et _al., 1986). MCAD is 
characterized by the excretion of d icarboxylic acids (adipate, suberate, sebacate 
and unsaturated sebacate), hydroxy acids, suberylglycine and octanoy l-ca rn itine
Table 1.10 C lassifica tion  of peroxisomal disorders
Group C haracteristics and subclassification
1 A c tiv it ie s  o f m ultip le  peroxisomal enzymes are impaired 
and associated w ith  a reduced number o f peroxisomes
a. Zellweger syndrome (cerebro-hepato-renal syndrome)
b. Neonatal adenoleukodystrophy
c. In fa n tile  Refsum disease
d. Rhizom elic chondrodysplasia punctata
2 General im pairm ent of peroxisomal functions but w ith  
normal number o f peroxisomes
a. Pseudo-Zellweger syndrome (3-oxoacyl-CoA thiolase 
deficiency)
b. Hyperpipocolic acidaemia
3 Im pairm ent of only one peroxisomal enzyme
a. Acatalasaemia (catalase deficiency)
b. X -linked adrenoleukodystrophy (very long-chain 
acyi-CoA synthetase deficiency)
c. Refsum disease (adult type) (phytanic acid oxidase 
deficiency)
d. Prim ary hyperoxaluria Type 1 (alanine: giyoxalate 
aminotransferase deficiency)
Reproduced from  Reinecke (1988)
(Tonsgard, 1986; Tracey et a l., 1988).
1.8.3 Disorders o f CO -hydroxyla tion
Disorders o f the Co -hydroxyla tion of fa tty  acids are rare. Although this 
pathway is im portan t in the generation o f the d icarboxylic acids seen in  Reyes 
syndrome, Zellweger syndrome and medium-chain acyl-CoA defic iency there is no 
evidence tha t th is  a c t iv ity  is elevated in these conditions (Okita, 1986; Roe et a l., 
1986; Tonsgard, 1986; Duran and Wadman, 1987; Tracey et al., 1988).
An increased level o f CO -oxidation has been associated w ith  S ilver Russel 
syndrome (dwarfism  of prenatal onset, typ ica l cranio facia l appearance and 
dystrophy) (Willems et al., 1985). Increased apparent Vmax values fo r  the 12- 
hydroxylation o f lauric  acid has observed in kidney microsomes derived from  a stra in  
o f spontaneously hypertensive rats (Shiverick et al., 1986). SDS-polyacrylamide gel 
electrophoresis of these microsomes showed an increased prominence of a 52,000 
dalton protein. Whether th is increase was cause or e ffe c t was not determ ined.
1.9 AIMS OF THE PRESENT STUDY
The aim of th is  study is to ve rify  the existence of a soluble cytosolic receptor 
fo r the xenobiotic peroxisome pro life ra tors. I f  possible, th is  receptor w ill be purified 
to homogeneity and an antibody raised. The purified receptor w ill be used to screen 
xenobiotics fo r the ir potentia l peroxisome p ro life ra tive  a b ility . By immunological 
techniques the tissue, sex and species d ifference in the d istribu tion  o f the receptor 
w ill be determined.
However, i f  the existence of such a cytosolic receptor cannot be verified  
then the "substrate overload" theory fo r the induction of peroxisome p ro life ra tion  
w ill be investigated. The in ter-re la tionsh ip  of microsomal CJ -oxida tion and 
peroxisomal 8 -oxidation w ill be followed a fte r a single dose o f sodium c lo fib ra te  in 
order to determ ine whether they are causally or casually linked. The 
in terre la tionship o f these parameters * a fte r fasting w ill also be
studied. The cascade type mechanism of induction (as proposed by Sharma et al., 
1988a) w ill also be investigated.
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2.1 CHEMICALS
B ritish  Drug Houses L im ited  (Poole, Dorset, U K ); A ce ty l acetone, activated
charcoal, ammonium acetate, c it r ic  acid, copper sulphate, dextran, d ie thyl ether, 
EDTA, hydrogen peroxide, 8 -hydroxyquinoline, magnesium chloride, 
m ercaptoethanol, potassium chloride, potassium cyanide, potassium phosphate, 
sodium carbonate, sodium chloride, sodium d ith ion ite , sodium potassium ta rtra te , 
sucrose, T riton  X-100, Sarcosyl and am berlite  MBI resin.
Sigma Chemical Company L im ite d  (Poole, Dorset, U K ): Acetyl-C oA, bovine serum
albumin, carn itine, coenzyme A, cyclohe.ximide, 5,5'-dithiobis (2-n itro-benzoic acid), 
di ami nobenzidine chloride, d ith io th re ito l, flav ine  adenine dinucleotide, HEPES, 
lau ric  acid, NAD+, NADH, NADPH, nicotinam ide, orthophenylenediamine, 
pa lm itoyl-C oA , PMSF, ra t serum albumin, SDS-molecular weight markers, sodium 
cholate, Tris (Trizm a base), Tween 2 0 , Tween 80, A n tifoam  A emulsion, dextran 
sulphate, MOPS, salmon sperm DNA, diethylpyrocarbonate, ethidium  bromide, 
TEKCD, ammonium persulphate and benzphetamine.
Bethesda Research Laboratories (Maryland, USA): U ltrapure enzyme grade agarose, 
cesium chloride, guanidium hydrochloride, guanidium isothiocyanate, H yb ri-do t 
nitrocellu lose f ilte rs , NAC prepac columns and nick translation k it.
Emulgen 911 was obtained from  KAO A tlas Co (Tokyo, Japan). 
Hydroxyl apatite  was obtained from  Bio-Rad (Richmond, CA, USA); g lycero l, LKB 
optiphase liqu id  s c in tilla n t from  Fisons (Loughborough, Leicestershire, UK) and 
nitrocellu lose sheets from Anderman and Co L im ited  (Kingston Upon Thames, 
Surrey, U K ).[ ^ c jL a u r ic  acid andP^pj-dCTP were obtained from  the Radiochem ical 
Centre (Amersham, Buckinghamshire, UK). F ico ll was obtained from  Pharm acia
Fine Chemicals AB (Uppsala, Sweden). A cry lage l and bisacrylagel were obtained 
from  National Diagnostics, Aylesbury, UK).
Nafenopin, [^h ]-n a fe n o p in ; c ip ro fib ra te  and [ 3 h ]  -c ip ro fib ra te  were kind 
g ifts  from  D r P Bentley (Ciba-Geigy, Basle, Sw itzerland) and D r F Bonner (S terling 
Winthrop, A lnw ick, UK), respective ly. C lo fib r ic  acid was a g if t  from  I Cl PLC 
Pharmaceuticals Division (Macclesfield, UK).
Pure cytochrome P-450 IV A l and anti P-450 IV A l serum were kind g ifts  
from  D r R Sharma (University o f Surrey). A n ti-b ifunc tiona l enzyme serum was a 
kind g if t  of D r D C in ti (University o f Connecticut Health Center, Connecticu t, 
USA). Donkey anti-sheep enzyme label, donkey an ti-rabb it enzyme label, pre- 
immune sheep sera and pre-immune rabb it sera were kindly supplied by Guildhay 
Antisera L im ited  (Guildford, Surrey, UK). Plasmid containing insert DNA fo r  
b ifunctional enzyme and acyl CoA oxidase were kind g ifts  from D r T Hashimoto 
(Matsumoto, Japan). 2.1kb P-450 IV A l  insert cDNA was a kind g if t  o f D r C 
McGeoch and Miss A Ball (University o f Surrey). A ctin  insert DNA was kind ly 
prepared by D r J Makowska (University o f Surrey). Human liv e r samples were kind 
g ifts  of D r C Ioannides (U niversity o f Surrey), D r A Boobis (Hammersmith Hospita l, 
London) and D r N Lawrence (Robens Ins titu te , G uild ford , Surrey, UK).
2.2 ANIMALS AND DRUG PRETREATlvENT
Male W istar albino rats (150-200g body weight; U n ivers ity  of Surrey breeders) 
were housed in cages w ith  sawdust bedding and allowed food (Spratts Anim al D ie t 
N o .l)  and water ad lib itum . A 12h lig h t/d a rk  cycle was in operation (0700-1900h 
ligh t) at 22°C and 50% re la tive  hum id ity. The animals were dosed w ith  sodium 
c lo fib ra te  (250mg/kg i.p . in 0.9% w /v saline) e ither once daily fo r three days or as a 
single dose. Contro l animals were dosed w ith  the vehicle, saline (0.9% w /v), e ithe r 
once daily fo r three days or as a single dose. When the animals were dosed w ith  
cyclohexim ide (2mg/kg i.p . in  0.9% w /v  saline), the dose of sodium c lo fib ra te  was 
administered 90 m inutes la te r.
*  > 97% pure as judged by T.L.C . analysis.
2.3 PREPARATION OF SUB CELLULAR FRACTIONS
Subcellular fractions, fo r  use in binding studies, were prepared from  the 
livers of untreated male W istar rats. The rats were k illed  by cervical dislocation, 
th e ir  livers  excised and perfused w ith  ice-co ld HEDG/KC1 buffer (25mM HEPES 
buffe r, pH7.4, containing 1.5 mM EDTA, Im M  DTT, 0.4M KC1 and 10% v /v  glycerol). 
A ll subsequent steps were carried out at 0-4°C. The livers were fin e ly  minced in 
HEDG/KC1 buffe r and homogenised using a Potter Elvehjem glass te flon  
homogeniser. The liv e r homogenate was adjusted to 33% (w/v) w ith  HEDG/KC1 
buffe r and subcellular fractions obtained by d iffe re n tia l centrifugation . The 
homogenate was centrifuged at lOOOg^ fo r 10 minutes (JA-17 ro to r in a Beckman 
J2-21 centrifuge) and the supernatant removed. The pellet was resuspended in  20ml 
of bu ffe r and centrifuged at lOOOg^^ fo r 1 0  minutes. This procedure was repeated 
and the fina l pellet containing nuclei and ce llu lar debris was resuspended in 15ml of 
HEDG/KC1 buffer.
Cytosolic fractions were obtained by centrifug ing the rat live r homogenate at
9000 (JA-17 ro to r) fo r 15 minutes, the supernatant removed and centrifuged atga v
106,000gav fo r 60 minutes (60 Ti ro to r in a Beckman LK65 re frige ra ted  
u ltracentrifuge). The supernatant represented the cytoso lic  frac tion  and the pe lle t, 
containing the microsomes was resuspended in  HEDG/KC1 buffe r. A ll live r fractions 
were stored at -80°C. Qne minor m od ifica tion  of the above method was the 
inclusion of 50pM PMSF (phenylm ethylsulfonylfluoride) in  the HEDG/KC1 bu ffe r.
2.4 PREPARATION OF MICROSOMES
Microsomes were prepared by u ltracen trifuga tion  using a m od ifica tion  of the 
method of Omura and Sato (1964). Livers were removed and perfused w ith  0.9% 
(w /v) sodium chloride to  remove contam inating haemoglobin, b lo tted dry and 
weighed. A ll subsequent steps were carried out at 4°C. Kidneys were decapsulated 
before homogenisation. O ther extrahepatic tissues were rinsed in 0.9% (w /v) sodium 
chloride, b lo tted  dry and stored at -80°C  until required. Livers and kidneys were
either scissor minced and homogenised in 0.25M sucrose using a P o tte r Elvehjem 
glass te flon  homogeniser or stored at -80°C  until required. The storage of whole 
tissues at -8.0°C did not adversely a ffe c t the s ta b ility  of cytochrome P-450.
Other extrahepatic tissues were scissor minced and homogenised in  0.25M 
sucrose using a Polytron (Northern Media, U.K.). A ll homogenates were adjusted to 
25-33% (w /v) w ith  0.25M sucrose. A liquots of homogenate were frozen at -80°C  for 
subsequent analysis.
The homogenates were centrifuged in a JA-17 ro to r in  a Beckman J2-21 
centrifuge at 12,600ggv and 4°C fo r 30 minutes to remove cell debris and 
m itochondrial fractions. The supernatant was decanted and centrifuged at 
105,000gav fo r one hour at 4°C in a Beckman LK65 re frige ra ted  centrifuge (60Ti 
ro to r). A liquots of the supernatant (cytosol) were frozen at -80°C . The microsomal 
pelle t was suspended in ice-cold 50mM potassium phosphate bu ffe r, pH7.25, 
containing 20% (v/v) g lycero l, using a m otor driven P o tte r Elvehjem glass te flon  
homogeniser, to a fina l volume of 5mls. The microsomal suspension was stored as 
lm l aliquots at -80°C  and under these conditions the cytochrome P-450 content and 
enzyme a c tiv ity  remained stable fo r periods of up to 12  months.
2.5 SPECTROPHOTO METRIC ENZYME ASSAYS
2.5.1 Cytochrome P-450
Cytochrome P-450 was rou tine ly determ ined as the reduced carbon monoxide 
adduct (Omura and Sato, 1964). M icrosomal samples were diluted w ith 50mM 
potassium phosphate bu ffe r (pH7.25), 20% (v /v) g lycero l, to  give a pro te in  
concentration of l-2 m g /m l. Reduction to the ferrous form  of the haemoprotein was 
achieved by the addition of sodium d ith ion ite . The sample was then sp lit between 
two quartz cuvettes and a baseline recorded using a Kontron-U vikon 860 
spectrophotometer. Carbon monoxide (40 bubbles at approxim ately 1/second) was 
gassed through the sample cuvette  only. The concentration of cytochrom e P-450 
was calculated using the difference extinc tion  coe ffic ien t (450-490nm) o f 
91mM"^cm
2.5.2 P rote in  D eterm ina tion
Protein concentrations of homogenate, cytosol and microsomes were 
determined by the method o f Lowry j 3t_al., (1951) using bovine serum albumin as 
standard, in  the presence of the appropriate sample bu ffe r.
2.5.3 D eterm ination o f Benzphetamine N-Demethylase A c t iv ity
Benzphetamine N-demethylase a c tiv ity  was measured by the fo rm ation  o f 
formaldehyde according to  the method of Nash (1953) w ith  the m odifications of 
W erringloer (1978).
2.6 DETERMINATION OF LAU R IC  A C ID  HYDROXYLASE ACTIVITY
The m etabolism  o f [ ^ c ]  lauric  acid to 1 1 - and 12-hydroxylated products was 
evaluated using e ithe r TLC  or HPLC as described by Parker and Orton (1980).
The 2ml incubation volume contained [ ^ c ]  lau ric  acid (O .lpC i in I O j j I  
methanol) and 0 .1m M p^c]-lau ric  acid (200 mM stock solution in  methanol d iluted to  
Im M  in 0.5M Tris-H C l bu ffe r, pH7.4). lm g of protein from  control samples and 
0.5mg o f pro te in  from  induced samples was used per assay. The tubes were pre­
incubated fo r 5 minutes at 37°C prio r to the addition of 4 0 j j 1 of 40mM NADPH to  
in itia te  the reaction. Microsomal blanks contained d is tilled  water instead of 
NADPH. Contro l and induced tissue samples were incubated at 37°C fo r 10 minutes 
and 5 minutes respective ly. The reaction was term inated by the addition of 300pl of 
3M HC1. Incubations were carried out in polypropylene stoppered tubes.
For the determ ination of a c tiv ity  in extrahepatic tissues 200pl of m icrosomal 
suspension, equ ivalent to 1-7 mg protein, was incubated fo r 18 hours.
1 0 ml of d ie thyle ther was then added to  the incubation m ixture  fo llow ed by 
m ixing on a ro ta ry  shaker fo r 20 minutes. The tubes were then spun at lOOOg fo r  5 
minutes to c la r ify  the phases a fte r which the upper (ether) layer was transferred  to  
a tes t tube and evaporated to dryness under a stream of nitrogen. The tes t tubes 
were sealed w ith  pa ra film  and stored at -8 0 °c  p rio r to analysis.
2.6.1 High Pressure L iqu id  Chromatography (LPLC ) Analysis o f 11- and 12- 
H ydroxylauric  A c id
The dried ether extracts were reconstitu ted in 150pl of HPLC eluting solvent 
(water:m ethanol:g lacia l acetic acid, 45:55:0.05 by volume) o f which lOOpl was then 
in jected onto a reverse-phase Microbondapak MCH-10 column (30 x 0.4cm, Varian 
Associates L im ited , Walton on Thames, UK). The m etabolites were resolved using 
the fo llow ing gradient program:
Time (min) % W ater* % Methanol
S tart 45 55
25 45 55
35 0 100
40 0 100
45 45 55
*  Containing 0.1% (v/v) glacial acetic acid
The flow  ra te  was lm l/m in u te . The eluate was passed through a Berthold 
LB503 Radiodetector (Lab-Impex, Twickenham, UK), containing a 200pl flow  cell, 
in terfaced w ith  a Commodore PET (series 4000), enabling quantita tive  analysis of 
lau ric  acid metabolism. The 11- and 12-hydroxyl a uric acids were successively 
eluted fo llowed by the unchanged lauric  acid. The rate of hydroxylation were 
calculated from  the frac tiona l conversion o f substrate to 11 - and 12 -hydroxy 
products obviating the need fo r the estim ation of recovery o f radioactive products.
2.6.2 Thin Layer Chromatography (TLC) Analysis o f Tota l 11- and 12-
Hydroxylaurate
The dried ether extracts were reconstitu ted in  60pl of methanol, o f which 
20pl was spotted onto s ilica gel GF plates 250 p (Merck, 20 x 20). The plates were 
developed in hexane:diethyl e ther:acetic acid (70:28:1.5 by volume) w ith  the solvent 
fro n t being allowed to m igrate 3/4 of the length of the plate. The rad ioactive  areas
corresponding to  unmetabolised lau ric  acid and 1 1 - and 1 2 -hydroxylauric acid were 
detected and quantitated by a Berthold TLC plate scanner (Berthold, UK).
2.7 METHODS RELATING TO THE QUALITATIVE AND QUANTITATIVE  
DETERMINATION OF CYTOCHROME P-450 IV A l
2.7.1 Enzyme-Linked Immunosorbent Assay (ELISA)
The technique o f ELISA as described by Vo lle r et_al., (1978) and m odified fo r 
the quantita tion of cytochrome P-450 IV A l by Sharma et al., (1988a) was utilised to 
quantita te this prote in in microsomal samples.
Microsomes were solubilised by the addition of lm g  cholate and 0.2mg 
Emulgen 911 per mg microsomal prote in w ith  s tirr in g  fo r 20 minutes on ice. The 
solubilised microsomes were suitably diluted w ith  sodium bicarbonate/carbonate 
buffer (0.1M, pH9.6) and 200pl aliquots loaded onto m ic ro titre  plates on a pmole 
to ta l P-450 basis (usually 0.2-0.4pmoles). The plates were le f t  overnight at 4°C  in a 
humid environment. The plates were washed w ith  phosphate buffered saline, pH7.4, 
containing 0.1 (w /v) ge la tin  and 0.05% Tween 20 (PBSGT). The antisera (cytochrome 
P-450 IV A l antibody) or pre-immune sera (as contro l) were d iluted in  PBSGT as 
required and applied to  the m ic ro titre  plate at 2 0 0 p l/w e ll.
The plates were incubated at 37°C fo r 2 hours, re-washed w ith  PBSGT, and 
the donkey anti-sheep enzyme labelled conjugate, horseradish peroxidase, 
(200p l/w ell) was applied. A fte r  a fu rth e r 2 hour incubation at 37°C and a PBSGT 
wash, the substrate (75ml of 0.025M c it r ic  acid, 0.05M disodium hydrogen phosphate 
buffer, pH5.6, containing 30mg (1 tab le t) orthophenylenediamine and 30yl (30% v/v) 
hydrogen peroxide) was added to the plate (150p l/w ell). Following an incubation of 
up to 30 minutes at 37°C the reaction was term inated by the addition of 2.5M 
sulphuric acid (50p l/w ell).
The absorbance of the wells was read at 492nm using a T ite rte k  p late reader 
(F low  Laboratories, U.K.). A ca lib ra tion  curve using e lec trophore tica lly  
homogeneous cytochrome P-450 IV A l was constructed between 0 and»0 6 pmoles of
pure protein. The amount of cytochrom e P-450 IV A l in the microsomal samples 
was determined from  the ca lib ra tion  curve a fte r adjustment of the absorbances fo r 
non-specific binding (pre-immune sera values).
2.7.2 Western Blot Analysis
Western b lo tting  involves the e lectrophoretic  transfer of separated proteins 
from  polyacrylam ide gels to  n itrocellu lose sheets which are then subjected to 
immunological analysis. The methods employed were m odifications of the basic 
procedures o f Towbin et_al., (1979), Burnette (1981) and reviewed by Bers and G arfin  
(1985),
2.7.2.1 Sodium Dodecyl Sulphate Polyacrylam ide Gel Electrophoresis (SDS-PAGE)
The method o f Laem m li (1970) was rou tine ly used to resolve the m icrosomal 
proteins.
Reagents
Acrylagel (30% w /v  acrylam ide)
Bisacrylagel (2% w /v N ,N-m ethylene-bis-acrylam ide)
Separating gel buffer: 1.5M Tris-HC L (pH8 . 8) containing 0.4% (w/v) SDS 
Stacking gel bu ffe r: 0.5M T ris-H C l (pH6. 8 ) containing 0.4% (w/v) SDS
Electrode buffer: 25mM T ris -H C l (pH8.3) containing 192mM glycine 
and 1% (w/v) SDS.
Sample solubilisation buffer: 62.5mM T ris -H C l (pH6 . 8) containing
2.3% (w/v) SDS; 15% (v/v) glycerol,
5% (v/v) 2-mercaptoethanol
and 0 .0 0 1 % (w /v) bromophenol blue.
Ammonium persulphate (10% w /v)
N,N-tetram ethylenediam ine (TEMED)
Prestained m olecular weight markers (MW-SDS-blue)
Protein Approxim ate M .w t
c^-M acroglobulin
6 -Galactosidase
180,000
116,000
Fructose-6 -phosphate kinase 84,000
Pyruvate kinase 58,000
Fumarase 48,500
Lacta te  dehydrogenase 36,500
Triosephosphate isomerase 26,600
Electrophoresis was performed at room tem perature using a ve rtica l slab gel 
assembly (BIORAD) in  which the gel was contained in  a glass and perspex casette. 
The glass plates were washed w ith  tap w ater, d is tilled  water and acetone p rio r to  
use. The cassettes were sealed w ith  vaseline and clamped in  a ve rtica l position. 
The lower (separating) gel was prepared by m ixing separating gel bu ffe r w ith  an 
amount of acrylagel and bisacrylagel to give the correct running gel acrylam ide 
percentage (7.5% acrylam ide; 0.2% bisacrylamide). The volume was then adjusted 
w ith  d is tilled  water and the polymerisation process in itia ted  w ith  the addition of 
TEMED and freshly prepared ammonium persulphate solution.
This solution was then poured in to  the cassette to a height of at least 125mm. 
A layer of d is tilled  w ater was introduced above the gel m ixture to ensure a f la t  
in terface between the separating and stacking gels fo llow ing polym erisation.
When polym erisation was complete the water layer was removed. The upper 
(stacking) gel consisted of stacking gel buffer, acrylagel, bisacrylagel and water to 
give a fina l percentage of 5% acrylam ide; 0.075% bisacrylamide. Polym erisation 
was in itia ted  as before and the stacking gel was poured on top o f the separating gel 
to a depth of 2-3cm. The sample wells were formed by the in troduction  of a perspex 
comb p rio r to com pletion of polymerisation.
A fte r  polym erisation the bottom edge spacer and sample comb were removed 
and the gel slab im m edia te ly placed in to  the electrophoresis tank. Electrophoresis 
buffer was poured in to  the anode and cathode reservoirs w ith  any air bubbles 
underneath the gel being removed using a syringe and fine  tubing.
A ll samples were diluted in sample solubilisation bu ffe r and boiled fo r 3 
minutes. A fte r  cooling, 5-20pi aliquots were applied to  the stacking gel sample well 
using a H am ilton syringe. Prestained molecular weight markers were included on 
each gel as w e ll as 0.5pmoles of pure cytochrome P-450 IV A l. Samples were, in 
general, loaded on an equiprotein basis (usually 10 pg/track).
A constant curent of 30mA was applied to  the gel until the ind ica to r dye had 
trave lled to w ith in  0.5cm of the bottom of the gel. The gel cassette was removed 
from the tank, the plates separated, and the lower gel cut out fo r e lectrophoretic  
transfer.
2 .7.2.2 E lectrophoretic Transfer and Immunochemical Staining
The lower gel, having been removed from  the gel cassette, was immersed in 
transfer buffer (20mM Tris, 150mM glycine, 20% methanol (v/v)) fo r  45 minutes 
prior to transfer. This p re-transfer stage allows fo r  any shrinking or swelling of the 
gel to occur p rio r to transfer.
The transfer is achieved by the use of a p lastic sandwich apparatus. A sheet 
of nitrocellulose paper (0.45pm pore size) was cut to the appropriate size and la id on 
two sheets of Whatman 3MM b lo tting  paper immersed in transfer bu ffe r. The gel 
was then la id  onto the nitrocellu lose sheet w ith  two other sheets of b lo tting  paper 
being placed on top. The whole assembly was then placed between two Scotch B rite  
scouring pads supported by a rig id  plastic grid. I t  is im portan t to ensure th a t no a ir 
bubbles are trapped between the f i l te r  and the gel because of the possib ility  o f low 
e ffic iency transfer and band d istortion occurring in these areas. The im m obilised 
assembly was then inserted in to  the e lectrophoretic transfer apparatus w ith  the
nitrocellu lose paper facing the anode. The tank was fille d  w ith  transfer buffer and 
electrophoretic transfe r took place at 30V/blot fo r  a period of tim e between two 
hours and overnight.
Follow ing e lectrophoretic  transfer the n itrocellu lose sheet was washed in 
phosphate buffered saline containing 1 % (w/v) bovine serum albumin and 0 .2 % (v/v) 
Triton X-100 (PBSBT) fo r  e ither two hours at room tem perature or overnight at 4°C. 
The PBSBT was then removed and replaced w ith  fresh PBSBT containing a n ti- 
cytochrome P-450 IV A l (1:1000 d ilu tion ) fo r  60 m inutes. The prim ary antibody was 
then removed and the f i l te r  subjected to  two 20 m inute washes w ith PBSBT. Donkey 
anti-sheep enzyme label (horseradish peroxidase) was then applied to the f i l te r  in 
PBSBT bu ffe r fo r  a fu rthe r 60 minutes. A fte r  a fu rth e r two 20 m inute washes w ith  
PBSBT the blot was washed fo r  5 minutes in PBS alone. The nitrocellu lose sheet was 
then developed in 0.1M Tris-H C l bu ffe r (pH7.5) containing 0.5mg/m 1 
di ami nobenzidine chloride and 1:5000 hydrogen peroxide (30 vols). The reaction was 
term inated by rinsing the nitrocellu lose sheet w ith  d is tilled  water. The developed 
blots were covered in  s ilver fo il and stored in the dark.
2.8 BIOCHEMICAL ANALYSIS OF TISSUE HOMOGENATES
2.8.1 Estimation of Cyanide Insensitive Palmitoyl-CoA 3-Oxidation
The method utilised was tha t o f Bronfman _et_al*> (1979). The oxidation of 
pa lm itoyl-CoA results in the reduction of FA D  and N A D +. In m itochondria, these 
are re-oxidised by the cytochrome chain which can be blocked by cyanide. In 
peroxisomes, FADH is re-oxidised by m olecular oxygen but the NADH accumulates 
and therefore an assay o f NADH production in the presence of cyanide serves as a 
measure of the peroxisomal fa tty  acid oxidase system.
A reaction m ixture containing CoA (75yM), FAD (180pM), N A D + (555yM), 
nicotinam ide (141mM), DTT (4.2pM), KCN (3pM) and BSA (255yg/m l) in  60mM T ris - 
HCl buffer (pH8.3) was fresh ly prepared and stored on ice. Both sample and 
reference cuvette  contained a 30pl aliquot of ra t liv e r homogenate solubilised w ith
an equal volume of 60mM T ris -H C l bu ffe r (pH8.3) containing 1% (w /v) T riton  X-100 
at 37°C fo r 2 minutes. To the solubilised homogenate was added 2ml of reaction 
m ixture and 0.9ml of the T ris  bu ffe r. The solution was equilibrated fo r  a fu rth e r 5 
minutes at 37°C. The reaction was in it ia te d  by the addition of 20pl pa lm itoy l-C oA  
(75pM) and the change in absorbance at 340nm at 37°C was recorded using a Cary 
219 spectrophotom eter. Results were expressed as nmol NADH 
produced/m inute/m g prote in  using the molar extinction  coe ffic ie n t of 
6220 M ^ cm ^ fo r  NADH at 340nm. For extrahepatic  tissues 200pl of homogenate 
(approximately 3-10 mg protein) was solubilised w ith  200yl of 60mM T ris -H C l 
(pH8.3) containing 1% (w/v) T riton  X-100. A fte r  5 minutes solubilisation at 37°C 
the homogenate was centrifuged b r ie fly  at 13,000 rpm (MSE m inifuge) and the 
supernatant removed fo r  assay as previously described.
2.8.2 Carnitine Acetyl Transferase
Total (peroxisomal and m itochondria l) carn itine  acetyl transferase a c tiv ity  
was measured by the method of Bieber _et_al., (1972) and Bock et_al., (1980). The 
assay is based on the measurement of free CoA formed during the acyl transfer 
from  acyl-CoA to added carn itine; the free  CoA being determined by the sulphydryl 
reagent 5,5'-dith iobis (2-nitrobenzoic acid) (DNB).
The 2ml incubation volume contained 2 0 0 pl of d iluted homogenate (1:5 in 
116mM T ris-H C l, pH8.0 containing 2.5mM EDTA, 0.2% (w /v) Triton X-100); lOOpl of 
acetyl CoA (2mM in d is tilled  water) and 1.7ml o f DNB (0.5mM in the above Tris 
buffer). The solution was mixed and centrifuged b rie fly  at 13,000rpm (MSE 
m inifuge) i f  required. The incubation m ixture  was divided between two 1ml cuvettes 
and the reaction in itia te d  by the addition of IO jjI of carn itine (1M in T ris  bu ffe r). 
The change in absorbance was recorded at 412nm, 25°C, in  a Cary 219 
spectrophotometer. The ra te  of reaction was calculated using the molar ex tinc tion  
co e ffic ie n t of the product at 412 nm of 13,600 M "^ c m " \
2.8.3 Immunological Detection of Peroxisomal Bifinctional Protein
2.8.3.1 ELISA
The method previously described fo r the quantita tion of cytochrome P-450 
IV A l in Section 2.7.1 was adapted fo r the quantita tion of peroxisomal b ifunctiona l 
prote in.
Freeze-dried sera from  a rabb it immunised w ith  b ifunctional prote in was 
supplied by D r D C in ti and reconstitu ted  in PBS prio r to  use.
Homogenate samples were solubilised w ith  an equal volume of 6 OmM Tris- 
H C l buffer (pH8.3) containing 1% (w/v) T riton  X-100 at room tem perature fo r one 
hour. The solubilised samples were then diluted as appropriate in sodium 
bicarbonate/carbonate buffer (0.1M, pH9.6) and loaded on a ng protein basis in a 
to ta l volume of 200pl per well. A standard curve of solubilised homogenate from  
control ra t live r (0.9% (w /v) saline, i.p . fo r three days), or c lo fib ra te  treated ra t 
live r (250 m g/kg, i.p., 3 days) was constructed from  0-10,000ng and 0-600ng prote in 
respective ly.
The plates were then processed as previously described w ith  the fo llow ing 
exceptions: pre-immune (normal) rabb it sera and donkey an ti-rabb it enzyme label 
were used instead of the corresponding sheep products.
2.8.3.2 Western B lo t Analysis
The method previously described in  Section 2.7.2 was adapted fo r  the 
immunological detection of peroxisomal b ifunctional protein. The polyacrylam ide 
gel was cast as described except that the acrylam ide and bisacrylam ide 
concentrations of the upper gel were 3% and 0.13% respectively. Samples were 
solubilised as before and loaded on a equiprotein basis (usually 30yg in  5y l to ta l 
volume). The other m od ifica tion  of the previously described method was the use o f 
donkey an ti-rabb it enzyme label (horseradish peroxidase) instead of the 
corresponding donkey anti-sheep product.
2.9 BIOCHEMICAL ANALYSIS OF CYTOSOLIC FRACTIONS
2.9.1 D eterm ination o f G lutathione Peroxidase A c t iv ity
G lutathione peroxidase a c tiv ity  was measured by the ra te  of disappearance of 
NADPH using t-b u ty l hydroperoxide as substrate as shown in the fo llow ing 
equations:
R O O H +2G S H  » R O H + H 20  + GSSG
GSSG + N A D P H + H +-----> 2GSH + NADP+
where ROOH is t-b u ty l hydroperoxide
The glutathione peroxidase a c tiv ity , in the presence of sodium azide to 
inh ib it peroxisomal catalase, was measured using the method described by Awasthi 
e tja l., (1975) and Lawrence and Burk (1976).
The incubation volume of 1ml contained potassium phosphate buffer (0.1M, 
pH7), NADPH (0.2mM), glutathione reductase (1 i.u.), glutathione (4mM), EDTA 
(4mM), sodium azide (4mM) and an appropriate volume of cytosol (d iluted in 
potassium phosphate buffer, pH7). The reaction m ixture  was pre-incubated at 37°C 
fo r 10  m inutes a fte r which the reaction was in itia ted  by the addition of lO p l of 
10 mM t-butylhydroperoxide to  the sample cuvette.
The ra te  of reaction was measured at 37°C by fo llow ing the decrease in 
absorbance at 340nm using a Cary 219 spectrophotom eter and expressed as ym ol 
NADPH oxidised/m in/m g prote in assuming a molar extinction co e ffic ie n t of 
6220 cm’ ^ fo r  NADPH at 340nm.
2.10 LIGAND-BINDING STUDIES
Subcellular fractions, obtained by d iffe re n tia l centrifugation as outlined in 
Section 2.3, were assayed fo r th e ir a b ility  to  specifica lly  bind Ph] -c ip ro fib ra te  or
P h ] - nafenopi 
The methodologies employed were m odifications of those of Kass (1985), 
Lalwani _et J*l»> (1983) and Gasiewicz and Neal (1982) as reported in M ilto n  e t a l., 
(1988).
The subcellular fractions were dialysed overnight against 2 x 1  l i t r e  changes 
of required bu ffe r, p rio r to use. Two mis o f sample (0-20mg protein) was added to  
tubes containing either P h ] - nafenopin (13 C i/m m ole) or P h ] -c ip ro fib ra te  
(8.04 C i/m m ole) w ith  or w ithout excess unlabelled ligand (500nmoles in 10yl o f 
ethanol). The tubes were vortexed and incubated at 4°C fo r 80 m inutes. A liquots 
were then removed fo r  determ ination of binding by e ither the charcoal-dextran 
method or hydroxylapatite  method.
2.10.1 Charcoal-Dextran Binding Assay
Dextran-coated pellets were prepared by dissolving dextran T70 (4.5g) in  
200ml o f HEDG/KC1 buffe r (25mM HEPES bu ffe r, pH7.4 containing 1.3mM EDTA, 
Im M  DTT, 0.4M KC1 and 10% (v /v ) g lycero l) and adding activa ted  charcoal (45g). 
The activa ted charcoal was resuspended using a magnetic s tir re r and 1.8ml aliquots 
(containing approxim ately 400mg charcoal and 40mg dextran) were transferred to 
LP3 tubes. The tubes were then centrifuged at 2000gav fo r 15 m inutes in a 
Beckman J6 -B centrifuge and the supernatant discarded.
500yl o f the subcellu lar - P h] -ligand incubation m ixture was added to a 
tube containing a charcoal-dextran pe lle t, the tube vortexed and incubated fo r 11 
minutes at 4°C. The charcoal-dextran was then removed by cen trifuga tion  at 
3500gav fo r 20  m inutes and the supernatant transferred to a p lastic  beta via l, 
containing 4.5ml of optiphase liqu id s c in tilla tio n  cockta il fo r the determ ination o f 
rad io ac tiv ity .
2.10.2 H ydroxylapatite  Binding Assay
H ydroxylapatite  was washed w ith  the appropriate bu ffe r until the pH of the 
washes remained at 7.4 and subsequently resuspended in two volumes of the same 
buffe r at 0-4°C.
2 0 0 pl of the subcellular frac tio n  - P h ]  -ligand incubation m ix tu re  was added 
to a tube containing 250jj1 of hydroxylapatite  suspension and incubated fo r 30
minutes at 4°C, w ith  gentle shaking every 10 m inutes. A t the end of th is tim e  1ml 
o f ice-cold bu ffe r containing Tween 80 (0.5% (v/v)) was added, the tubes vortexed 
and centrifuged at 1500rpm fo r 5 minutes. The supernatant was removed, the 
hydroxylapatite pe lle t resuspended in absolute ethanol (2 ml) and transferred to a 
plastic beta v ia l, containing optiphase liqu id  sc in tilla tio n  cockta il (4.5 m l), fo r  the 
determ ination of rad io ac tiv ity .
2.11 TECHNIQUES RELATING TO THE MOLECULAR ANALYSIS
OF RNA SAfvPLES
2.11.1 Extraction of Total Cellular RNA
The m ajor technical problem in the iso lation of RNA from tissue samples is 
the prevention o f RNA hydrolysis and degradation by ribonucleases. In an a ttem pt 
to minimise any degradation a ll solutions were made using s te rile  water (e ither 
autoclaved or treated w ith  diethylpyrocarbonate (DEPC) -a ribonuclease inh ib ito r) 
and autoclaved p rio r to use whenever possible. A ll solutions containing DEPC were 
autoclaved to destroy any remaining DEPC. Where autoclaving was not possible, 
solutions were sterilised by u ltra filtra tio n . A ll glassware and p ipe tte  tips were 
autoclaved before use and s terile  disposable equipment used. Latex gloves were 
worn at a ll times to avoid contam ination by exogenous RNAase found on skin.
Total ce llu la r RNA was extracted  by m odifica tions of e ither the method of 
Chirgwin_et_al., (1979) or Chomczynski and Sacchi (1987) from  either fresh tissue or 
from  tissue which had been frozen and stored at -80°C im m ediate ly a fte r its  
removal from the ra t.
One gram of tissue was homogenised in 16ml of 4M guanidium isothiocyanate 
solution, pH7, containing 0.5% sodium N -lauroyl sarcosine (sarcosyl) 25mM sodium 
acetate, 0.1M 2-mercaptoethanol and 0. 1 % antifoam  A in a polytron homogeniser 
fo r 30-60 seconds at fu ll speed. The homogenate was then centrifuged fo r  1 0  
minutes at 9000rpm at 10°C in a Beckman J2-21 centrifuge (JA-17 ro to r). 
Homogenate was gently layered onto a 3.5ml of 5.7M CsCl, pH7.4, containing lOmM
EDTA, in a 13ml quickseal polyallom er centrifuge tube until all air bubbles had been 
excluded. The tubes were heat sealed and centrifuged overnight at 36,000rpm 
(20°C) in a Beckman u ltracen trifuge (60Ti ro tor).
A fte r cen trifuga tion  the liqu id  was removed leaving a pe lle t at the base of 
the tube. Excess supernatant was removed w ith  s te rile  cotton swabs and the pelle t 
resuspended in  5mls of 7.5M guanidium hydrochloride solution, pH4.5, containing 
20mM potassium acetate, lOmM DTT. The resuspended pelle t was transferred to a 
s te rile  10ml Falcon tube and dissolved by a combination of vigorous m ixing and brie f 
heating in a 6 8 °C water bath. To th is solution was added 0.23ml of 0.3M EDTA, 
0.25ml of 2M potassium acetate (pH5) and 2.5ml of ice-cold ethanol, thoroughly 
mixed and the RNA precip ita ted overnight at -20°C. The tubes were then spun at 
9,000rpm fo r 10 minutes at 10°C, the liqu id  removed and the tubes dried w ith  s te rile  
swabs. The RNA pe lle t was dissolved in 2mls o f s te rile  water and centrifuged fo r 10 
minutes at 9,000rpm and 10°C. The aqueous phase was transferred to a ste rile  
Falcon tube and the pelle t resuspended in 2ml ste rile  water prior to centrifugation  
fo r 10 minutes at 9,000rpm at 10°C. The aqueous phases were combined and 0.4ml 
3M sodium acetate (pH4.8) and 8 ml ice-cold ethanol were added. The samples were 
precip ita ted overnight at -20°C  and then centrifugation  fo r 20 minutes at 10,000rpm 
and 10°C. The supernatant was removed and all traces of ethanol wiped from  the 
tubes. The pellet was dissolved in  0.5ml s te rile  water and stored at -20°C .
For the routine extraction  o f to ta l RNA from  a large number o f tissue 
samples a m od ifica tion  of the method of Chomczynski and Sacchi (1987) was used. 
This rapid method yields RNA o f su ffic ien t qua lity fo r use in dot b lo t analysis. One 
gram of tissue was homogenised in 1ml of denaturing solution (4M guanidium 
thiocyanate, containing 25mM sodium c itra te , pH7.0, 0.5% (v/v) sarcosyl and 0.1M 
2 -m ercapto-ethanol) using a Polytron homogeniser. The homogenate was then 
transferred to a s te rile  Falcon tube and 0.1ml 2M sodium acetate, pH4, was added. 
The solution was vortexed and subsequently 1ml of water-saturated phenol and 0.2ml 
chloroform /isoam yl alcohol (49:1) were added w ith thorough m ixing a fte r each
addition. The fina l suspension was placed on ice fo r  15 m inutes prior to
centrifugation  fo r 20 minutes at 10,000gav and 4°C. The aqueous phase was
transferred to  a fresh s te rile  tube, 1 ml of isopropanol added, thoroughly mixed and
the RNA precip ita ted at -20°C fo r 1 hour. A fte r  centrifugation fo r 20 minutes at
10,000g , 4°C , the pellet was redissolved in  denaturing solution by vortexing andav
b rie fly  heating in a 65°C water bath. The RNA was again precip ita ted  fo r 1 hour at
-20°C fo llow ing the addition of one volume of isopropanol. The RNA was pelleted
by centrifugation  at 10,000g , 4°C , fo r 10 minutes. The pelle t was resuspended ina v
75% (v/v) ethanol, sedimented, vacuum dried and resuspended in  250jj1 of s te rile  
water. The resu ltan t RNA solution was stored at -20°C un til required.
2.11.2 Determ ination of RNA P u rity  and Concentration
RNA aliquots were diluted 1:1000 w ith  s te rile  w ater and transferred to 1ml 
quartz cuvettes. The samples were scanned between 200 and 320nm. RNA absorbs 
at 260nm and protein at 280nm. A 260:280 ra tio  of 2.0 is ind ica tive  of pure RNA, 
and a ra tio  of less than 2.0 assumes prote in and/or phenol contam ination. The 
concentration o f RNA is determ ined using the absorbance at 260nm where 1 O.D. 
un it is equal to 40pg/m l (Maniatis et al., 1982).
2.11.3 RNA Agarose Gel E lectrophoresis
A Biorad horizontal m ini-gel system was used w ith  a gel form er giving 
dimensions of 10cm x 7cm. The electrophoresis tank and perspex gel fo rm er were 
cleaned w ith  absolute alcohol and tape was used to seal the ends o f the gel form er. 
The method of Lehrach et_al., (1977) was adapted and used.
0.525g of agarose was dissolved in a to ta l volume of 25.2ml of RNAase free 
water by heating in a m icrowave oven and mixed w ith 6.3ml of 37% (v/v) 
formaldehyde and 3.5ml of 10 x running bu ffe r (20ml of 2M MOPS, pH7, 0.82g 
sodium acetate, 0.4ml of 0.5M EDTA). The m olten m ixture was then poured in to  the 
m in i-ge l form er and a sample comb inserted. Once the agarose had set the comb
and tape were removed and the gel slab placed in the electrophoresis tank which had 
been fille d  w ith 1 x running buffer. The gel was covered to a depth of 1cm w ith  
running buffe r and the electrophoresis tank placed on ice.
Samples fo r electrophoresis were prepared by mixing 20yg o f RNA w ith 2 y l 
of 10 x running buffe r, 3.5pl formaldehyde and 10y l o f deionised form am ide (2g 
A m berlite  MB1 resin was mixed w ith 50ml form am ide fo r 1 hour at 4°C and the 
resin subsequently removed by f iltra tio n ) . The samples were vortexed and 
centrifuged b rie fly  p rio r to incubation at 65°C fo r 15 minutes. The samples were 
cooled on ice, 2 y l of loading buffe r (50% (v/v) g lycero l, Im M  EDTA, 0.4% (w /v) 
bromophenol blue and 0.4% (w /v) xylene cyanol), vortexed and centrifuged b rie fly . 
Using a Gilson p ipette , 20jj1 of sample was loaded per well. The gel was run at 
150mA un til the bromophenol blue dye had m igrated three quarters of the length o f 
the gel. The gel was removed from  the form er and stained in ethidium  bromide 
(50yl of 20mg/ml stock solution in 150ml ste rile  water) fo r 1 hour. The RNA was 
then visualised under u ltra v io le t lig h t. I f  a permanent photographic record was 
required the gel was destained in s te rile  water p rio r to photography.
2.11.4 Preparation of F ilte rs  fo r RNA Dot B lo t Analysis
Dot b lo t analysis was carried out using a m od ifica tion  of the method of White 
and Bancroft (1982). Total RNA was dissolved in  lOOpl of s te rile  water to which 
was added 150yl o f formaldehyde and 150pl of 20 x SSC (3M sodium chloride and 
0.3M sodium c itra te , pH8 ). The samples were mixed and then incubated at 65°C fo r 
15 minutes. The nitrocellu lose f i l te r  was soaked tw ice  in 10 x SSC fo r 5 m inutes and 
placed in to  the dot blot apparatus (BRL). The RNA samples were then applied to 
the wells under a slow vacuum. The wells were subsequently washed w ith  400pl of 
10 x SSC, the f i l te r  removed and a ir dried. Once dry, the f i l te r  was baked at 80°C 
for 3 hours. The baked f ilte rs  were stored between sheets of Whatman 3MM paper 
un til required.
2.11.5 Nick Translation and Probe Preparation
The method o f nick transla tion takes advantage o f the a b ility  o f E .co li DNA 
polymerase 1 to combine the sequential addition of nucleotide residues to the 3 '- 
hydroxyl term inus of a nick (generated by DNase I) w ith  the e lim ina tion of 
nucleotides from  the adjacent 5'-phosphoryl term inus.
The nick translation k it  was purchased from  BRL and an incubation m ixture  
set up which contained lOOng insert DNA; 5 pi dATP, dGTP, dTTP; lOQyCi "^P-dCTP 
and s te rile  water to a volume of 40 y l. The m ixture  was vortexed b r ie fly  and 5 y l of 
enzyme solution (DNA polymerase 1 and DNase 1) was added. The solution was 
mixed, centrifuged b r ie fly  and incubated at 150°C fo r 2 hours. The reaction was 
term inated by the addition of 5y l of 0.3M EDTA. The radiolabelled probe was then 
diluted to  1ml w ith  0.5M NaCl in TE bu ffe r (lOmM Tris, Im M  EDTA, pH8.0).
NACS prepac cartridges (1cm x 0.5cm) containing NACS 52 (a deriva tive  o f
hydroxylapatite) were used to  remove unincorporated a [ ^ p ]  - nucleotides (M aniatis
_et_al., 1982). The column was attached to  a 2ml syringe and hydrated w ith 5 x 1ml
volumes of 2M NaCl in TE bu ffe r and equ ilibrated w ith  10 x 1ml washes o f 0.5M
NaCl in TE buffer. The column was secured in a re to rt stand and the nick
translation m ixture  loaded onto the column. The column was washed w ith  10 x 1ml
volumes of 0.5M NaCl in TE bu ffe r and eluted w ith 4 x 0.1ml aliquots of 2M NaCl in
32TE bu ffe r. A geiger counter was used to m onitor the binding o f the P labelled 
probe to the column and its  subsequent elution.
2.11.6 F ilte r Hybrid isation w ith  Radioactive Probes
The baked f ilte rs  were soaked in 5 x SSC before being transferred to 250ml o f 
pre-hybridisation bu ffe r, warmed to  42°C in a p lastic container. Pre-hybrid isation 
was carried out fo r 7 hours at 42°C in a shaking water bath. The bu ffe r was 
removed and replaced w ith  hybridisation bu ffe r containing the rad ioactive  probe 
which had previously been boiled fo r 5 minutes to denature the double stranded
DNA. The f ilte rs  were hybridised fo r  a minimum of 15 hours at 42°C in a shaking 
water bath.
Prehybridisation Buffer
Deionised form am ide 
50 x Denhardts solution
(2% w /v F ico li, 2% w/v BSA, 2% w /v polyvinyl 
pyrro lid ine)
20 x SSC
Boiled salmon sperm DNA (lO m g/m l)
Sterile water 
Poly A (20m g/m l)
Poly C (20mg/m l)
250ml 
1 0 ml 
125ml 
1 0 0 ml 
5ml 
0.25ml 
0.25ml 
1 0 ml
F ilte rs  were washed a fte r hybrid isation to remove non-specifica lly bound 
probe. The hybrid isation buffer was removed and replaced w ith  2 x  SSC, 0.1% (w /v) 
SDS fo r  three washes of 30 minutes each. This was followed by 2 x 45 m inutes 
washes w ith  0.5 x SSC, 0.1% (w /v) SDS at 55°C. A fina l wash w ith  5 x SSC was 
carried out at room tem perature fo r 30 minutes. A fte r  each wash the amount o f 
ra d io a c tiv ity  associated w ith  the f i l te r  was monitored w ith  a geiger counter. I f  at 
any stage the amount of rad ioac tiv ity  appeared to be low then the f i l te r  was 
subjected to the fin a l washing conditions. A fte r  the fina l wash was completed the 
f ilte rs  were a ir-dried on Whatman 3MM paper and then placed in an X -ray cassette 
w ith  an in tensify ing screen w ith  fast X -ray f i lm  (Kodak GB X2) fo r at least four 
days at -70°C. The X -ray f ilm  was developed and, i f  required, a quan tita tive
Hybridisation B u ffe r
Deionised form am ide 
50 x Denhardts solution 
20 x SSC
50% (w /v) dextran sulphate 
Boiled salmon sperm DNA (lO m g/m l) 
Poly A (20m g/m l)
Poly C (20mg/m l)
Sterile water
250ml
50ml
125ml
12.5ml
62.5ml
0.25ml
0.25ml
assessment of the in tens ity  o f the dots was made using a Gelman densitom eter. 
Also i f  the f i l te r  was not required fo r reprobing, a square area of f i l te r  around the 
dot, and including the dot was cut out fo r determ ination of rad io ac tiv ity  by liqu id  
sc in tilla tio n  counting.
I f  the f ilte rs  were required fo r reprobing they were washed fo r  60 minutes at 
70°C in s te rile  water, dried and again placed in a cassette w ith  X -ray  f ilm  to 
confirm  that a ll ra d io ac tiv ity  had been removed. W ith careful washing i t  was 
possible to  reprobe the f ilte rs  a maximum of a fu rth e r two times.
2.11.7 Preparation of Insert DNA
pBr322 plasmid containing either the insert DNA for the peroxisomal 
b ifunctiona l enzyme or acyl CoA oxidase were kind g ifts  o f D r T Hashimoto. The 
isolation and characterization of these cDNAs has previously been reported (Osumi 
et_al., 1984, 1985).
HB101 competent cells were purchased from  BRL and stored at -70°C  until 
required. Transform ation of these cells was carried out according to the supplied 
instructions. P rior to transform ation the competent cells were thawed on ice, 
gently mixed and lOOyl aliquots transferred to ch illed s te rile  polypropylene tubes. 
The plasmid DNA to be used fo r the transform ation was diluted w ith  50mM C aC ^, 
lOmM Tris -H C l, pH8 , to give a DNA concentration of lO ng /y l. 2 and 5 y l aliquots 
(20 and 50ng respective ly) o f diluted plasmid DNA were then added to the 
competent cells and the solution thoroughly mixed by p ipetting. A transform ation  
m ixture  containing 0.05ng o f control DNA (pBr322) was also set up in  order to check 
the e ffic ien cy  of the transform ation.
The cells were incubated on ice fo r 30 minutes, heat-shocked by placing in  a 
42°C water bath fo r 45 seconds and placed on ice fo r  a fu rthe r 2 m inutes. 900yl o f 
room tem perature LB broth (10% w /v  Bacto-tryptone, 5% w /v  Bacto-yeast ex tra c t, 
10% w /v  NaCl) was added to each tube and the tubes shaken at 225rpm (37°C) fo r 1 
hour. The reaction m ixture  was diluted 1:10 w ith  LB broth and lOOyl and 200yl
aliquots were spread onto LB plates (1.5% w /v  Bacto Agar in LB broth) containing 
e ither te tracyc line  (12.5 pg/m l) or am pic illin  (35pg/m l) or LB broth alone. The 
plates were incubated at 37°C. Aliquots o f the transformed cells were also used to  
innoculate LB broth containing te tracyc line  or am pic illin  or LB broth alone. 
A n tib io tic  containing liqu id  media which showed growth were made in to  glycerol 
stocks (fina l g lycerol concentration 15% v/v) and stored at -70°C un til required. 
Colonies were picked from  the antib io tic-conta in ing  agar plates and used to 
innoculate te tracyc line -con ta in ing  LB broth. The liqu id  cultures were incubated as 
before and g lycero l stocks made.
2.11.8 Preparation o f Plasmid DNA
Plasmid DNA was prepared by a m od ifica tion  of the alkaline lysis method of 
Birnboim and Daly (1979). An overnight cu lture  was set up by innoculating 25ml of 
LB broth, containing te tracyc line  (12.5pg/m l), w ith  lOOpl of glycero l stock and 
incubating overn ight at 37°C. A 5ml aliquot of the overnight cu lture  was then used 
to innoculate 250ml of LB -te tracyc line  broth which was shaken at 200Or pm at 37°C. 
The optica l density at 600nm of the culture was monitored un til i t  reached 0.6 - 0.7 
absorbance units. A t this point 1ml of chloramphenicol (62.5mg/ml in 100% ethanol) 
was added to the culture to give a fina l concentration of 250m g/litre  and the culture 
incubated fo r a fu rthe r 12-16 hours. The cells were then pelleted at 6000rpm fo r 20 
minutes (2°C) and the supernatant discarded. The pelle t was resuspended in 5ml of 
25mM Tris -H C l, pH8 , containing 50mM glucose, lOmM EDTA and 2m g/m l lysozyme. 
The solution was vortexed and allowed to stand at room tem perature fo r 5 minutes. 
A fte r this tim e 10ml of 0.2M NaOH, 1% (w /v) SDS was added, the solution gently 
mixed and incubated on ice fo r 5 minutes. 7.5ml of pre-cooled 5M potassium 
acetate, pH4.8, was then added, the tube mixed gently and again incubated on ice 
fo r 5 minutes. The solution was centrifuged at 20,000rpm fo r 20 m inutes and the 
supernatant transferred to a centrifuge tube to which was added 0 .6  volumes of 
isopropanol. A fte r  m ixing and standing at room tem perature fo r 15 minutes the
solution was centrifuged at 12,000rpm fo r 30 minutes at 20°C. The supernatant was 
discarded and the pelle t washed w ith 70% (v/v) ethanol at room tem perature. The 
pellet was then dried under vacuum and resuspended in 5ml of TE bu ffe r (lOmM 
Tris-H C l, pH8.0, Im M  EDTA). The solution was then transferred to  a 10ml 
measuring cylinder containing 9.5g o f cesium chloride.
The cesium chloride was disolved by gentle inversion and 300pl of ethidium 
bromide (lO m g/m l in TE bu ffe r) added to give a fina l concentration of 500pg/m l. 
The volume of the solution was then adjusted to 10ml w ith  TE bu ffe r and pipetted 
into a 13ml quick seal polyallom er tube (Beckman). The tube was then f ille d  w ith  
cesium chloride (0.95g/m l in  TE buffe r) ensuring th a t all a ir bubbles were excluded 
and heat sealed. Following centrifugation at 44,000rpm fo r 36 hours at 20°C (60Ti 
ro to r) the DNA bands were visualised under u ltra v io le t ligh t. The lower, plasmid 
DNA band was removed w ith  a hypodermic syringe and transferred to a s te rile  
Falcon tube. The ethidium bromide was then extracted w ith  equal volumes of 
cesium chloride saturated isopropanol until the top layer became clear, discarding 
the upper layer each tim e. A liquots (200pl) of the lower aqueous layer were then 
transferred in to  eppendorf tubes and 50yl of 3M sodium acetate, 250yl of s te rile  
w ater and 300yl of isopropanol were added. The solution was vortexed and allowed 
to stand at room temperature fo r 30 minutes. The tubes were then spun at 
13,000rpm fo r 15 minutes, the supernatant removed and the pe lle t dried under 
vacuum. The pellet was then resuspended in lOOpl of s te rile  w ater and stored at - 
20°C. The pu rity  of the preparation was checked by electrophoresis on 1% agarose 
gels.
2.11.9 Extraction of DNA Insert from  Plasmid
The DNA insert was cut from  the plasmid by the enzyme PST1. The reaction 
m ixture  contained lO y l of plasmid, 2.5yl o f spermidine (40mM), 2 .5y l PST bu ffe r, 
2y l PST1 and 8 y l of s te rile  water, and was incubated overnight at 37°C. When the 
reaction was complete 3y l of dye was added, the tube centrifuged b r ie fly  and then
incubated at 65°C fo r 3 m inutes. The samples were then loaded onto a 1% agarose 
gel and electrophoresed at 150mA. The gel was stained w ith  ethidium bromide as 
previously described and visualised under u ltrav io le t ligh t. An area of agarose gel 
containing the insert DNA was cut out and stored at -20°C until required.
The insert DNA purified  from  the agarose using a Geneclean k it  (Bio 101 Inc, 
CA, USA) according to  the supplied instructions. The excised agarose was weighed 
and 2 volumes of sodium iodide added. The tube was vortexed and heated at 55°C 
fo r 5 minutes or until the agarose had dissolved. Once dissolved, 5 y l of vortexed 
glassmilk was added, the tube vortexed and re-incubated at 55°C fo r a fu rth e r 5 
minutes. The tube was then vortexed, incubated on ice fo r 5 minutes, spun at 
13,000rpm fo r 5 seconds (MSE m inifuge) and the supernatant removed. The pelle t 
was then washed three times w ith  cold "NEW" buffer (-20°C) by vortexing, rapid 
pelle ting and removal of supernatant. A fte r the last wash the tube was spun fo r  10 
seconds and then pulsed to ensure the removal of all traces o f "NEW" buffer. The 
pellet was then resuspended in 5 y l of s te rile  water, vortexed and incubated at 55°C 
fo r 2.5 minutes. The tube was then spun at 13,000rpm for 30 seconds, the 
supernatant removed and reta ined. The pelle t was washed tw ice and the 
supernatants combined. The purity  o f the insert was re-checked by agarose gel 
electrophoresis and the insert DNA stored at -20°C  until required. The insert DNA 
was then utilised fo r  the preparation o fP ^p ]labe lled  cDNA probe by nick trans la tion  
as previously described.
CHAPTER 3
TISSUE DISTRIBUTION OF PEROXISOMAL B-OXIDATION AND  
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CHAPTER 3
TISSUE DISTRIBUTION OF PEROXISOMAL 3-OXIDATION AND  
LAURIC A C ID  HYDROXYLASE IN THE RAT AND THE 
EFFECT OF STARVATION ON THESE PARAMETERS IN THE LIVER.
3.1 CHEMICALS
Since peroxisomes were recognized as d is tinct ce llu la r organelles, they have 
been found in the vast m a jo rity  of mammalian tissues. The phenomenon of 
peroxisome p ro life ra tion  in both liv e r  and kidney is well documented (Hawkins et a l.,
1987). Peroxisomes have also been identified , both b iochem ically and 
im m unocytochem ically, in  a range of tissues, from  both control and hypolipidaem ic 
treated animals. These tissues include both white and brown adipose tissue, heart, 
in testine, skeleta l muscle, brain, spleen, testis, adrenal gland and ocular tissues (Bas 
and Giacobino, 1983; Alexson and Cannon, 1984; Norseth and Thomassen, 1983; 
Thorn assen _et_al., 1985; Veerkamp jjt_ a l., 1983; Veerkamp and Van M oerkerk, 1986; 
Katoh et a l., 1987; MacDonald and Swan, 1986; Dabholkar, 1988; Van Veldhoven and 
Mannaerts, 1985; Nemali _etjal.j 1988; Henry and DeMorrow, 1986). Other, tissues in 
which peroxisomal 8 -oxidation has been detected include the preputial and harderian 
glands, stomach, urinary bladder, thymus, seminal vesicle, prostate gland and 
pancreas (Leighton and Lazo, 1982).
Although the prim ary s ite  of drug metabolism is the liv e r, cytochrom e P-450 
has been detected in numerous extrahepatic tissues. These tissues include lung, 
kidney, in testine, heart, bone m arrow, ocular tissue, blood vessels, m amm ary tissue, 
adrenal gland and brain (Schwartzman eit_al., 1986,1987; Abraham et_al., 1985, 1987; 
Dees _et _al., 1982; Levere and Abraham, 1982; A troshi _et_al., 1987; Volk, e t a l.,
1988). This lis t  is fa r  from  complete and a more comprehensive lis t  of cytochrom e 
P-450 containing tissues has been compiled by Testa (1986).
The CJ and CO-1  hydroxylation of fa tty  acids have been shown to occur in a 
range of tissues including live r, kidney, lung, colon, in testine  and in 
polymorphonuclear leukocytes (Kupfer, 1980; Newton _et_al., 1985; Clancy et al., 
1984; Shak jet_al., 1985; Shak and Goldstein, 1985). I t  has been suggested th a t there 
may be two or three isozymes of cytochrome P-450 which catalyze these 
hydroxylations (O rtiz  de Montellano and Reich, 1984). These isozymes may be 
responsible not only fo r  the hydroxylation of fa tty  acids but also fo r the 
hydroxylation of eicosanoids such as prostaglandins and leukotrienes (Ball and 
Keppler, 1987; Hammerstrom _et_al., 1985; Kupfer, 1980; Shak and Goldstein, 1985; 
Sumimoto et_al., 1988).
Peroxisomal 8 -oxidation has been shown to be induced by a range of 
xenobiotic compounds and by certa in  physiological conditions, including starva tion 
(Hawkins _et jd . ,  1987). Starvation has been reported to cause an increase in 
peroxisomal 8 -ox ida tion in the liv e r of rats (Ishii _et_al., 1980b; Brem er _et_al., 1981; 
Mortensen and Gregerson, 1982; Thomassen_et_al., 1982; Hertz and Bar-Tana, 1987) 
although other groups have fa iled  to  find such an increase (Mannaerts _etjal., 1979; 
Slauter and Yamazaki, 1984; Locci-Cubeddu _et _al., 1985; Veerkamp and Van 
Moerkerk, 1986). There are reports of other enzymes of the peroxisome p ro life ra to r 
domain, namely pa lm itoy l-C oA  hydrolase and fa t ty  acid binding pro te in , being 
induced by starvation (Berge _et_al., 1984a; Berge and Aarsland, 1985; Paulussen et 
al., 1986). Starvation has been reported to depress some cytochrom e P-450 
dependent enzyme ac tiv itie s  in the ra t, and to enhance others (Kato and G ille tte , 
1965; Kato et al., 1970; Gram _et _al., 1970; Wade et al., 1985). One cytochrom e P- 
450 dependent enzyme a c tiv ity  th a t is induced is thedJ-hydroxylation o f fa t ty  acids 
in rat live r and kidney (Lu_et_al., 1969; Bjorkhem, 1973, 1976; Hasumura et a l., 
1983). Recently, two specific  isozymes of cytochrome P-450 have been shown to be 
induced by fasting, namely cytochrome P-450^ and cytochrome P-450 IV A l (Hong et 
al., 1987; Hardw ick et_al., 1987).
Therefore, in  order to  fu rthe r probe the link  between peroxisomal B-oxidation 
and m icrosomal CJ-oxidation, shown by Sharma et al., (1988a) and in  chapter 5, i t  
was decided to study these la tte r  a c tiv itie s  in a range of tissues from  contro l and 
trea ted animals. The e ffe c t of starvation on these paramteters was also studied.
3.2 RESULTS
3.2.1 Tissue distribution of cytochrome P-450
The aim of th is b rie f study was to obtain a qua lita tive , ra the r than 
quantita tive , representation o f the tissue d istribu tion of the m icrosom al co -and 
peroxisomal 8 -oxidation of fa tty  acids. Tissue samples (live r, kidney, heart, lung, 
brain, testes, in testine  and soleus muscle) were obtained from  control ra ts, and ra ts  
treated w ith  sodium c lo fib ra te  (250 m g/kg, i.p.) fo r three days, rap id ly  frozen and 
stored at -70°C until required. The tissues were then processed to  provide 
homogenate, microsomes and RNA samples. The cytochrome P-450 content of the 
microsomal samples was determined as previously described (section 2.5.1.). The 
liver and kidney m icrosomal samples produced normal reduced C O -difference 
spectra but, however, no cytochrome P-450 could be detected in the other tissues 
despite the use of large volumes of microsomal sample. A typ ica l reduced - CO- 
d ifference spectrum obtained w ith  brain microsomes is shown in F igure 3.1b, and 
from th is i t  can be seen that there is no peak at 450 nm although there is a peak at 
approxim ately 420 nm. This peak may be due to  cytochrome P-420 or due to  
contam ination of the microsomal sample w ith  haemoglobin. Figure 3.1.a shows the 
oxidized CO -difference spectrum of a brain microsomal samples which gives an 
indication of the extent of haemoglobin contam ination as the cytochrom e P-420 
makes no contribu tion to the spectrum under these conditions. There are tv/o 
methods that can be used to  quantita te cytochrome P-450 in the presence of large 
amounts of contam inating haemoglobin or at extrem ely low levels. The method o f 
Johannesen and DePierre (1978) allows fo r the estim ation of cytochrom e P-450 in  
the presence o f large amounts of haemoglobin, e.g. in  lung microsomes, by reducing
Sp
ec
tr
al
 
an
al
ys
ts
 
of 
br
ain
 
m
ic
ro
so
m
es
CL
cn
E
8
n
o
o
o
o
C
0Ucoo
c
'5
4->O
t -
CL
CD
0
>
"cji
o
C/3
jQ
03 03
*c0
TD
0
t_
0
S
£0
0
71
Ero
co
=3
<
§
o  g
"~ i 0  X —-
CL
Ero
CO
jd
cn3Ou
JD
~o
0
jQ
JD
3JD
o
u
c- **zu-> O
°  c£ E
CL 3W u
8  o
£ §■0  CO
0 0«♦- >«+-
4->V  0
>
0 
T3
O
U
■O
0o
3■O
0c_
•acoa0
CO
0  JD U
haemoglobin w ith  ascorbate and PES (phenazine ethosulphate). These conditions, 
however, are not s u ffic ie n t to  chem ically reduce the cytochrome P-450. Carbon 
monoxide is then bubbled through the m icrosomal sample which is then divided and 
the baseline recorded. The sample cuvette  is then reduced by the addition of a few  
grains of sodium d ith ion ite  and the spectrum recorded. An a lterna tive  to th is 
method is the use o f second derivative spectrophotom etry, as described by Ghersi- 
Egea et al. (1987), which involves the m athem atical analysis of the reduced CO- 
d ifference spectrum, enhancing rapid changes in the d irection of the curve w h ils t 
supressing slow changes. The presence of a trough at approxim ately 450 nm in the 
second deriva tive  spectrum indicates the presence of cytochrome P-450. F igure 
3.1c shows a typ ica l second derivative reduced CO -difference spectrum of brain 
microsomes and was derived from  the spectrum shown in Fig 3.1.b. By using th is  
method i t  was possible to show the presence of cytochrome P-450 in  the microsomes 
of heart, lung, brain, testes, in testine and soleus muscle. However, standardization 
of th is  technique to provide quantita tive results requires a large number of 
determ inations and, if  possible, the analysis of pure sample.
3.2.2 Tissue d is tribu tion  o f cytochrome P-450 IV A l
The tissue microsomal samples were analyzed fo r  cytochrome P-450 IV A l 
content by ELISA as outlined in  section 2.7.1. The samples were loaded on a prote in 
basis as the cytochrom e P-450 content was not known. I t  was not possible to  de tect 
cytochrome P-450 IV A l in the microsomal samples, apart from  liv e r and kidney. 
Figures 3.2 and 3.3 show the e ffe c t of loading increasing amounts o f ra t liv e r  
microsomes on the observed response in the cytochrom e P-450 IV A l ELISA assay. I t  
can be seen th a t the observed response is linear over low  amounts of pro te in  loaded 
(Fig. 3.2) but as higher amounts of prote in are loaded the response becomes non­
linear and eventua lly ta ils  o ff (F ig. 3.3). A s im ila r e ffe c t has been observed w ith  
human liv e r microsomes (Fig. 3.4). This may, in  part, be due to in terference in  the 
assay from  the cholate/Emulgen used to solubilize the proteins, possibly due to  
m ice lle  fo rm ation  resulting in decreased adsorption of the proteins onto the ELISA
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Figure 3.2.
Typical cytochrome P-450 IVA l ELISA calibration 
curve constructed using clofibrate induced microsomes
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Figure 3.3.
Effect of amount of protein loaded on cytochrome P-450 IV A l ELEA
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plate. W ith samples of low specific  content, such as ra t brain and human liv e r 
microsomes, large amounts of protein, and consequently detergent, need to be 
loaded onto the ELISA p la te  in order to detect the presence of cytochrome P- 
450 IV A l. Therefore i t  would appear th a t the ELISA technique is not sensitive 
enough to detect cytochrom e P-450 IV A l in  human live r samples or in ra t 
extrahepato-renal tissues.
Western blot analysis, however, does not suffer from  the same lim ita tions  as 
the ELISA assay and can handle much la rger amounts of protein. Figure 3.5. shows 
a Western blot of tissue microsomes using the antibody raised against ra t hepatic 
cytochrom e P-450 IV A l. From  th is i t  can be seen th a t cytochrome P-450 IV A l can 
be detected in  contro l ra t liv e r, kidney, lung, soleus and in induced liv e r, kidney and 
possibly testes. The presence of cytochrome P-450 IV A l in induced ra t tes ticu la r 
microsomes is equivocal, w ith  the cross-reacting proteins having a d iffe ren t 
m o b ility  to  those seen in live r. As also seen in Figure 5.11. the antibody raised to  
pure cytochrome P-450 IV A l recognizes two proteins of sim ilar e lectrophoretic  
properties. I t  was possible to detect cytochrome P-450 IVA1 in human liv e r 
microsomes by Western b lot analysis (Fig. 3.6). However, i t  would appear from  this 
b lo t tha t the human live r microsomes contain only one cross-reacting pro te in  in the 
cytochrome P-450 region, compared to  the two seen w ith  ra t liv e r microsomes. This 
one human prote in has s im ila r e lectrophoretic  properties to pure ra t  cytochrome 
P-450 IV A l.
RNA samples extracted from  the tissues were subjected to dot b lot 
hybrid ization w ith  a cytochrome P-450 IV A l cDNA probe. Cytochrom e P-450 IV A l 
mRNA was detected in  contro l brain, soleus, kidney and liv e r, and in  induced brain, 
heart, kidney and live r (data not shown).
3.2.3 Tissue distribution of lauric acid hydroxylase
The tissue microsomal samples were assayed fo r  lau ric  acid hydroxylase 
a c tiv ity  using s im ila r conditions to those optimised fo r contro l ra t liv e r, namely 
1 mg prote in incubated fo r 20 minutes at 37°C and 100 pM lau ric  acid. L ive r and
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Figure 3.6.
Western b lo t analysis o f human liv e r microsomes fo r 
cytochrom e P-450 IV A l
1  2  3  4  5  6  7
Western b lo t analysis was ca rried  out as described in  section 2.7.2. 0 .5pm o les  of 
e le c tro p h o re tica lly  pure cytoch rom e  P-450 IVA1 was loaded in track  1. In tracks  2 
and 3, 10 yg o f con tro l and induced ra t liv e r microsomes was loaded. Tracks 4-7 
conta ined 10 pmoles o f human liv e r  microsomes obtained from  d iffe re n t sources.
kidney samples were incubated fo r 10 minutes. The extracted  m etabolites were 
separated by TLC  and quantified using a TLC  plate scanner. Under these conditions 
lauric  acid hydroxylase a c t iv ity  was only detected in the liv e r and kidney of both 
control and induced rats. Accordingly, the TLC  plates were then subjected to 
autoradiography fo r 10 days. The autoradiographs appeared to be more sensitive 
than the plate scanner, w ith  fa in t bands appearing, at s im ilar R f values to 11 and 
12-hydroxylauric acid, in some tissues. These results are summarised in  Table 3.1. 
To increase the sensitiv ity  o f the assay, tissue samples (200 y l of microsomes, 
equivalent to 1-7 mg protein) were incubated fo r 18 hours at 37° and the 
metabolites analyzed as before. The results are summarised in Table 3.2. Analysing 
the TLC Plates on the Berthold TLC plate scanner enabled quantita tion o f the 
metabolites. However, th is  method of analysis does not allow  fo r the resolution of 
close running peaks, as were observed when the TLC plates were subject to 
autoradiography as before (Fig. 3.7.), and therefore the percentage product form ed 
quoted in  Table 3.2. is probably due to more than one m etabolite . When induced ra t 
liver microsomes were incubated in the absence of NADPH the lauric  acid was not 
metabolized. A ll tissues examined appeared to produce one or more m etabolites 
that were considerably less polar than the parent lau ric  acid. The production of 
these m etabolites was not NADPH dependent in induced ra t live r microsomes and 
was not a chemical degradation product of lauric  acid. The tissue d is tribu tion  of 
lauric  acid hydroxylase and cytochrome P-450 IVA1 is summarised in  Table 3.3.
3.2.4 Tissue distribution of peroxisomal B-oxidation and
bifunctional protein
The peroxisomal B-oxidation a c tiv ity  o f the tissue homogenate samples was 
determined as previously described and was detected in the live r, kidney, heart, 
intesine and soleus muscle of induced rats. No detectable a c tiv ity  was found in  lung 
or testes and l i t t le  a c tiv ity  was found in  the brain. The peroxisomal B-oxidation 
a c tiv ity  was not determined in contro l tissues due to  lack o f sample. The 
b ifunctional prote in was detectable in control and induced live r, but not o ther
Table 3.1.
Lauric acid hydroxylase activity of tissue microsomal samples 
(20 minute incubation)
Tissue Presence of spot 
of s im ilar R .^ value to 
11/12-hydroxy LA
Presence (and number) o f 
spots w ith  R^. values 
between 11/12-hydroxy LA  
and LA
Liver contro l + -
induced ^ + -
Kidney contro l + -
induced + -
Heart control - _
induced + + (2)
Testes contro l + -
induced + -
Brain contro l + (?) -
induced + -
Soleus contro l + -
induced + + ( 2)
Intestine control - + ( 2)
induced +
CDcsT+
Lung control + -
induced - -
g
greatly  reduced upon induction 
LA  = lauric  acid
Rats were dosed w ith  sodium c lo fib ra te  (230 mg/kg in  0.9% w /v  saline, i.p.) 
fo r three days p rio r to sacrifice.
Table 3.2.
Lauric acid hydroxylase activity of tissue microsomal samples
(18 hour incubation) '
Tissue Presence of spot 
of s im ilar R .^ 
value to 1 1 /1 2  
hydroxy LA
Presence (and 
number) o f spots 
w ith  Rj. values 
between 1 1 / 1 2 - 
hydroxy LA  and LA
% 11  & 1 2 - 
hydroxy L4 
(calculated t 
TLC plate 
scanner)
L iver contro l + + (3) 30b
induced3 + . + (4) 98b
Kidney contro l + + (3) 14b
induced + + ( 2) i—■
 cr
Heart contro l + - 3
induced - - 1
Testes contro l + (?) + ( 2) 4
induced + (?) + ( 1) 1
Brain contro l + - . 1
induced + (?) + ( 2) 4
Soleus contro l - - 1
induced N .D . N .D . N.D.
Intestine contro l + + (3) 1
induced + + (3) 2
Lung contro l + + ( 1 ) 7
induced + - 1
N. D. = not determined 
LA  = lau ric  acid
a Rats were dosed w ith  sodium c lo fib ra te  (250 mg/kg in  0.9% w /v  saline, i.p.) 
fo r three days p rio r to sacrifice .
b see Fig. 3.7
Table 3.3.
Summary of tissue distribution of cytochrome P-450 IV A l
Tissue Detection by 
ELISA
Western
Blot
mRNA Enzyme
a c tiv ity
L iver co n tro l + + + +
induced + + + +
Kidney contro l + + + +
induced + + + +
Heart contro l - - - +
induced - - + +
Testes contro l - - +
induced - ? - +
Brian contro l - - + +
induced - - + +
Soleus contro l - + + +
induced - - - N.D.
Intestine contro l - - - +
induced - - - +
Lung control - + - +
induced - - - +
N .D . = not determined
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tissues, by ELISA and Western b lot analysis (data not shown). RNA dot b lot 
hybrid ization showed the presence of both b ifunctional prote in and acyl-C oA oxidase 
mRNA in contro l and induced live r, induced kidney and control soleus muscle (data 
not shown).
3.2.5 E ffe c t o f fasting on cytochrom e P-450 IVA1 and
peroxisomal 3-oxidation
To examine the e ffe c t of starvation on peroxisomal 3-oxidation and the 
microsomalCJ -oxida tion o f fa tty  acids, food was w ithdrawn from  a group of ra ts fo r 
24 hours p rio r to sacrifice . The livers from  the fed and starved rats were pooled, 
form ing two groups. The analysis of these samples is summarised in F ig . 3.8 and the 
Western blot analyses shown in Figs. 3.9a. From these figures i t  can be seen that 
food deprivation fo r 24 hour increases lauric  acid hydroxylase a c tiv ity , peroxisomal 
3-oxidation a c tiv ity  and the levels of b ifunctional protein. Cytochrom e P-450 IV A l, 
when expressed as a % of to ta l cytochrome P-450 is m arg ina lly increased, but is 
unchanged when expressed as a specific  content (nmol P-450 IV A l/m g  protein).
3.3 DISCUSSION
The results presented here fo r the tissue d is tribu tion  of peroxisomal 3- 
oxidation and lau ric  acid hydroxylase are in accordance w ith  previous reports 
(Kupfer, 1980; Nemali e t _al., 1988). This study is not d e fin itive  and care fu l 
consideration must be given to the in te rp re ta tion  of these results. I t  should be 
noted tha t absolute ac tiv ities  cannot be ascribed to any tissue, except liv e r, as the 
assays were not carried out under the optim al conditions fo r the individual tissues 
studied. Extreme care should be taken in assigning a lack of a c t iv ity  in a tissue 
extract to the absence of the enzyme systems being studied. An analysis o f a tissue 
fo r the presence of a particu la r enzyme system should take in to  account the various 
component ce ll types occurring in  that tissue. Subtle changes of the enzyme 
system, in a pa rticu la r cell type, may not be detected due to  the presence of a large 
number of non-responsive cells swamping th is  e ffe c t. Immunocytochemical analysis
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and/or in situ hybrid ization w ith  specific  cDNA probes w ill be useful in analyzing 
the response of the d iffe ren t cell types. This approach w ill allow us to establish 
whether the enzymes of peroxisomal B-oxidation and cytochrome P-450 IVA1 are
CL
located w ith in  the same cells. Although the co-induction of these two paymeters in 
whole ra t  liv e r has been reported (Sharma et a l., 1988a) there are no reports of th e ir 
co-induction at a ce llu lar level. The induction of peroxisomal B-oxidation and 
cytochrom e P-450 IV A l in d iffe ren t tissues, and ce ll types, may not only be due to 
the presence of tissue (cell) specific  regulatory elements fo r these genes but may 
also re fle c t the tissue d istribu tion of the inducing agent. I t  has been shown th a t 
fo llow ing oral adm in istra tion of c ip ro fib ra te  there are re la tive ly  low  levels in the 
extraheptic  tissues o f the ra t, which is consistent w ith the hepatotrophic e ffec ts  
(i.e. hepatic peroxisome pro life ra tion  and development of live r tumours) exerted by 
this compound. The tissue d istribu tion  of c ip ro fib ra te  shows a corre lation w ith  the 
reported p le io trop ic  response (Waddell ^t_a l., 1989). Similar observations have been 
made w ith  the tissue d istribu tion o f DEHP (Daniel and B ra tt, 1974; Bergman and 
Albanus, 1987). The existence of peroxisomal B-oxidation and lau ric  acid 
hydroxylase a c tiv ity  in control tissues may re fle c t the function o f these enzymes, 
e.g. energy production or the de tox ifica tion  of fa tty  acids and prostaglandins as 
occurs in the lungs of pregnant rabbits (Powell and Solomon, 1978; Kubo et al., 
1988).
In F igure 3 .7 . i t  can be seen that the incubation of rat hepatic microsomes 
w ith  lau ric  acid fo r 18 hours results in the fo rm ation  of several m etabolites which 
are not produced when these microsomes are incubated fo r 10  m inutes under 
identica l conditions. The id en tity  and nature of the m etabolites, which have 
values in term ediate between those of lauric  acid and 1 1 / 1 2 -hydroxylauric acid, are 
unknown but the ir production appears to be NADPH dependent. I t  is possible th a t 
these metabolites are in chain (CO-2, CJ- 3 and C J -4 ) hydroxylated products, as have 
been described as being produced from  lauric  acid by the microsomes of various
it
plant species (Salain et al., 1978, 1986; Beneviste et al., 1982). Subterminal
hydroxylation o f lauric  acid and pa lm itic  acid, catalyzed by a cytochrome P-450- 
dependent enzyme system, has also been shown to occur in a fungus, Fusarium 
oxysporum (Shoun _et _al., 1985). Prostaglandins have been shown to undergo (c^-2) 
hydroxylation (Holm  ejt _al., 1985a,b). The exact iden tity  o f the previously 
undetected m etabolites, th e ir  rates of production, th e ir  cytochrome P-450 
dependency and response to  inducers remains to be determined. The function and 
significance of these metabolites also needs to be investigated as does th e ir 
relevance to the induction mechanism of peroxisome p ro life ra tion  and the to x ic ity  
of the fa t ty  acids. I t  may not necessarily be the m ajor m etabolite produced by an 
enzyme system th a t is the most im portant tox ico log ica lly  as the active  m etabolite  
may be produced in only small amounts yet be extrem ely potent. The CJ -  
hydroxylation of very long chain fa tty  acids may have a biosynthetic role in some 
tissues such as porcine epidermal keratinocytes where CJ-hydroxy acids form  part of 
the epidermal water barrier (Wertz and Downing, 1986).
The results presented here indicate that starvation increases lip id  
m etabolism , in particu la r peroxisomal 6 -oxidation and lauric  acid hydroxylase. This
•I
is in accordance w ith  previous observations (Bjorkhem, 1973, 1976; Ishii et al., 
1980a) but is the f ir s t  repo rt of these ac tiv ities  being co-induced by starvation. The 
magnitude of the response, however, is slight compared to  induction of xenobiotics, 
being comparable to the induction seen in ra ts fed high fa t diets (Nilsson e t al., 
1986). The induction o f these parameters by starva tion may have a relevance to the 
lip id  metabolism  of the diabetic state, under which conditions the CJ -hydroxyla tion 
of medium chain fa t ty  acids and peroxisomal 6 -oxidation has been shown to be 
increased (Bjorkhem, 1973, 1976; Sharma, 1988). The possible role of cytochrom e P- 
450 IV A l in  the hepatic response to diabetes is discussed in chapter 8.
CHAPTER 4
EXAM INATION OF THE EVIDENCE FOR A SOLUBLE 
CYTOSOLIC RECEPTOR FOR PEROXISOME PROLIFE RAT ORS
CHAPTER 4
EXAM INATION OF THE EVIDENCE FOR A SOLUBLE 
CYTOSOLIC RECEPTOR FOR PEROXISOME PROLFERATORS
4.1 INTRODUCTION
Many s truc tu ra lly  diverse hypolipidaem ic agents have been shown to  increase 
both hepatic peroxisome numbers and certa in  associated enzyme ac tiv itie s  when 
administered to rodents, pa rticu la rly  the induction of enzymes involved in the 
peroxisomal B-oxidation of long-chain fa tty  acids (Reddy and Lalw ani, 1983; 
Hawkins e t al., 1987). As well as inducing certa in  peroxisomal parameters, 
hypolipidaem ic agents such as c lo fib ra te , c ip ro fib ra te  and nafenopin also induce an 
isozyme of cytochrom e P-450 (P-450 IVA1) which has a high sp e c ific ity  fo r  the w- 
hydroxylation of lau ric  acid (Gibson et al., 1982; Tamburini et al., 1984).
Recently the enzymes of peroxisomal B-oxidation and cytochrom e P-450 
IV A l have been shown to be coordinately induced by hypolipidaem ic agents (Sharma 
et a l., 1988a, 1988b). In addition, chronic peroxisome p ro life ra tion  has been 
associated w ith  an increase in  the incidence of hepatocellular tumours in rodents 
(Reddy e t aL, 1980a). The mechanism of carcinogenesis o f these hypolip idaem ic 
agents is as yet unknown but i t  is w idely held that they act through a non-genotoxic 
mechanism. Furtherm ore, peroxisome p ro life ra tion  has been extensively studied
n
both iri vivo and in  v itro  and appears to be a species-specific phenomenon (Blumcke 
et aL, 1983; De La Iglesia et al., 1982; Elcombe and M itche ll, 1986; G a rio t e t al., 
1984; Gray and De La Iglesia, 1984; Hawkins, 1988; Jackh et a l., 1984; Lake et a l., 
1984; O rton et a l., 1984; Svoboda et a l., 1967).
An explanation has been sought to account fo r the species, tissue and sex 
differences in peroxisome pro life ra tion  and the mechanism o f induction o f the 
enzymes of peroxisomal B-oxidation and microsomal w -oxidation of fa t ty  acids. One 
postulated mechanism involves the existence of one or more specific  cytoso lic  
receptor(s) fo r  the peroxisome pro life ra tors (Lalwani et al., 1983a; Reddy and Rao,
1986), analogous to  the Ah receptor fo r TCDD (Nebert and Gonzalez, 1985). 
Recently, a peroxisome pro life ra tor-b ind ing  protein has been isolated from  ra t liv e r  
and p a rtia lly  characterised (Lalwani et al*? 1987).
Therefore i t  was decided to purify  the cytosolic receptor fo r peroxisome 
pro life ra tors  to  homogeneity and to  use this pure prote in to raise an antibody. W ith 
the antibody to the receptor i t  w ill be possible to  screen tissues and species using 
ELISA and Western b lo tting  techniques. Further analysis of the receptor could allow  
us to  understand the in te rac tion  between the receptor and the genes fo r  the 
enzymes of peroxisomal 8 -oxidation and cytochrome P-450 IV A l. I t  would also be 
possible to screen a range of compounds to pred ict whether they would be 
peroxisome p ro life ra to rs  in vivo by th e ir a b ility  to  bind spec ifica lly  to  the purified 
receptor in v itro . Thus, the main aim of th is  thesis is to detect spec ific  binding o f 
peroxisome p ro life ra to rs  to liv e r cytosol.
4.2 RESULTS
4.2.1 Assessment o f the Binding o f P h ] C ip ro fib ra te  andphl] Nafenopin
to  R at L iv e r Cytosol
The binding o f P h ] -c ip ro fib ra te  and P h ] -nafenopin to ra t liv e r cytosol 
was examined using the method of Lalwani et al., (1983a) as m odified by Kass 
(1985). However, under these conditions i t  was not possible to detect any 
displaceable binding, ie, a difference between the amount o f P h ] - ligand bound to  
cytosolic prote in (to ta l) and the amount bound in  the presence of excess unlabelled 
ligand (non-specific). This, in part, agrees w ith  the data o f Kass (1985) where i t  was 
found that in a re la tive ly  large number of experiments the non-specific binding was 
identica l to or higher than, the to ta l binding.
Having fa iled  to  consistently show displaceable binding using the method of 
Lalwani et ah, (1983a) i t  was decided to use a d iffe re n t ligand binding technique, 
that o f Gasiewicz and Neal (1982). This technique utilises the binding o f proteins to  
hydroxylapatite  (HAP) and has been frequently used in studies on the  TCDD
receptor.
The binding o f P h i] -c ip ro fib ra te  to subcellular fractions was studied using 
the HAP binding technique and a range of buffers. The subcellular fractions were 
dialysed overnight against the appropriate bu ffe r before assay and the 
hydroxylapatite  was resuspended in the corresponding buffer. The binding o f Ph]- 
c ip ro fib ra te  to bovine serum albumin was included as a positive control to show the 
binding o f ligand to prote in and the ligand-prote in complex to the hydroxylapatite . 
Bovine serum albumin was chosen as a positive contro l as hypolipidaem ic compounds 
have previously been shown to bind to this protein (Cayen, 1985; Meisner, 1976).
4.2.2 Binding ofpH]ciprofibrate to subcellular fractions and BSA
Table 4.1 shows the binding of P h ] -c ip ro fib ra te  to the various subcellu lar 
fractions and to  BSA. From th is  data i t  can be seen that there is no displaceable 
binding under any of the conditions used. The binding o f BSA to the hydroxylapatite  
can be taken as a validation of the binding technique. The assay re lies on the 
assumption th a t the 'receptor' is insoluble in the presence of hydroxylapatite . The 
va lid ity  of th is assumption, however, can only be resolved by studying the binding o f 
pure 'receptor' to hydroxylapatite . As a valid binding assay would be an in teg ra l 
part of the pu rifica tion  of the 'receptor' i t  is extrem ely d if f ic u lt  to determ ine 
whether the 'receptor' is soluble in the presence of hydroxylapatite . I there fo re  
believe that there is no evidence to suggest that the 'receptor' is not being detected 
due to its  in a b ility  to bind to hydroxylapatite. I t  can also be seen from  Table 4.1 
that the buffers that give the highest levels of binding to  HAP are HEDG/KC1; 
50mM HEDG and lOOmM Tris. I t  was decided to  utilise  these buffers in  fu tu re  
binding studies. BSA also showed fa r greater (30-100x) to ta l binding than the 
subcellular fractions. Potassium phosphate buffers produce the lowest levels of 
to ta l binding which is consistent w ith  th e ir use in  prote in pu rifica tion  to elute 
proteins bound to hydroxylapatite . I t  was also noted tha t there was neglig ible 
binding o f the ligand to  the hydroxylapatite (data not shown).
In order to  obviate the possibility o f the receptor being denatured by
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proteolysis during homogenate preparation phenylm ethylsu lfonylfluoride (PMSF) 
was included in the bu ffe r systems. Fresh subcellular fractions were made using 
these buffers and used to compare the binding of P h ] - c ip ro fib ra te  or P h ] - 
nafenopin using e ithe r the charcoal-dextran binding assay or the hydroxylapatite  
binding assay. This data is shown in Tables 4.2 and 4.3. In general, there does not 
appear to be s ign ificant, reproducible, displaceable binding of e ither ligand to  any of 
the subcellular fractions. The presence of PMSF in the buffer seems to give an 
increased amount of both to ta l and non-specific binding but does not seem to  a ffe c t 
the amount ( if  any) o f displaceable binding. The low  amount of displaceable binding 
seen in  certa in  cases in  Table 4.2, although s ta tis tic a lly  s ign ificant, represents a 
vanishingly low  level of binding. From th is data i t  appears that the HAP technique 
consistently gives higher values fo r  to ta l and non-specific binding than th a t of the 
charcoal-dextran method.
I t  was decided to  analyse fu rthe r the binding o f the ligands to BSA. In Table
4.4 i t  can be seen th a t i t  is possible to show displaceable binding of both P h ] -  
c ip ro fib ra te  and Ph] -nafenopin to BSA.
4.2.3 Binding o f p H jc ip ro f ib ra t e andpH]-nafenopin to  RSA
In order to  fu rth e r m im ic the binding seen in ra t liv e r cytosol the binding o f
the ligands to ra t serum albumin (RSA) was studied. When RSA was used to  obtain a 
Scatchard p lo t, a non-linear p lot resulted and i t  was not possible to draw a 
sa tis factory  line  or curve. Displaceable binding was seen at a range of ligand 
concentrations but i t  was not possible to saturate the to ta l binding. As the RSA 
used was not fa tty  acid free the anomalous Scatchard plot could be due to the 
P h ] - c ip ro fib ra te  and P h ] -nafenopin displacing fa tty  acids from  high a ff in ity  
sites and the fa t ty  acids binding to  low  a ff in ity  sites. When fa t ty  ac id -free  RSA was 
used, displacement curves and a Scatchard p lot (Figures 4.1 and 4.2) were obtained 
from which the capacity of the RSA and the dissociation constant (K ^ ) fo r
nafenopin were determined. These were 85,500 fm ol/m g and 0.52 x 10
respective ly. The spread of points that constitu te  the Scatchard p lot may represent
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a v a ria b ility  o f the binding o f nafenopin to RSA. This may be a face t of the nature 
o f the binding of peroxisome pro life ra to rs , and fa tty  acids, to albumin which has 
been shown to  possess two or more binding sites fo r these compounds. (Meisner, 
1976; Meisner and Neat, 1978). Thus, the single line drawn fo r the Scatchard p lo t 
shown in  F ig . 4.2. is most lik e ly  an approximation fo r a fa r more complex s itua tion .
One possible explanation fo r  the lack of binding to a cytoso lic  receptor could 
be that the stra in  o f rats used were unresponsive to peroxisome p ro life ra tion . To 
check th is , ra ts  were dosed fo r  three days w ith  sodium c lo fib ra te  (250mg/kg i.p .) and 
the livers analysed. The results are summarised in  Table 4.5. As can be seen the 
strain of rats used show induction of peroxisomal 8 -oxidation and cytochrom e P-450 
IV A l.
4.3 DISCUSSION
The data presented in th is chapter is not in agreement w ith  th a t o f Lalwani 
et al., (1983a, 1986, 1987). No consistent, reproducible, displaceable binding could 
be shown w ith  e ithe r [^F lj-na fenop in  or [ ^ h ] - c ip ro fib ra te  to  ra t liv e r  microsomes, 
cytosol, nuclear fra c tio n  or whole homogenate. The previously reported pool of 
displaceable binding sites in  ra t liv e r cytosol from  th is  laboratory (Kass, 1985) was 
only obtained from  a large number of determ inations, the m a jo rity  o f which showed 
no displaceable binding at all. In th is  study, i t  was also noted th a t displaceable 
binding o f Ph] -c ip ro fib ra te  could be detected in  the lysosom al/light m itochondrial 
and m icrosomal fractions.
In view of the fa c t that the previously reported receptor (Lalwani et a l., 
1983a, 1986) was iden tified  by using the charcoal-dextran binding assay, i t  is 
in form ative to note several features of this assay which may influence 
in te rp re ta tion  o f the data. The charcoal-dextran assay suffers from  several 
inherent d iff ic u ltie s , including stripping o f the [ ^ h ] - ligand from  the ligand-pro te in  
complex, the long centrifugation  tim e required to separate the charcoal-dextran 
bound ligand from  the protein-bound ligand and the in a b ility  to  analyse the nuclear
Table 4.5
Liver Parameters for Control and Clofibrate-Dosed Rats
PARAMETER CONTROL INDUCED
Peroxisomal 8 -ox ida tion1 
(nm ol/m in/m g)
8.53 -0 .3 8 30.71 -  6.26
Lauric acid (w-1) hydroxylase 
(nm ol/m in/m g) 
(nm ol/m in/nm ol P-450)
1.01 -0 .4 7  
1.37 -  0.38
1 .4 6 -0 .1 1  
2 .2 2  -  0.26
Lauric  acid (w) hydroxylase 
(nm ol/m in / mg) 
(nm ol/m in/nm ol P-450)
1.64 -  0.42 
2.32 - 0.78
5.45 -0 .5 4  
8.32 1 1.01
Tota l lau ric  acid hydroxylase 
(nm ol/m in / mg) 
(nm ol/m in/nm ol P-450) 
ra tio  (w /w -1)
2.69 -0 .5 0
3.69 -  1.08 
1.66
6.90 -0 .5 0  
10.54 - 1.08 
3.74
% Cytochrom e P-450 IV A l 0.97 -0 .2 8 22.58 - 3.28
Carnitine acetyl transferase 
(nm ol/m in/m g)
37.50 - 4.46 116.14 -  13.79
3 “Measured as CN insensitive palm itoyl-CoA oxidation 
Determ ined by ELISA 
Values are means + S.D. of duplicate determinations of four individual samples.
frac tions fo r binding. This in a b ility  to analyse the nuclear frac tions is due to  the 
globular nature of th is frac tion  which results in i t  being pelleted along w ith  the 
charcoal-dextran bound ligand, thus underestimating the amount of binding present.
Indeed, charcoal is used to remove fa t ty  acids from serum (Chen, 1967). 
Problems may also arise when studying the nature of the binding of the  ligand to the 
cytosol. As increasing ligand concentrations are used the amount of charcoal- 
dextran required to  remove the excess unbound ligand may need to be increased. 
This change in  assay conditions may present additional problems when in te rp re ting  
the data.
When analysing the data of Lalwani et al., (1983a) i t  can be seen that the 
binding characteristics assigned to th e ir receptor are low  a ff in ity  and high capacity. 
The usual c r ite r ia  fo r  designating prote in binding as a 'receptor’, ie , low  capacity- 
high a ff in ity  binding, id e n tifica tio n  of an endogenous ligand, co rre la tion  w ith  
biological response, e tc , are not adequately satisfied by th e ir  data. Table 4.6 
shows a comparison between the alleged peroxisome p ro life ra to r 'receptor' and other 
hepatic receptors and binding proteins. In addition, the fa ilu re  to detect the
receptor in heart and skeleta l muscle is not consistent w ith  the induction by 
nafenopin of peroxisomal 8 -oxidation in these tissues (M itche ll, 1985; Behrens et al., 
1983; Leighton and Lazo, 1982). I t  should also be noted th a t the  binding 
characteristics reported by Kass (1985) are based on an erroneous ca lcu la tion and 
when re-ca lcu lated, are 1.5 x 10 ^M (K ^ ) and a capacity of 670pmoles/mg cytoso lic  
prote in. These again represent high capacity, low  a ff in ity  binding which is more 
characteris tic  of binding proteins ra ther than specific  receptors.
The observed binding of [ ^ h ] - c ip ro fib ra te  and [ ^ h ] - nafenopin can be 
rationalised as binding to ce llu lar proteins other than a receptor. Indeed, i t  has been 
shown here, and by numerous other groups (Cayen, 1980a,b, 1985; Mason, 1975; 
Meisner, 1976; Meisner and Neat, 1978) th a t hypolipidaem ic agents exh ib it 
displaceable binding to  serum albumin. Other proteins that have been shown to bind 
peroxisome p ro life ra to rs  include glutathione S-transferase (Awasthi e t al., 1984;
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Fo lio t et al., 1984, 1986) and carn itine pa lm itoy l transferase 1 (Foxworthy and 
Eacho, 1988).
Lalwani et ah, (1986, 1987) have reported the pa rtia l pu rifica tion  of the 
'receptor' or peroxisome pro life ra tor-b ind ing  protein (PPbP) by ligand a ff in ity  
chromatography. This involved the covalent binding of ligand (nafenopin, 
c ip ro fib ra te  or c lo fib ric  acid) to a column support m ate ria l (F ig. 4.3) and subsequent 
a f f in ity  chromatography of rat liv e r cytosol. From this process they obtained 
proteins of m olecular weight 79, 70 ( -  2), 54 and 31kD th a t were spec ifica lly  eluted 
by bu ffe r containing hypolipidaemic ligand. The 70kD prote in was the m ajor band 
eluted and was designated PPbP. Recently, H ertz and Bar-Tana (1988) have 
detected the presence of acylated membrane and cytosolic live r proteins from 
cultured ra t hepatocytes treated w ith  Ph] -MEDICA 16, P h] -nafenopin or P h] - 
bezafibrate . These ligands all acylated several common proteins (32, 52, 56 and 
72kD) and several other proteins dependent on the ind iv idual ligand used. These 
common acylated proteins have molecular weights which are very s im ila r to those of 
the proteins isolated by a ffin ity  chromatography (Lalwani et al., 1987). The id e n tity  
of these acylated proteins and the ir ro le, i f  any, in  peroxisome p ro life ra tion , 
remains as yet unresolved.
It  has been suggested that peroxisome pro life ra tors generally a ll contain a 
carboxylic acid m oiety or a functiona l group tha t is readily converted to  a 
carboxylic acid m oiety. Exceptions to th is rule are the compounds L Y  171883 
(Eacho £ t  aL, 1986) and 2-hydroxy-3-propyl-4- [ 6 (te trazo l-5 -y l)] hexyloxy 
acetophenone or 4-THA (Foxworthy and Eacho, 1988) which contain a te trazo le  
group. This te trazo le  group, however, is a bioisostere o f the carboxylic  acid 
functional group, ie, i t  has chemical and physical s im ila rities  that resu lt in  broadly 
sim ilar biological properties (Thornber, 1979). Therefore, i t  seems surprising th a t 
Lalwani et al., (1987) chose to bind the carboxylic acid group to  the column leaving 
just the hydrophobic part o f the compounds available fo r binding to  cytoso lic  
proteins. This is shown in F igure 4.3. Therefore, only hydrophobic in te ractions are
Figure 4.3.
Ligand affin ity column material used in the purification
of peroxisome proliferator binding protein (PPbP)
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Derived from  Lalwani et al., (1986,1987).
like ly  to  take place between the a ffin ity  column m ate ria l and the proteins. This 
appears to cast doubts on any reported specific  in teractions.
In order to accommodate the d iversity o f s tructure  o f the peroxisome 
p ro life ra to rs  (Figs. 1.1 and 1 .2) i t  has been suggested (Lalwani et al., 1983a, 1987; 
Reddy and Rao, 1986) tha t there is e ither one receptor protein w ith  two or more 
receptor sites, or two or more receptor proteins w ith  a single receptor site. Indeed, 
the s truc tu ra lly  dissim ilar peroxisome p ro life ra to r Wy-14,643 did not compete w ith  
P h ]-n a fe n o p in  fo r  the specific binding sites of ra t liv e r cytosol (Lalwani et al., 
1983a). This adds great com plexity to  the understanding o f the mechanism of 
induction of peroxisome p ro life ra tion  and cytochrome P-450 IV A l.
R ecently, several groups have cast doubt on the existence of a specific  
cytosolic receptor fo r peroxisome pro life ra to rs , e ithe r due to th e ir in a b ility  to  
detect such a prote in or the postulation of a lte rna tive  mechanisms of induction 
(Chatterjee et al., 1987; Elcombe and M itche ll, 1986; H ertz and Bar-Tana, 1988; 
Sharma et al., 1988a; M itche ll, 1985; Siest ejt al., 1988; S to tt, 1988).
Other c ircum stantia l evidence that argues against the existence of such a 
receptor is the  p ro life ra tion  of peroxisomes under conditions other than the 
adm in istra tion of specific xenobiotics. These other inducers include high fa t diets 
(Neat e t al., 1980; Thomassen j 3t  al., 1982), starvation (Ishii et a l., 1980), diabetes 
(Horie et al., 1984) and cold adaptation (Nedergaard et al., 1980).
Taking the data from  this present study in conjunction w ith  an in depth 
analysis of the lite ra tu re  I conclude that there is no firm  evidence fo r  the existence 
of specific  cytosolic receptor(s) fo r the peroxisome p ro life ra tion  agents. Therefore 
other mechanisms of induction need to be evaluated and th is  problem is addressed in  
the la te r chapters of th is  thesis.
CHAPTER 5
TEMPORAL RESPONSE OF RAT LIVER TO A SINGLE DOSE 
OF SODIUM CL OF IB RATE -  BIOCHEMICAL AND IMMUNOCHEMICAL
ANALYSIS.
CHAPTER 5
TEMPORAL RESPONSE OF RAT LIVER TO A SINGLE DOSE 
OF SODIUM CL OF IB RATE -  BIOCHEMICAL AND IMMUNOCHEMICAL
ANALYSIS.
5.1 INTRODUCTION
The adm in istration of certa in  hypolipidaemic compounds to rodents results in 
a s ign ificant hepatomegaly which is due to both hypert: rophy and hyperplasia 
(Reddy and Lalwani, 1983). The hypertrophy is characterized by a p ro life ra tion  of 
the smooth endoplasmic reticu lum  and an increase in size and number of 
peroxisomes. To a lesser ex ten t there are also changes in m itochondria l size, shape 
and number (Hawkins et al., 1987). Associated w ith  the hypertrophy is an induction 
o f several enzymes as shown in  Table 5.1.
Many groups have shown co-ordinate induction of certa in  o f these enzyme 
a c tiv itie s  fo llow ing  the adm in istra tion of peroxisome p ro life ra to rs  to  rodents (Berge 
and Aarsland, 1985; F la tm ark e tjaL , 1988; Fournel et a l., 1986; Fukami et a l., 1986; 
Lake jet_al., 1984b; Oesch and Schladt, 1987; Schladt _et _al., 1987; Sharma et al., 
1988a). Other studies have fo llowed the tim e course of induction (Chatterqee et a l., 
1987; F la tm ark et_al., 1988; Hardw ick jet ja l., 1987; Harrison et al., 1988; Reddy et 
a l., 1986). Most of the studies that have shown co-ordinate induction of enzymes 
have used in vivo experim ental protocols which involved exposure of the te s t animal 
to the inducer fo r  periods o f between 3 and 14 days, w ith  biochemical analysis o f the 
liv e r at the end of th is period. Some of the previously reported tim e course studies 
have e ither used a m u ltip le  dosing protocol (Price _et_aL, 1986) or i f  a single dose of 
inducer was used then only one enzyme a c tiv ity  or associated param eter was 
evaluated (Hardwick et al., 1987; Reddy et al., 1986). The tim e course o f response 
of hepatocyte cultures to  inducers has also been reported (Chatterjee e t a l., 1987).
Table 5.1.
Enzymes induced by peroxisome proliferators
Enzyme Reference
Cytochrome P-450 IV A l
Peroxisomal B-oxidation pathway 
Catalase
Cytosolic epoxide hydrolase 
B ilirub in  UDP-glucuronytransferase 
Carn itine acetyl-CoA transferase 
Carn itine pa lm itoy l-C oA  transferase 
M icrosomal carboxyl esterase 
Acyl-C oA hydrolase 
Aldehyde dehydrogenase 
Alcohol dehydrogenase 
O rnith ine decarboxylase 
F a tty  acid binding prote in
Hardwick et a l., 1987 
Parker and Orton, 1980
Reddy and Lalw ani, 1983
Reddy and Lalw ani, 1983
Oesch and Schladt, 1987
Fournel et al., 1986
Markwell et a l., 1977
Sharma et a l., 1988a
Ashour et al., 1987
Berge and Thomassen, 1985
Kramar and Krem ser, 1984
Lamboeuf and Blanquat, 1980
Fukami et al., 1986
Kawashima et al., 1985
To fu rthe r define the relationship of some of these inducible enzyme 
a c tiv itie s  i t  was decided to study the tim e course o f induction in ra t  liv e r  fo llow ing  
a single dose of the peroxisome p ro life ra to r sodium c lo fib ra te .
5.2 RESULTS
5.2.1 Parameters evaluated fo r  the tim e  course o f induction.
The tim e course o f induction was followed at three levels, fo llow ing a single 
in traperitoneal (i.p.) dose of sodium c lo fib ra te , namely:
(i) Enzyme a c t iv ity
(ii)  Immunodetectable protein
( iii)  mRNA
The data re la ting  to  the molecular biology o f induction w ill be presented in  
chapter 6 .
The animals were dosed and subcellular fractions obtained as previously 
described in sections 2.2. and 2.4. respectively. The 0 hour tim e point samples were 
obtained from  non-dosed animals. A ll dosing was performed at the same tim e  of day 
(0900 hours) and the animals sacrificed at the appropriate tim e. The parameters 
u tilized  to  define the tim e  course of induction are outlined in tables 5.2. - 5.4.
5.2.2 B iochem ical analysis o f induced tim e  course samples.
The e ffe c t of a single i.p. dose of sodium c lo fib ra te  on the live r/body  weight 
ra tio  and to ta l cytochrome P-450 specific  content are shown in  Figures 5.1. and 5.2. 
respective ly. For both o f these parameters there appears to be no s ta tis tic a lly  
s ign ificant increase (p=0.05) above contro l values although a trend is evident. The 
tim e course o f response of glutathione peroxidase and benzphetamine N - 
demethylase enzyme activ ities  (Figs. 5.3a and 5.4. respective ly) show no 
s ta tis tica lly  s ign ifican t (p=0.05) increases or decreases compared to the 0 hour 
values. There have been con flic ting  reports of the response of g lu ta th ione 
peroxidase fo llow ing the adm inistration of peroxisome pro life ra tors  (Antonenkov e t
Table 5.2.
Enzyme activities parameters studied
Enzyme A c t iv ity Enzyme System Subcellular
F raction
Laurie acid hydroxylase Cytochrome P-450 IV A l Micros omes
Benzphetamine N-demethylase Various cytochrome P-450 
isozym es
Micros omes
CN" insensitive 
palm itoyl-CoA oxidation
Peroxisomal A cy l-C oA  oxidase Homogenate
C arnitine acetyl-CoA 
transferase
Carnitine acetyl transferase Homogenate
G lutathione peroxidase Glutathione peroxidase Cytosol
Table 5.3.
Immunochemical analyses of time course samples
Assay Protein detected Subcellular F raction
Western B lot qua lita tive
Cytochrome P-450 IV A l Micros omes
ELISA quantita tive
Western B lot qua lita tive
Bifunctiona l Enzyme Homogenate
ELISA quantita tive
Table 5.4.
Other parameters studied
R ela tive  liv e r weight
Total cytochrome P-450 specific  content
Figure 5.1.
Temporal response of liver body weight ratio to the administration 
of a single i.p. dose of sodium clofibrate (250 mg/kg)
to >4 7J
H O U R S
t  i h e
Each tim e  point is the mean of three samples, except fo r the 0 hour tim e  point 
which is the mean of eight samples.
100% = 4.93 g live r/100  g body weight
F igure 5.2.
Temporal response of total cytochrome P-450 to the administration 
soo
CDQ£t—
2
CDO
U.
CD
of a angle i.p. dose of sodium clofibrate (250 mg/kg)
200
100
o 4 e 12 16816 24 7220
H 0 U R 8
TIME
Each tim e  point is the mean of duplicate determ inations o f three samples, except 
fo r  the 0  hour time point which is the mean of duplicate determ inations of e ight 
samples.
1 0 0 % = 0.62 nmoles cytochrome P-450/mg protein.
values fo r results s ign ifican tly  d iffe re n t (Student's t-te s t) from  con tro l data (0 hr tim e  point) at: 
PC0.05; * *  PC0.01; * * *  P<0.001.
Figure 5.3a.
Temporal response of glutathione peroxidase to the administration 
of the single i.p. dose of sodium clofibrate (250 mg/kg)
>00
0 4 I  W *4 *0 71 I I I
H O U R 8
T I M E
Each tim e  point is the mean of duplicate determ inations of three samples, except 
fo r  the 0 hour tim e point which is the mean of duplicate determ inations of e ight 
samples.
100% = 0.693 ymoles NADPH oxidised/m in/m g protein.
Figure 5.3b.
Effect of sodium clofibrate and ciprofibrate on in vitro  
glutathione peroxidase activity in control ra t liver cytosol
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al., 1987; Hietanen _et _ah, 1983; C irio lo  _et _al., 1982, 1984). Most groups have 
reported a decrease in glutathione peroxidase a c tiv ity  upon chronic adm in istra tion 
of peroxisome pro life ra tions. I t  has been reported that c ip ro fib ra te  is an 
irrevers ib le  in h ib ito r of glutathione S-transferase (Awasthi &t_al., 1984), an enzyme 
which also has glutathione peroxidase a c tiv ity . Therefore the possib ility  o f in v itro  
inh ib ition  of the Se-dependent glutathione peroxidase was examined, the results of 
which are shown in  F ig . 5.3b. No such inh ib ition  of glutathione peroxidase a c tiv ity  
in contro l ra t liv e r  cytosol was observed even at concentrations of up to 1 mM 
c ip ro fib ra te  or sodium c lo fib ra te .
The reverse phase HPLC analysis of the hydroxylation products of lau ric  acid 
shows a p re fe ren tia l induction of the 1 2 -hydroxylase (U  -hydroxylase) a c tiv ity  over 
the 11-hydroxylase (CJ -1 hydroxylase) a c t iv ity  (Figs. 5.5 - 5.7) as illu s tra ted  by the 
increase in the ra tio  o f the CJ : CJ -1 hydroxylated products. Both enzymic 
parameters are s ig n ifica n tly  induced at several points throughout the tim e course 
and both show a biphasic response w ith  peaks at approxim ately 30 minutes and 18 
hours post dose. The m ajor peak o f induction occurs 18 hours post dose and at th is 
tim e the (C J-1) hydroxylase and U )-hydroxylase ac tiv itie s  are induced 3.5 and 6 -fo ld  
respective ly. Lauric acid has been shown to be a suitable marker substrate fo r 
cytochrome P-450 IV A l (Gibson j 3t_al., 1982).
Peroxisomal B-oxidation, as measured by the CN"-insensitive oxidation of 
pa lm itoy l-C oA , also shows a sign ificant increase fo llow ing adm in istra tion o f sodium 
c lo fib ra te  (Fig. 5.8). However, in  contrast to the biphasic response of the laura te  
hydroxylases there appears to be a monophasic response w ith the peak level o f 
enzyme a c tiv ity  occurring between 18 and 24 hours post dose, representing 
approxim ately a fo u r-fo ld  increase over control (zero tim e) values. C arn itine  
acetyl-CoA transferase, which is involved in the transfer of fa tty  acyl-CoA 
derivatives though the m itochondrial and peroxisomal membranes, is also 
s ign ifican tly  increased in a biphasic manner fo llow ing adm in istra tion o f sodium 
c lo fib ra te  (Fig. 5.9).
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5.2.3 Immunochemical analysis of induced tim e course samples.
The content of cytochrome P-450 IVA1 in  m icrosomal samples was 
determined by ELISA and was shown to respond to adm in istration of sodium 
c lo fib ra te  in a s ign ificant biphasic manner (F ig. 5.10). This response appears to 
m im ic that of lauric  acid CO -hydroxylase a c tiv ity , the marker a c tiv ity  fo r 
cytochrome P-450 IV A l. The level of th is isozyme in  contro l microsomes is 1-2% of 
to ta l cytochrom e P-450 which is s ligh tly  lower than that reported by other workers 
(Hardw ick j j t  _al., 1987; Sharma j j t  _al., 1988a) and reaches a maximum level of 
approxim ately 6% a fte r  24 hours post dose. Western b lo t analysis o f the tim e course 
samples is shown in Figure 5.11. I t  can also be seen th a t the antibody raised to  
e lec trophore tica lly  homogenous cytochrome P-450IVA1 recognizes two proteins of 
s im ilar m olecular weight. The Mowjer molecular weight prote in of th is pair appears 
to have s im ila r e lectrophoretic  properties to  that of cytochrome P-450 IV 'A l. The 
id e n tity  and significance of the second band are discussed section 5.3.
The level of peroxisomal b ifunctional enzyme in live r homogenates was 
determined by ELISA and the tim e course of its  induction is shown in F igure 5.12. 
The absolute amount of th is protein could not be determined due to  the lack o f 
ava ila b ility  of pure b ifunctional enzyme as a standard. Levels were expressed in 
re la tion to a ca lib ra tion  curve derived from  contro l ra t live r homogenate. The 
b ifunctiona l enzyme may possibly show a biphasic response w ith  a m ajor peak 
between 18 and 24 hours post dose and the m inor peak a fte r approxim ate ly 2 hours. 
There was an 11-fold increased in  b ifunctional enzyme at the tim e o f m axim al 
induction. Western b lot analysis of the homogenate samples showed a sim ilar 
pattern of response to th a t obtained by ELISA (Fig. 5.13). Two lower m olecular 
weight proteins are also recognized by the antibody to  b ifunctional pro te in . These 
represent proteolysis products and have previously been reported (Nem ali e t al., 
1989).
The b ifunctiona l enzyme has been shown to be peroxisomal in o rig in  although 
there may be a small microsomal localisation (Cook ^ t_ a l., 1987; Ghesquier e t a l., 
1987).
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5.2.4 Correlation M atrix analysis of parameter changes.
In order to ra tiona lize  the in ter-re la tionsh ip  between the parameters studied, 
a corre la tion  m atrix  was constructed to highlight any positive or negative 
corre lations tha t may exist. The m atrix  (Fig. 5.14) was constructed using the means 
of the tim e point groups ra ther than the individual samples values. In th is  way i t  was 
hoped to  avoid undue bias in the analysis due to  a large number of variables 
c lustering around the contro l value end of the regression line. Also, a large number 
of observations can lead to the appearance o f s ign ifican t spurious corre lations in  the 
m a trix  due to the large degrees of freedom involved. In th is m atrix , fo r  fourteen 
observations, and twelve degrees of freedom, the corre la tion coe ffic ie n t in a linear 
regression analysis is s ign ifican tly  related (99% probab ility ) i f  the corre la tion 
co e ffic ie n t is greater than 0.661. From this analysis inferences can be drawn as to 
the relationship between the corre lated parameters.
The measurement o f to ta l cytochrome P-450 only appears to  corre la te  
s ign ifican tly  w ith  the ra tio  of CJ IoJ -1 hydroxylated products of lauric  acid and does 
not appear to be specific  marker fo r microsomal or peroxisomal changes. 
Cytochrome P-450IVA1 content correlates well w ith  the peroxisomal parameters 
(peroxisomal 3-oxidation, b ifunctional enzyme level and carn itine  ace ty l-C oA  
transferase) and w ith  the CJ-hydroxylase a c tiv ity  of the microsomes. The CJ-1 
hydroxylase a c tiv ity  appears only to corre late w ith  the w -hydroxylase a c tiv ity . The 
liver/body weight ra tio  does not appears to corre la te  w ith  any other parameter 
fo llow ing a single dose o f sodium c lo fib ra te .
5.2.5 Analysis of liver samples following saline administration
In order to ascertain whether any of the observed responses, p a rticu la rly  the 
biphasic response, was due to either the stress of the in jection  or to natural diurnal 
variations in enzyme levels and ac tiv ities , the -tim e  course of response fo llow ing  a 
single i.p . dose of 0.9% (w /v) saline was studied. The tim e  course fo llow ed was from  
0 to 18 hours, w ith  the zero tim e point (or contro l) animals not being in jected .
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Specific content 
GPX
BZP
RLW
LA 11-OH
LA 12-OH
Ratio 12/11
Cytochrome P-450 IV A l
Peroxisomal 6 -oxidation 
B ifunctional enzyme 
CAT
nmoles cytochrome P-450/mg protein
glutathione peroxidase a c tiv ity  (pmoles NADPH 
oxidised/m in/m g protein)
Benzphetamine N-demethylase (nmol HCHO 
form ed/m in nmol P-450)
re lative live r weight (liver/body weight ra tio )
lauric acid 11 -hydroxylase a c tiv ity  
(nmol fo rm ed/m in /nm ol P-450)
lauric acid 1 2 -hydroxylase a c tiv ity  
(nmol fo rm ed/m in /nm o l P-450)
ra tio  of rates of production of 11-OH and 12-OH 
lauric  acid
Cytochrome P-450 IV A l content (determ ined by ELISA) 
expressed as a percentage of to ta l cytochrom e P-450.
CN" insensitive pa lm itoy l-C oA  oxidation
Bifunctional enzyme content determined by ELISA, 
e
Carnitine ac^ftyl-CoA transferase a c tiv ity .
Sim ilar parameters to the induced tim e course were studied, i.e . peroxisomal 13- 
oxidation; b ifunctiona l enzyme level; cytochrome P-450 IV A l content; to ta l (11+12) 
lau ric  acid hydroxylase (by TLC); re la tive  liv e r weight and specific  content of to ta l 
cytochrom e P-450. Western b lot analyses fo r  cytochrome P-450 IVA1 and 
B ifunctiona l enzyme were also performed.
For a ll parameters studied there were no sign ificant diurnal variations 
observed or evidence of a response to the stress of the in jection  (data not shown).
5.3 DISCUSSION
The data presented in th is chapter shows a clear biphasic response in 
cytochrome P-450 IV A l, and its  marker enzyme a c tiv ity  (lauric ac idu)-hydroxylase) 
to  the adm in istration of a single in traperitonea l dose o f sodium c lo fib ra te . 
Carnitine acetyl-CoA transferase also shows a s im ila r pattern of induction whereas 
the peroxisomal markers (CN” insensitive pa lm itoyl-C oA  oxidation and b ifunctiona l 
enzyme content) show equivocal evidence of a biphasic response. This is the f ir s t  
report of a biphasic response of a cytochrome P-450 isozyme to  an inducer. 
However, i t  should be noted that few studies, i f  any, have been carried out using 
such short tim e points. This biphasic response appears to be a real response, and not 
an a rte fac t arising in  the analysis of the samples, because of the range of 
parameters th a t show th is response. Also, each point on the tim e course curve 
represents the mean of duplicate analyses o f samples from  three ind iv idual animals. 
Therefore the f irs t,  minor peak is not lik e ly  to  be due to the inclusion of one 
"sensitive" animal. The control (0 hour) group consists of eight ind iv idual animals. 
The biphasic nature of the response w ill be fu rth e r discussed in section 6.3.
The corre la tion  m atrix , generated from  the means of the groups, shows a 
s ign ifican t re lationship (p=0.01) between cytochrome P-450 IVA1 content and 
peroxisomal parameters. This is in accordance w ith  the co-induction observed by 
Sharma et al. (1988a) fo llow ing m u ltip le  dosing w ith  a range of hypolip idaem ic 
compounds.
There is no sign ificant hepatomegaly as seen w ith  prolonged adm in istration of 
peroxisome p ro life ra to rs  (Sharma _et _al., 1988a). This may be due to the 
incorporation of newly synthesized proteins in to  pre-existing membranes in the 
in it ia l stages o f the response. This may be fo llowed by an increase in  the re la tive 
area o f the endoplasmic reticulum  and an increase in peroxisome numbers and 
perisomal volume upon sustained induction of microsomal and peroxisomal proteins. 
This is in accordance w ith reports tha t the increase in peroxisomal B-oxidation is 
largely dissociated from  hepatomegaly and peroxisome p ro life ra tion  in the rat 
(Lazarow jj t ja l : ,  1982; Eliassen and Osmundsen, 1984).
The h a lf- life  of the peroxisomal proteins appears to be of the order of 2-3 
days. This is in accordance w ith the estimations o f M iyazawa _et_al., (1980a) which 
were derived from  the withdrawal of inducer in a feeding study. Lauric acid 
hydroxylase a c tiv itie s  and cytochrome P-450 IVA1 also have ha lf life s  of 
approxim ately 2-3 days.
Several highly s ign ificant correlations are shown in Fig. 5.14. However, 
in te rp re ta tion  o f the corre lation m atrix  must be undertaken w ith  care. Any 
observed corre la tion  between parameters, especially a fte r m u ltip le  dosing of 
inducer, can only te ll us th a t at the end of the study the parameters are re la ted  but 
not the mechanism by which this end point was achieved. It  may be that the 
parameters are linked by a common mechanism o f induction, or th a t the induction of 
one parameter may require the prior induction of another parameter.
The major peak of enzyme a c tiv ity  and immunodetectable pro te in  levels 
appear to occur between 18 and 24 hours post dose w ith  the inference tha t the la u ric  
acid 6 J -hydroxylase a c tiv ity  reaches a peak before the peroxisomal B-oxidation 
a c tiv ity . To investigate whether there is a sequential induction of these enzyme 
a c tiv itie s  i t  w ill be necessary to repeat the tim e course concentrating on the tim e 
points between 18 and 24 hours. It would also be advantageous to e ither use a higher 
dose of sodium c lo fib ra te  or a more potent peroxisome p ro life ra to r, such as
c ip ro fib ra te  or methyl clofenapate, in order to emphasise the induced a c tiv itie s  over 
th e ir contro l levels. Even i f  i t  was possible to dissect the tem poral induction of two 
enzyme ac tiv ities  i t  would not conclusively prove th e ir sequence of induction. Their 
rates of induction w ill re fle c t the rates of DNA transcrip tion, mRNA s ta b ility  and 
transla tion, the incorporation of haem into the apoprotein (in the case of 
cytochrom e P-450) and the translocation o f the prote in to its  u ltim a te  subcellular 
location. A ll these processes may mask any fine  temporal differences in the 
induction of enzyme ac tiv ities .
There are fundamental differences in  the enzyme assays used as peroxisomal 
and m icrosomal enzyme activ ities . The assay fo r  acyl-CoA oxidase (CN" insensitive 
pa lm itoy l-C oA  oxidation) is performed on solubilised homogenate and is not a 
measure of the function ing in tac t peroxisomes. The solubiliza tion process could also 
lead to  the quantita tion of acyl-CoA oxidase which has not yet been incorporated 
in to  the peroxisomes. The assay of microsomes fo r  lau ric  acid hydroxylase a c tiv ity  
is a measure o f the in te rac tion  of cytochrome P-450 IV A l haemoprotein, NADPH- 
cytochrom e P-450 reductase, cytochrome b^ and its  lip id  environment, and as such 
is a re fle c tion  of the a c tiv ity  of the in ta c t system. These differences may have 
subtle e ffec ts  on the in te rp re ta tion  of the observed enzyme ac tiv ities .
I t  can be seen in  F igure 5.11 that the antibody to  cytochrom e P-450 IV A l is 
not m onospecific but recognizes two bands o f s im ila r molecular weight. The lower 
molecular weight prote in (51,500 daltons) appears to have identica l e lectrophore tic  
properties to th a t of pure cytochrome P-450 IVA1. This cross re a c tiv ity  is iden tica l 
to that observed by Hardw ick et _al., (1987) who independently purified  cytochrom e 
P-450 IV A l and raised an antibody to this protein. L i t t le  is known about the id e n tity  
and substrate sp e c ific ity  o f this second band. I t  is assumed that i t  is an isozyme of 
cytochrom e P-450 and from  Fig. 5.11. i t  would appear th a t the two proteins are co- 
ord inate ly regulated. Both bands are present in contro l and induced ra t liv e r 
microsomes. R ecently i t  has been reported (Gonzalez, 1989) th a t a second cDNA 
species has been obtained by screening a rat liv e r  cDNA lib ra ry  w ith  the
antibody to  cytochrom e P-450 IV A l. This cDNA has approxim ately 75% nucleotide 
sequence homology to the cDNA fo r cytochrome P-450 IV A l and may represent a 
cDNA species re la ted to  the second prote in  band seen by Western b lo t analysis. I t  
has been calculated (Hardwick j 3t_al., 1987) th a t the m olecular weight of th is  second 
band is approxim ate ly 52,000 dal tons. As there is presently no firm  evidence as to 
whether the two bands seen on a Western b lot represent two d iffe re n t proteins i t  
may be that they represent one prote in which has undergone post-translationa l 
m od ifica tion  such as peptide cleavage or glycosylation.
The existence of this second, cross reacting, band in the Western b lot puts 
great res tric tions  on the in te rp re ta tion  of data generated by ELISA analysis. The 
levels of cytochrom e P-450 IV A l detected by ELISA w ill be a summation of the 
contribu tion .of both bands. The re la tive  levels o f these two proteins is presently 
unknown due to lack o f in form ation on the re a c tiv ity  o f the upper band w ith  the 
antibody. I t  should be noted th a t these two bands can only be separated under 
certa in  conditions as outlined in  section 2.7.2a, namely a resolving gel of a minimum 
length of 13 cm and consisting of 7.5% acrylam ide. By either increasing the 
percentage of acrylam ide in the resolving gel, or reducing the length of the 
resolving gel, the resolution o f these two bands is lost. Recently, K if fe l e t al., 
(1988), have purified  an isozyme of cytochrome P-450 from  c lo fib ra te  treated rat 
liv e r and have postulated tha t i t  is d iffe re n t from  cytochrome P-450 IV A l. 
However, su ffic ie n t resolving conditions were not used fo r the Western b lot analysis 
and therefo re  the relationship o f the ir isozyme and cytochrome P-450 IVA1 is 
unclear. Due to the existence of these two closely re la ted bands the best method 
fo r quantita tion of cytochrome P-450 IVA1 would be Western b lo t analysis. 
However, th is  method is tim e consuming and is not conducive to the screening o f a 
large number o f samples. Both methods of analysis w ill lead to the quantita tion of 
both apoprotein and functiona l protein. This may lead to  some discrepancy between 
enzyme a c t iv ity  and estimated isozyme levels.
An a lterna tive  method of expressing cytochrome P-450 IV A l content, ra ther 
than as nmol/nmol to ta l P-450, is as nm ol/pg protein. This obviates the problems of 
quantita tion of apoprotein and the presence of cytochrome P-4z0 in  the microsomes 
which, although not being represented in the estim ation o f to ta l cytochrom e P-450 
would contribu te to any estim ate of cytochrome P-450 IV A l content. In th is study 
the tim e course was identica l regardless of whether the cytochrom e P-450 content 
was expressed as a percentage of to ta l P-450 or as a specific  content.
None of the parameters studied show sign ificant diurnal variations such as 
have been reported fo r to ta l cytochrome P-450 content (Haen and G olly, 1986), 
re la tive  liv e r  weight, certa in  microsomal enzyme ac tiv ities  (Chedid and N a ir, 1972) 
and the inducing a b ility  o f benzo(a)pyrene (Belanger et al., 1986). There may indeed 
be subtle diurnal variations in the enzymes of hepatic fa tty  acid oxidation which 
may be detected w ith  a greater number of animals per group.
In conclusion, there appears to be a de fin ite  biphasic response of cytochrome 
P-450 IV A l and lau ric  acid hydroxylase to the adm in istra tion of a single dose of 
sodium c lo fib ra te . The response of peroxisomal 13-oxidation is monophasic in nature, 
although b ifunctiona l prote in may respond in a biphasic manner. There are 
indications tha t the main peak o f lau ric  acid hydroxylase a c tiv ity  precedes th a t o f 
peroxisomal 3-oxidation.
CHAPTER 6
TEN/P ORAL RESPONSE OF RAT LIVER TO A SINGLE DOSE 
OF SODIUM CL OFIB RATE -  MOLECULAR ANALYSIS
CHAPTER 6
TEMPORAL RESPONSE OF RAT LIVER TO A SINGLE DOSE 
OF SODIUM CL OPERATE -  MOLECULAR ANALYSIS
6.1 INTRODUCTION
In the past f ive  years the study of the molecular biology of the phenomenon 
of peroxisome p ro life ra tion  has become a rapid ly expanding fie ld . This has, in  part, 
been due to  a desire to understand the regulation of the genes of the "peroxisome 
p ro life ra to r domain" and also a desire to understand the molecular basis of the 
human inherited peroxisomal disorders.
The genes fo r  several of the peroxisomal, and associated, enzymes have been 
cloned and th e ir nucleotide sequences elucidated. However, l i t t le ,  i f  any, 
in fo rm ation  is available as to the nucleotide sequence of the 5' and 3'-non coding 
regions of these genes.
The gene fo r  ra t cytochrome P-450 IV A l has been cloned independently by 
two groups (Hardw ick et__al*> 1987; Earnshaw et__al«> 1988), w ith  the two genes being 
essentially identica l apart from  the presence of an additional 75 nucleotides inserted 
in to  the 31 non coding region of the cDNA sequenced by Earnshaw et al. This 
d ifference has been ascribed to  d iffe ren tia l splicing. Neither group has reported the 
nucleotide sequence of the 5' regulatory region of the gene.
The genes of several of the enzymes of peroxisomal B-oxidation have been 
cloned. These include the genes fo r ra t acyl-CoA oxidase (Osumi et__al., 1984), ra t 
peroxisomal enoyl-CoA hydratase: 3-hydroxyacyl-CoA dehydrogenase b ifunctiona l
protein (Osumi et al., 1985; Chatterjee et al., 1987) and ra t 3-ke toacy l-C oA
thiolase (Osumi et a l., 1987). Recently, the nucleotide sequence of the gene coding
fo r  human peroxisomal 3-oxoacyl-CoA thiolase has been reported (Bout e t al.,
1988). The 5' flanking sequences fo r the rat genes coding fo r  acyl-C oA oxidase and 
the b ifunctional prote in have been studied (Osumi et__al., 1987). They have been 
shown to  share several common features, both genes lacking a TA TA  box, which is a
general prom oter signal of many genes of higher eukaryotes, in th e ir putative 
promoter regions. Instead, they both contain a GC box which has recently  been 
found in  the promoters of various genes and shown to be the binding s ite  of a 
transcrip tion fac to r, Spl (Kadonaga et al, 1986). Recently cytochrom e P-450 IV A l 
has also been shown to  lack a TATA box (Gonzalez, 1989).
Several groups have used cDNA probes to  analyse the changes in mRNA 
levels fo llow ing the adm in istration of peroxisome pro life ra to rs  to rats. These 
studies have shown th a t the observed increases in the mRNAs fo r  cytochrom e P-450 
IV A l, acyl-CoA oxidase and the b ifunctional prote in are due to transcrip tiona l 
activa tion of these genes (Reddy et aK, 1986; Osumi et ah, 1985; C hatte rjee  e t al., 
1987; Hardwick et al., 1987). These increases in the ra te  of transcrip tion  have been 
shown to occur in vivo as early as one hour a fte r adm in istra tion o f inducer (Reddy et 
al., 1986; Osumi et al., 1985; Hardwick et al., 1987). However, when a rat 
hepatocyte cu lture system was used there appeared to be a 10-15 hour delay before 
increased levels of b ifunctional protein mRNA were detected (C hatterjee et al., 
1987).
In th is chapter the levels, and in te r-re la tionsh ip , o f the mRNAs fo r 
cytochrome P-450 IV A l, acyl-CoA oxidase and b ifunctional prote in were studied 
fo llow ing the adm in istration of a single i.p . dose of sodium c lo fib ra te . This 
complements the data present in Chapter 5.
6.2. RESULTS
6.2.1 Extraction of RNA
Total RNA was extracted from  live r by the method of Chomczynski and 
Sacchi (1987) as outlined in section 2.11.1. The RNA preparations obtained by th is  
method contained ribosomal RNA, messenger RNA and traces o f a sm all molecular 
weight species o f RNA which was te n ta tive ly  id en tified  as transfe r RNA. A lthough 
th is method did not produce RNA samples that were of as high p u rity  (i.e. free  from  
low m olecular weight contam ination) as did the caesium chloride gradient 
centrifugation  method, the RNA was of su ffic ien t qua lity  fo r use in  RNA dot b lot
hybrid ization experiments. The difference between the RNA samples obtained by 
these methods is shown in Fig. 6.1. The number o f samples tha t can be com fortably 
handled by the caesium chloride gradient method is lim ite d  by the number of quick 
seal tubes tha t can be accommodated in the centrifuge ro to r (usually 8), the length 
of centrifugation  (36 hours) and the high cost of the caesium chloride used to  form  
the gradient. The method of Chomczynski and Sacchi (1987) allows fo r the 
simultaneous handling o f up to  30 samples at re la tive ly  low  cost, w ith  the extraction 
procedure taking approxim ately 24 hours. Therefore, i t  was only log is tica lly  
feasible to  handle a large number of tissue samples by using the "rap id " extraction  
method.
6.2.2 Preparation o f cDNA probes
The cDNA probes used in th is study were either provided as insert DNA 
(cytochrome P-450 IV A l and actin) or as insert DNA in plasmid (acyl-CoA oxidase 
and b ifunctional protein) as indicated in  section 2.1 . In order to produce su ffic ien t 
amounts o f insert DNA fo r acyl-CoA oxidase and b ifunctiona l prote in , i t  was 
necessary to  transfect E.Coli HB 101 cells w ith  the plasmid and make bulk plasmid 
preparations as described in sections 2.11.7 - 2.11.9. Insert DNAs corresponding in 
size to  those reported by Osumi et al., (1984,1985) were obtained. I t  was noted that 
the acyl-CoA oxidase cDNA insert was prone to being lost in the fin a l Geneclean 
steps and gave high background non-specific binding when used in  RNA dot blot 
analysis.
6.2.3 H ybrid iza tion  o f RNA to  cytochrome P-450 IV A l,
b ifunctiona l prote in and acyl-CoA oxidase cDNA probes
The RNA samples were analyzed either ind iv idua lly , or pooled to provide 
time point samples, by hybrid ization to P ^J -la b e lle d  cDNA probes. Figs. 6.2 - 6.4 
show the tim e course of increase in the levels of the mRNAs fo r  acyl-C oA oxidase, 
b ifunctional prote in and cytochrome P-450 IV A l. As can be seen in  F ig . 6.2. 
cytochrome P-450 IV A l mRNA shows a biphasic response to a single i.p . dose of 
sodium c lo fib ra te . This is in accordance w ith the increased seen in  cytochrom e P-
Fig. 6.1.
Agarose gel electrophoresis o f RNA samples obtained 
by tw o d iffe re n t ex tra c tion  procedures.
Track 1
Track 2
Track 3 
T rack 4
Track 3 
Track 6
C on tro l ra t liv e r, caesium ch lo ride  g rad ien t, 20 yg R N A 
loaded.
Na c lo fib ra te  trea ted  ra t liv e r , caesium ch lo ride  g rad ien t, 
20 yg RNA loaded.
C on tro l ra t liv e r , "rap id  m ethod", 40 yg R N A loaded.
Na c lo fib ra te  trea ted  ra t liv e r , "rap id  m ethod", 40 yg R N A  
loaded.
C on tro l ra t liv e r , "rap id  m ethod", 20 yg R N A  loaded.
Na c lo fib ra te  trea ted  ra t liv e r , "rap id  m ethod", 20 yg R N A  
loaded.
450 IV A l pro te in  and lauric  acid Cd -hydroxylase a c tiv ity  (Figs. 5.10 and 5.6 
respective ly). The bifunctional prote in mRNA shows a s im ila r biphasic pattern , 
whereas the acyl-CoA oxidase mRNA appears to respond in a monophasic manner. 
There was no change in  the level of actin  mRNA throughout the tim e course (data 
not shown). The level of actin mRNA serves as a positive contro l fo r the 
hybrid ization analysis, as its expression is not a ffected  by the adm in istra tion of 
sodium c lo fib ra te , and can be used to show th a t there has not been a general, non­
specific , increase in  mRNA production and that equivalent amounts of RNA have 
been loaded per dot.
I t  appears, as shown in Figs. 6.2 - 6.4, tha t the induction of cytochrom e P- 
450 IV A l mRNA preceeds th a t o f the b ifunctional prote in and acyl-CoA oxidase 
mRNAs by several hours. This is in accord w ith  the observation made in chapter 5 
th a t lau ric  acid w -hydroxylase a c tiv ity  preceeds peroxisomal 3-oxidation a c tiv ity  
fo llow ing a single dose of c lo fib ra te .
RNA samples from  the saline tim e course were also hybridized to  the probes 
fo r cytochrom e P-450 IVA1, acyl-CoA oxidase, b ifunctional prote in and actin. 
There were no changes in the levels of these mRNAs during the saline tim e course 
(data not shown). This is in accordance w ith  data reported in chapter 5.
6.3 DISCUSSION
The results reported in this chapter re-emphasise the biphasic response of 
cytochrom e P-450 IV A l to  the adm in istration of a single i.p . dose of sodium 
c lo fib ra te . This biphasic response is seen at the level o f mRNA, prote in and enzyme 
a c tiv ity . There appears to be a monophasic response of the acyl-CoA oxidase 
mRNA which complements the monophasic response seen in  CN’  insensitive 
pa lm itoy l-C oA  oxidation. The mRNA fo r the b ifunctional pro te in  shows a biphasic 
response, s im ila r to th a t observed in cytochrom e P-450 IV A l mRNA, which is seen 
to a lesser extent in  the levels of immunodetectable b ifunctional prote in (Figs. 5.12 
and 5.13). This may represent differences in the regulation of acyl-C oA oxidase and
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the bifunctional protein.
The early part of the biphasic response is extremely rapid and, indeed
unusual. The only previous report of such a biphasic response was the induction of
cytochrome P-450 IAI and IA II mRNAs in rat liver by 3-MC (Bhat et al., 1987).
In a previous study, sim ilar in nature to  th a t reported in chapter 5 and 6 , no 
evidence of a biphasic response of cytochrome P-450 IV A l to  a single dose of
inducer was seen (Hardw ick et al., 1987). I t  should be noted th a t th is la tte r  study,
however, used c lo fib ra te  (the ethyl ester of c lo fib ric  acid) and not c lo fib r ic  acid 
which has been shown to be the active  form . The hydrolysis of the ester has been 
shown to be rapid (Cayen, 1985). This may, in  part, explain the differences observed 
in the response of cytochrome P-450 IV A l.
The biphasic response may be explained by regarding the induction of 
cytochrom e P-450 IV A l as an adaptive response to  perturbations in  fa t ty  acid 
metabolism. Once the in it ia l perturbation is overcome then the level of cytochrome 
P-450 IV A l returns to normal. However, a fu rthe r perturbation may occur, in 
response to  the same dose of inducer which results in the second peak o f the 
biphasic response. The monophasic response of acyl-CoA oxidase mRNA and 
peroxisomal 8 -oxidation may re fle c t the a b ility  o f the peroxisomes to  handle the 
short-te rm  perturbation in fa tty  acid levels w ithout induction occurring. 
A lte rn a tive ly , the stimulus fo r the induction of peroxisomal 8 -oxida tion may not 
occur in  the early part of the tim e course. A longer, more pronounced accum ulation 
of fa t ty  acids may be required fo r  the induction of peroxisome p ro life ra tion .
The increase in certa in parameters a fte r 30 minutes may seem to be 
exceedingly rapid and i t  may be considered tha t th is is due to  the orig ina l zero tim e  
values being underestimated. Even i f  th is  was the case there would s t i l l  be a 
biphasic response, the f ir s t  part of which is a rapid decrease in  proteins tha t are 
subsequently induced.
I t  can be seen that the appearance of cytochrome P-450 IV A l m RNA
preceeds that of b ifunctional protein mRNA, a lbe it by only a few  hours. Recently, 
s im ila r results have been shown in ra t hepatocyte cell cu lture  using nafenopin as the 
peroxisome p ro life ra to r (B ieri, personal communication).
I t  may be tha t at the very short tim e points there is more than one level of 
contro l of cytochrome P-450 IV A l, ie . there may be both increased translation and 
transcrip tion. This remains to be resolved. I t  should be noted th a t the zero tim e 
point values are derived from untreated animals, i.e . they were not in jected. 
A lthough there is no evidence from  the saline tim e course th a t the stress o f 
in jection  is responsible fo r  the f irs t  peak o f the biphasic response there remains the 
possib ility  th a t the e ffe c t of sodium c lo fib ra te  is potentia ted by the stress o f 
in jection.
When studying short tim e points (less than 1 hour post dose) the possib ility 
exists th a t the liv e r may continue to respond to the inducer even a fte r the surgical 
removal of the liv e r from  the body. The average tim e of processing the liv e r, from  
removal to  homogenization, is 15 minutes. As th is  is of a s im ila r length of tim e to 
that o f the shortest tim e point this may add complications to the in te rp re ta tion  of 
the data from  the shorter time points. This may possibly be overcome by rap id ly  
freezing the livers in liqu id  nitrogen im m ediate ly a fte r th e ir removal from  the body.
The signal observed when the cytochrom e P-450 IV A l cDNA probe is 
hybridized to  the RNA samples may represent hybrid ization to more than one mRNA 
species in accordance w ith  the two closely re la ted proteins observed in the Western 
b lot (Fig. 5.11.). However, i t  has not been possible to show more than one such 
mRNA species on a northern blot, although Southern b lo t analysis indicates th a t the 
cytochrome P-450 IV A l fa m ily  contains two or three genes (Hardw ick et a l., 1987).
Recently, a scheme fo r the mechanism of induction o f the proteins o f the 
"peroxisome p ro life ra to r domain" has been proposed (Sharma et__al., 1988a). This 
scheme (Fig. 7.1.) involves the induction of the enzymes of peroxisomal B-oxidation 
being a consequence of the prior induction of cytochrome P-450 IV A l. This scheme
has been based on in v itro  experiments, using both mono-and d icarboxylic fa tty  
acids, and on the relationship of the enzyme ac tiv ities  involved. The data presented 
in chapters 4 and 5 are not inconsistent w ith  th is  scheme.
The rapid increase in cytochrome P-450 IV A l mRNA and prote in , in  response 
to a single i.p . dose of sodium c lo fib ra te , needs to  be fu rth e r examined. I t  is 
necessary to  determ ine whether th is  is a compound specific  phenomenon and also 
whether th is response is peculiar to the route of adm in istra tion used.
U ltim a te ly  we can only gain vague insights in to  the mechanism of induction 
of the proteins of the "peroxisome p ro life ra to r domain" by tim e  course studies, 
especially i f  the individual events are closely re la ted tem pora lly . G reater insight 
into the mechanism(s) involved w ill be gained from  the analysis of the 5' upstream 
regu la tory sequences of the genes involved and the comparison o f these sequences 
between the d iffe ren t genes.
CHAPTER 7
EXAM INATION OF A CASCADE-TYPE MECHANISM OF INDUCTION  
FOR CYTOCHROME P-450 IV A l AND PEROXISOME PROLFERATION.
CHAPTER 7
EXAMINATION OF A CASCADE-TYPE MECHANISM OF INDUCTION  
FOR CYTOCHROME P-450 IV A l AND PEROXISOME PROLIFERATION.
7.1. INTRODUCTION
I t  has been proposed by Sharma et al., (1988a) tha t the induction of 
cytochrome P-450 IVA1 and peroxisomal B-oxidation are two related, but yet 
d is tinc t, phenomena. They have proposed that the induction of peroxisomal B- 
oxidation is as a consequence of the induction of cytochrom e P-450 IV A l, the 
stimulus fo r the peroxisomal induction being long chain d icarboxylic acids which 
have been form ed by OJ -oxidation (catalyzed by cytochrom e P-450 IVA1) o f the 
corresponding m onocarboxylic fa t ty  acids. The proposed scheme to show the in te r­
relationship of the microsomal and peroxisomal changes in fa tty  acid oxidation a fte r 
hypolipidaem ic challenge is illustra ted in F ig. 7.1. The va lid ity  o f this scheme can 
be examined by analysing the perturbations caused by specific  inducers or inh ib itors. 
There are five  strategies that can be adopted to  dissect th is proposed mechanism of 
induction in rats.
1. Inh ib ition of prote in synthesis by cyclohexim ide.
Follow ing the inh ib ition  of protein synthesis the ra t is challenged w ith  
inducer. This protocol w ill show i f  there are any pro te in  dependancies associated 
w ith  the mechanism(s) o f induction.
2. Inhib ition of cytochrome P-450 by broad range inhib itors.
Compounds such as SKF 525-A, metyrapone, 2-isopropyl-4-pentenamide 
(AIA), 1-am inobenzotriazole (ABT) and cobalt have been shown to be general 
inh ib ito rs  of cytochrom e P-450 (N ette r, 1980; Testa and Jenner, 1981; O rtiz  de 
Montellano and Correia, 1983; Reich and O rtiz  de Montellano, 1986). Follow ing the 
inh ib ition  of cytochrome P-450 the ra t would be challenged w ith  inducer. Care must
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be taken when in te rp re ting  the data from  such an experim ent as not all isozymes of 
cytochrome P-450 are necessarily inh ib ited to the same extent. Also, i t  should be 
noted th a t when using inh ib itors which e ither destroy haem (A IA  and ABT) or 
in te rfe re  w ith  its  synthesis (cobalt) the in te rp re ta tion  of the results may be 
com plicated by the regulatory e ffe c t of haem on cytochrom e P-450 gene 
transcrip tion  (Bhat and Padmanaban, 1988a,b; Dwarki et al., 1987); Srivastava et al.,
1989).
3. Inhib ition of cytochrome P-450 IV A l by specific  inh ib ito r.
F a tty  acid analogues bearing a term ina l acetylen ic group have been shown to 
irrevers ib ly  in h ib it both lau ric  acid (cd) and (co-1) hydroxylase ac tiv itie s , w ith  the 
O -hydroxylase being inh ib ited to the greatest exten t (CaJacob and O rtiz  de 
Montellano, 1986). Two such compounds have been shown to be active in  vivo, 
namely sodium 10-undecenyl sulphate (10-SUYS) and 2 ,2 -d im e thy l-ll-dodecyno ic  
acid (DMDYA), the structures of which are shown in F ig . 7.2. By using these 
compounds i t  may be possible to  im plica te  a specific  isozyme of cytochrom e P-450 
in the induction mechanism. I t  is also necessary to  define which isozymes are 
responsible fo r  the lau ric  acid c j -hydroxylase a c t iv ity  seen in ra t  liv e r microsomes 
and to  v e rify  tha t th is a c tiv ity  is inhib ited by e ithe r 10-SUYS and DM DYA.
4. Induction of peroxisomal 8 -oxidation by d icarboxylic  acids.
I t  may be possible to induce peroxisomal 8 -oxida tion w ithout inducing 
cytochrom e P-450 IV A l. This may be verified  by dosing rats w ith  d icarboxylic fa t ty  
acids or d icarboxylic fa tty  acid analogues. The la tte r  group have great potentia l, 
being resistant to fu rthe r metabolism by 8 -oxidation. Such chemicals include 
tiadenol d icarboxylic acid, perfluorinated dicarboxylic acids, polymethylenemethane 
thiosulphonates, MEDICA 16 and 2,2,4,4,6,8,8-heptamethylnonane dicarboxylic acid 
(Berge e t al., 1987; Bar-Tana, et al., 1988; Salam and Bloxham, 1987; and Ikeda et 
al., 1988). The structures o f these compounds are shown in F ig . 7.2.
Figure 7.2
Potential specific inh ib ito rs  and inducers fo r the 
ve rifica tion  o f the proposed mechanism o f induction
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5. Inh ib ition of the oxidation of c j -OH monocarboxylic fa t ty  acids
The CJ-OH monocarboxylic fa tty  acids produced by cytochrom e P-450 IV A l 
are oxidised as outline below:
HOOC(CH2 )nCH2OH p .  % HOOC(CH2)nCHO ~  * HOOC(CH2)nCOOH
alcohol aldehyde
dehydrogenase dehydrogenase
I t  may be possible to  in h ib it aldehyde dehydrogenase w ith  d isulfiram  
(te trae thy lth iu ram  di sulfide) and ascertain whether the stimulus fo r the induction
of peroxisomal 8 -oxidation is the C J -O H  m onocarboxylic fa t ty  acid or the
d icarboxylic fa t ty  acid.
Each protocol w ill, i f  the scheme shown in F ig. 7.1. is co rrect, produced 
predictable results which are summarised in Fig. 7.3.
I t  was chosen to study the e ffe c t of a prote in synthesis inh ib ito r (protocol 1) 
on the induction process fo r s im p lic ity  and a va ila b ility  of chemicals.
7.2 RESULTS
7.2.1 Gross morphological e ffec ts
The dosing protocol fo r this experiment is outlined in F ig. 7.4. There was a
90 m inute lag tim e between the f ir s t  and second in jections to  ensure th a t the
inducer was administered when the inh ib ition  of prote in synthesis, by cyclohexim ide, 
was maximal (Chianale et al., 1988; Rothblum  ejt ah, 1976). Both doses were 
administered in tra -peritonea lly  as described in section 2 .2 . and a ll animals were 
sacrificed 24 hours post dose.
The animals in group E (dosed w ith  sodium c lo fib ra te  fo llowed by 
cyclohexim ide) were found dead when due fo r sacrifice . This dosing protocol was 
repeated to obviate the possib ility tha t the deaths were due to the in jec tion  of 
excess cyclohexim ide or the puncturing of v ita l organs. In the repeat experim ent 
two out of the three animals died between 4 and 24 hours a fte r the second dose.
Figure. 7.3
Predicted results for the protocols used to examine the
inter-relationship of the induction of cytochrome P-450 IV A l and
peroxisomal 8-oxidation.
Cytochrome P-450 IV A l Peroxisomal 8 -oxidation
mRNA Protein Enzyme mRNA Enzyme
a c tiv ity  a c tiv ity
Protocol.
1. + -
2. +  + -  -  -
3. + + - - -
4. - - - + +
5. - + +
Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IV A l
and peroxisomal 8-oxidation.
Group
F irs t dose 
(0  min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cyclohexim ide saline
E sodium c lo fib ra te cycloheximide
Dose = cyclohexim ide 2 mg/kg
levels sodium c lo fib ra te  250 mg/kg
saline 0.9% (w /v)
The th ird  animal appeared to be extrem ely sick and had lost 11% (25 g) of to ta l body 
weight during the course of the experiment. This may have in part, been due to the 
to x ic ity  of the compounds reducing the food intake. Post mortems were carried out 
on these three animals. L iver sections from  the surviving animal showed occasional 
isolated necrotic fo c i, occasional scattered single ce ll necrosis (possibly endothelial 
or Kupfer ce ll) and slight vacuolation of the centrilobu lar hepatocytes. The 
vacuolation was shown to be lip id  by oil red O staining. The other two animals also 
showed s im ilar hepatic lesions but these were p a rtia lly  masked by au to ly tic  changes. 
Sections from  the corresponding control animals were not available. From  this b rie f 
post m ortem i t  was not possible to ascribe a cause of death. A ll animals also 
showed the classical acute tox ic  e ffec ts  of cyclohexim ide, namely diarrhoea and 
bleeding in to  lungs, in testine and bladder.
7.2.2 Effect of cycloheximide on induction of microsomal parameters
The e ffe c t of the trea tm ents on protein content, cytochrom e P-450 specific  
content and re la tive  live r weight are shown in F igure 7.5. From these histograms it  
can be seen tha t trea tm ent w ith cyclohexim ide alone (group D) causes s ign ificant 
decreases in liv e r protein content compared to  saline dosed (group A) animals. The 
adm in istration of cyclohexim ide p rio r to tha t o f sodium c lo fib ra te  (group c) appears 
to abolish the increase in cytochrome P-450 specific  content caused by the 
adm in istration o f sodium c lo fib ra te  alone (group b). R e la tive  liv e r  weight is 
s ign ifican tly  decreased, compared to  contro l, when both cyclohexim ide and sodium 
c lo fib ra te  (group c) are administered. The values fo r the one surviving animal in 
group E have been included fo r comparison, although i t  is not possible to make any 
conclusions from  this data.
The e ffe c t of the treatm ents on lau ric  acid hydroxylase a c tiv ity , as 
determined by T .L .C ., is shown in  Fig. 7.6. The adm in istra tion of cyclohexim ide 
prio r to the adm in istration of sodium c lo fib ra te  almost to ta lly  abolished the 
inductive e ffe c t o f sodium c lo fib ra te  on lauric  acid hydroxylase. The adm in istra tion 
of cyclohexim ide alone reduces the enzyme a c tiv ity  when i t  is expressed as nmol
Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA l
and peroxisomal 8-oxidation.
Group
F irs t dose 
(0  min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cyclohexim ide saline
E sodium c lo fib ra te cyclohexim ide
Dose = cyclohexim ide 2 mg/kg
levels sodium c lo fib ra te  250 mg/kg
saline 0.9% (w/v)
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Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA1
and peroxisomal /3-oxidation.
Group
F irs t dose 
(0  min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cyclohexim ide saline
E sodium c lo fib ra te cyclohexim ide
Dose = 
levels
cyclohexim ide 2 mg/kg
sodium c lo fib ra te  250 mg/kg
saline 0.9% (w /v)
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hydroxylaurate form ed min/mg protein but not when expressed as nm ol/m in/nm ol 
cytochrom e P-450. The levels of cytochrome P-450 IVA1 apoprotein are shown in 
Fig. 7.7. Again, the inductive properties o f sodium c lo fib ra te  are almost to ta lly  
counteracted by the p rio r adm in istration of cyclohexim ide. This e ffe c t is also 
shown in the Western b lot analysis of pooled samples (F ig. 7.8). As was seen in 
chapter 4, both immunodetectable proteins appear to  be co-ord inate ly regulated.
7.2.3 E ffe c t o f cyclohexim ide on peroxisomal parameters
Figure 7.9. shows the analysis o f the liv e r  homogenate fo r b ifunctiona l 
p ro te in  content and peroxisomal 8 -oxidation. The inductive e ffe c t of sodium 
c lo fib ra te  on both these parameters is almost to ta lly  counteracted by the p rio r 
adm in istra tion of cyclohexim ide. This is also shown by the Western b lot analysis of 
the homogenate samples fo r b ifunctional protein (Fig. 7.10).
7.2.4 E ffe c t o f cyclohexim ide on cytochrom e P-450 IVA1 and 
acyl-CoA mRNA levels
The e ffe c t of these treatm ents on the levels o f cytochrome P-450 IVA1 and 
acyl-CoA oxidase mRNAs are shown in Fig. 7.11. I t  can be seen th a t when the ra t is 
dosed w ith  cyclohexim ide p rio r to dosing w ith  sodium c lo fib ra te  there is an increase 
in cytochrom e P-450 IVA1 mRNA but not in the mRNA fo r acyl-CoA oxidase.
A corre lation m atrix  (Fig. 7.12) was constructed which shows highly 
s ign ifican t corelations (at p=0.01 and n -2 = ll,  r=0.684) between a ll peroxisomal 
markers and cytochrome P-450 IVA1 pro te in  and enzyme a c tiv ity . I t  should be 
noted th a t these corre lations may be biased, as most determ inations are clustered 
around the control end of the regression line.
7.3 DISCUSSION
This series of experiments, designed to study the e ffe c t of cyclohexim ide on 
the induction of cytochrome P-450 IVA1 and peroxisomal 8 -oxidation, has produced 
several in teresting observations. F irs tly , i t  appears th a t when cyclohexim ide is 
administered 90 minutes p rio r to a dose of sodium c lo fib ra te  the inductive  e ffe c t of
Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA1
and peroxisomal 8-oxidation.
Group
F irs t dose 
(0 min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cyclohexim ide saline
E sodium c lo fib ra te cyclohexim ide
Dose = 
levels
cyclohexim ide 2 mg/kg
sodium c lo fib ra te  250 mg/kg
saline 0.9% (w /v)
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Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA1
and peroxisomal B-oxidation.
Group
F irs t dose 
(0 min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cyclohexim ide saline
E sodium c lo fib ra te cyclohexim ide
Dose = cyclohexim ide 2 mg/kg
levels sodium c lo fib ra te  250 mg/kg
saline 0.9% (w/v)
Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA1
and peroxisomal 6-oxidation.
Group
F irs t dose 
(0 min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cycloheximide saline
E sodium c lo fib ra te cyclohexim ide
Dose = cyclohexim ide 2 mg/kg
levels sodium c lo fib ra te  250 mg/kg
saline 0.9% (w /v)
F igu re  7.8
Analysis of hepatic m icrosomal samples fo r cytochrome P-450 IVA1
by Western b lo ttin g
A B C D E STD
W estern b lo t analysis was ca rried  out, as described in section 2.7.2. on pooled 
samples fro m  each group. 10 pg o f m icrosom al p ro te in  was loaded per tra c k , 
w ith  0 .5pm oles of e le c tro p h o re tica lly  pure cytochrom e P 4 5 0  IVA1 loaded as 
standard.
Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA1
and peroxisomal 6-oxidation.
Group
F irs t dose 
(0 min.)
Second dose 
(90 min.)
A saline saline
B
i
saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cyclohexim ide saline
E sodium c lo fib ra te cyclohexim ide
Dose = cyclohexim ide 2 mg/kg
levels sodium .clofibrate 250 mg/kg
saline 0.9% (w/vt)
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Figure 7.4
Dosing protocols used in experiment to show the effect
of cycloheximide on the induction of cytochrome P-450 IVA1
and peroxisomal 8-oxidation.
Group
F irs t dose 
(0 min.)
Second dose 
(90 min.)
A saline saline
B saline sodium c lo fib ra te
C cyclohexim ide sodium c lo fib ra te
D cycloheximide saline
E sodium c lo fib ra te cyclohexim ide
Dose = cyclohexim ide 2 mg/kg
levels sodium c lo fib ra te  250 mg/kg
saline 0.9% (w/v)
Figure 7.10
Analysis of hepatic homogenate samples for bifmctional protein by
Western blotting
180
116
841
58
4 8 5
365
266
A  B C D  E
Western blot analysis was carried out, as described in section 2.8.3., on pooled 
samples from  each group. 30 yg of homogenate protein was loaded per track . 
Tracks A-E re fer to the dosing protocols used.
M olecular weight markers are as described in section 2.7.2.1.
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Figure 7.12
Correlation matrix for the association between 
selected microsomal and peroxisomal parameters.
Protein
content
RLW S.C. P.CoA B if L .A . S.C.
IV A1
Protein
content 0.33 0.57 0.13 0.18 0.21 0.24
RLW 0.84 0.67 0.65 0.60 0.71
S.C. 0.27 0.75 0.77 0.87
P.CoA 0.97 0.98 0.95
BiF 0.97 0.93
L . A. 0.93
S.C. IV A1
RLW = Relative L ive r Weight
S.C. = Cytochrome P-450 specific  content
P.CoA = peroxisomal J3-oxidation
BiF = B ifunctional prote in content
L .A . = Laurie acid hydroxylase a c tiv ity  (nmole/m in/nm ole)
the sodium c lo fib ra te  on the microsomal and peroxisomal enzyme activ ities  is 
ablated. There is an increase in the leve l of cytochrome P-450 IVA1 mRNA but not 
in the level of acyl-CoA oxidase m RNA. This is in accordance w ith  the mechanism 
o f induction proposed by Sharma et al. (1988a), namely th a t the induction o f 
peroxisomal 8-oxidation requires the p rio r induction of c a ta ly tic a lly  competent 
cytochrom e P-450 IVA1 protein. I t  can also be seen th a t the induction o f 
cytochrome P-450 IV A l mRNA is not cyclohexim ide sensitive (Fig. 7.11). This 
im plies th a t there is no dependency of the induction of cytochrom e P-450 IV A l on 
the synthesis o f a prote in fa c to r such as the so called SHIP pro te in  (steroid hormone 
inducible protein), as has been postulated fo r the induction of cytochrom e P-450
o L C
by adrenocorticotrophic hormone (ACTH) in  the bovine adrenal gland (Waterman et 
al ., 1984).
The data presented in  F ig. 7.11 also shows no evidence of the phenomenon of 
superinduction, i.e . the increase in  level o f mRNA, above th a t in the presence o f 
inducer alone, when cyclohexim ide and inducer are co-adm inistered. Superinduction 
has been shown to occur w ith  cytochrom e P "^^^c+cj nnRNAs when cyclohexim ide and 
po lycyclic  arom atic hydrocarbons are administered to  the rat (Israel and W hitlock, 
1983; Israel et al., 1985). The superinduction phenomenon is ind ica tive  o f the 
presence of a lab ile  repressor of gene transcrip tion. There is, a t present, no 
evidence fo r  the existence of such a repressor associated w ith  the cytochrom e P-450 
IV A l gene.
A t a dose level of 2 mg/kg cyclohexim ide, pro te in  synthesis has been shown 
to be inhib ited by 80%, w ith  the in h ib ition  lasting approxim ately 14 hours, w ith  no 
le tha l to x ic ity  (Rothblum et al., 1976). However, i t  has been reported tha t there are 
increased rates of protein synthesis fo llow ing the period of inh ib ition . This, coupled 
w ith  the reported ha lf l i fe  of c lo fib ra te  being approxim ately 8 hours (Cayen, 1985) 
may account fo r  the levels o f some parameters in animals from  group c being 
s ligh tly  higher than the contro l values.
A most s trik ing  observation in  th is series of experiments is the extrem e
to x ic ity  of dosing protocol E (sodium c lo fib ra te  fo llowed by cyclohexim ide). The 
m o rta lity  ra te  was 83% (5 out of 6 animals) and was surprising as there were no 
overt signs o f to x ic ity  when the reverse dosing protocol was employed 
(cyclohexim ide fo llowed by sodium c lo fib ra te ). I t  was not possible to ascribe a 
cause of death in these animals, the fa t ty  vacuolation seen was not necessarily 
linked w ith  the cause of death. Indeed, th is  type of vacuolation is characte ris tic  of 
both the tox ic  e ffe c ts  of cyclohexim ide (Jazcilev ich and V illa -T rev ino , 1970) and the 
adm in istra tion of hypolipidaemic compounds (M itche ll, e t al., 1985c; Price et al., 
1986).
The to x ic ity  may, in  some way, be re lated to  the biphasic response in  lau ric  
acid hydroxylase observed in chapters 5 and 6. I t  can be seen in  F ig . 7.11. th a t 
there is an increase in cytochrome P-450 IV A l mRNA regardless of whether 
cyclohexim ide is administered prior to , or a fte r, the sodium c lo fib ra te . In both 
instances there is no increase in the level of acyl-CoA oxidase mRNA. This implies 
th a t the stimulus fo r the induction of acyl-CoA oxidase is not generated in the f ir s t  
90 minutes fo llow ing adm inistration of sodium c lo fib ra te . The short term  increase 
in  lau ric  acid O -hydroxylase a c tiv ity  may produce an accumulation of d icarboxylic 
acids which are not su ffic ien t to cause an induction of peroxisomal 8-oxidation. 
A fte r  4 hours the f irs t  part of the biphasic response is overcome, and a second 
stimulus causes the increased levels o f cytochrom e P-450 IV A l m RNA that are 
observed a fte r 24 hours. The concept o f m u ltip le  s tim u li fo r  the induction o f 
cytochrome P-450 IV A l are discussed in  chapter 8.
The adm in istration o f sodium c lo fib ra te  may cause an accum ulation o f fa t ty  
acids, both mono- and dicarboxylic, th a t are po ten tia lly  to x ic  to  the ce ll. I t  has 
been reported th a t long chain d icarboxylic fa tty  acids can uncouple oxidative  
phosphorylation and cause m itochondrial swelling (Tonsgard and Getz, 1985; K im ura, 
1986). This accumulation of po ten tia lly  to x ic  fa t ty  acids would norm ally be handled 
by the induction of peroxisomal 8-oxidation. The hepatocyte may also respond to  
increased levels o f free fa tty  acids by incorporating them in to  phospholipids.
However, d icarboxylic  fa t ty  acids cannot be handled in th is way and must re ly  on 
peroxisomal 8-oxidation fo r  th e ir  de tox ifica tion  (Mortensen, 1984; Vamecq et al.,
1985). However, in  group E cyclohexim ide has blocked th is  induction, resulting in 
the observed le tha l to x ic ity . As no le tha l to x ic ity  is observed when cyclohexim ide is 
administered p rio r to sodium c lo fib ra te  i t  may im ply tha t the short-term  induction 
of cytochrome P-450 IV A l is responsible fo r the generation of the to x ic  insult. This 
explanation fo r  the observed le tha l to x ic ity  remains unsubstantiated.
To gain fu rth e r insight in to  th is to x ic ity  i t  w ill be necessary to repeat the 
experiment w ith  carefu l m onitoring o f the animals, ensuring tha t they are sacrificed 
p rio r to death. The animals should be subjected to  fu ll post-m ortem  exam ination, 
including re levant controls, and analysis of the fa t ty  acid composition of the live r 
and blood performed. The importance o f the lag tim e  between the dose o f 
cyclohexim ide and sodium c lo fib ra te  should be assessed.
I t  is not known whether th is  le tha l to x ic ity  is re la ted to the induction of the 
enzymes of the peroxisome p ro life ra to r domain by sodium c lo fib ra te . I t  w ill be 
in teresting to  ascertain whether th is to x ic ity  is compound specific , i.e . res tric ted  
to sodium c lo fib ra te  only, or a general property o f the xenobiotic peroxisome 
pro life ra tors . I f  the to x ic ity  is re lated to enzyme induction i t  w ill be in fo rm ative  to 
examine the e ffe c t o f this dosing protocol on species, such as hamsters and guinea 
pigs, tha t have been classified as e ither weakly responsive, or non-responsive to  the 
peroxisome p ro life ra tive  e ffec ts  of xenobiotics such as c lo fib ra te  and c ip ro fib ra te .
In summary, the results presented in th is chapter appear to be in accord w ith  
the mechanism of induction outlined in  F ig. 7.1. Further experiments o f th is nature 
using other specific  inducers and inhib itors, as outlined in section 7.1., w ill enable us 
to fu lly  validate the individual stages involved.
CHAPTER 8 
DISCUSSION
CHAPTER 8 
DISCUSSION
The aim of th is  study was to  investigate the evidence fo r  the existence of a 
soluble cytosolic receptor fo r  the xenobiotic peroxisome pro life ra to rs , as proposed 
by Lalwani et al., (1983a, 1987). The concept o f such a receptor was postulated to  
explain the structura l d ivers ity  of the inducers, the species differences in 
peroxisome p ro life ra tion  and the tissue sp e c ific ity  of peroxisome p ro life ra tion  in the 
ra t.
8.1 STRUCTURE AC TIV ITY RELATIONSHIPS OF XENOBIOTIC
PEROXISOME PROLIFERATORS 
The xenobiotic peroxisome pro life ra tors are a group o f s truc tu ra lly  diverse 
chemicals (see Figs. 1.1 and 1.2), which show d is tinc t s tructu re  a c tiv ity  
relationships. Many studies have demonstrated potency differences between various 
phthalate esters and re lated compounds. For example, the branched chain ester 
DEHP has been shown to  be more potent at producing peroxisome p ro life ra tion  in  
ra t liv e r than the s tra igh t chain d ie thyl, d i-n-hexyl and mono-and d i-n -oc ty l 
phthalate esters (Moody and Reddy, 1978b; Lake et al., 1984c, Mann et al., 1985). In 
another study i t  has been shown th a t the branched chain phthalate esters, namely 
DEHP and diisodecyl and diisononyl phthalates, are more potent than the stra igh t 
chain compounds such as n-butylbenzyi, d i-n -bu ty l and diundecylphthalates (Barber 
et al., 1987). Similar results have been obtained w ith  the monoester phthalates 
(Gray et al., 1983b; M itch e ll et al., 1986; Lake e t al., 1987). The s tra igh t chain 
phthalates, unlike MEHP, are extensively m etabolized which may explain th e ir lower 
potencies (A lbro and Moore, 1974). DEHP, like  other phthalate esters, is hydrolysed 
by esterase enzymes to  MEHP and 2-ethyl he xanol, both of which are peroxisome 
p ro life ra to rs  in the ra t (Lake e t al., 1975; Moody and Reddy, 1978b). Studies w ith  
prim ary ra t hepatocyte cultures have indicated tha t phthalate monesters tend to  be 
more potent peroxisome pro life ra tors  than the corresponding alcohols (Gray e t al., 
1983b; Rhodes et al., 1984). I t  has been shown that m ono(2-ethylhexyl)phthalate is
s ligh tly  more potent than the 3-ethylhexyl derivative and 5 tim es more potent than 
the 1-ethylhexyl derivative (Lake et aL, 1986c, 1987). S im ila r results were obtained 
using e thy lbu ty l derivatives but these compounds were 2-3 tim es less potent than 
the corresponding ethylhexyl derivatives. These studies have led Lake et al., (1986b) 
to propose that the potency o f the monosubstinted phthalate esters appears to be 
re la ted to both the alkyl chain length and the position o f side chain substitu tion. 
Studies on the potency o f 2-ethylhexanoic acid and its  s tructura l analogues has led 
to the proposal th a t the most e ffec tive  p ro life ra to rs  all have an ethyl group as the 
substituent on carbon 2 ( 8  carbon) o f the main chain, which consists of six carbons 
(Lundgren et al., 1987c, 1988a,b). A fu rth e r observation was th a t a charged group is 
required fo r  e ffec tive  induction of peroxisome p ro life ra tion , e.g. 2-ethylhexanoic 
acid is a more potent peroxisome p ro life ra to r than 2-ethylhexanol. O ther s tructure  
a c tiv ity  re la tionship (SAR) studies by Lundgren et ah, (1987c, 1988b) on several 
peroxisome pro life ra tors  produced the proposal th a t the most potent compounds 
possess a blocked a-carbon atom. The s truc tu re  of some of the compounds used in  
these studies are shown in  Fig. 8.1.
The chlorophenoxyacetic acids are a group o f chemicals that have been the 
subject of extensive SAR analysis (Bacher and Gibson, 1988; Fournel e t al., 1985;
v
Katoh et aL, 1984; Lundgren et al., 1987a,c, 1988a,b;). I t  was shown tha t c lo fib ric  
acid was more potent at inducing peroxisomal 8-oxidation than was 2-(4- 
chlorophenoxy)-2-m ethylacetic acid which, in  tu rn , was more potent than 4- 
chlorophenoxyacetic acid (Katoh e t al., 1984), emphasizing the im portance of the 
blocked a carbon atom. The positioning, and number, o f the chlorine atoms on the 
phenyl ring is o f importance. For example, 2,4,5-T is more potent at inducing la u ric  
acid6J-hydroxylase than are 2,4-D or M CPA (Bacher and Gibson, 1988). However, 
the e ffe c t of the blocked a carbon atom, and position and exten t of ch lorination o f 
the phenyl ring, is not straight forward as 2,4-dichlorophenoxybutyric acid (2,4-DB) 
appears to be less potent than 2,4-dichlorophenoxyproprionic acid (2,4-DP) (Bacher 
and Gibson, 1988). This is in contrast to  the e ffe c t of the substitu tion oti the a-
Figure 8.1.
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carbon atom on the induction of peroxisomal 8-oxidation (Katoh et al., 1984), and 
serves to highlight the in te rac tive  nature of the s tructura l elements of the 
peroxisome pro life ra tors .
Studies on the induction of peroxisome p ro life ra tion  by perfluorinated fa t ty  
acids and th e ir  analogues has shown the im portance of chain length and the presence 
of a carboxylic acid group in  the molecule (Ikeda et al., 1985, 1986). The 
perfluorinated fa tty  acids are subject to  l i t t le ,  i f  any, metabolism and are therefo re  
ideal fo r S.A.R. studies. Follow ing a single i.p. in jec tion , perfluoro-n-decanoic acid, 
perfluoro-n-octanoic acid and l-H ,l-H -pen tadeca fluo ro -n -octano l were shown to be 
inducers of PPA80 and lau ric  acid CJ-hydroxylase, whereas pe rfluo ro -n -bu tyric  acid 
and the perfluorinated paraffins, perfluorodedecane and perfluorooctane did not 
induce these enzymes. The structures of these compounds are shown in  F ig . 8.1.
Analysis of a range of xenobiotic peroxisome pro life ra tors  has led to the 
proposal that a ll these compounds appear to consist of a carboxylic function  carried 
on a hydrophobic backbone to yield an amphipathic carboxylate (Hertz e t al., 1988). 
The carboxylic function  may e ither be present in it ia lly ,  as in the case of MEDICA 
16, the fib ra tes and 2,4,5-T, or may be derived by m etabolic oxidation of the 
respective alcohols or aldehydes. The free  carboxylic function , o r a derivative 
thereof, is presumably d ire c tly  involved in the inductive process, w h ils t the nature 
of the hydrophobic backbone may determ ine the potency of the compound.
However, this generalisation does not hold up in all cases. Two compounds, 
LY171883 and perfluoro-n-octane sulfonic acid have been shown to  be peroxisome 
pro life ra tors  w ithout possessing a carboxylic function (Eacho et ah, 1986; Ikeda et 
al., 1987). LY  171883 contains a te trazo le  m oiety which is a bioisostere of the 
carboxylic acid m oiety, i.e. they have chemical and physical s im ila ritie s  th a t results 
in broadly s im ilar biological properties (Thornber, 1979). Indeed, the dissociation 
constants (pKa) o f LY  171883 and c lo fib ric  acid are s im ilar (6.6 and 6.2 
respectively). The sulphonic acid group is also a bioisostere of the carboxylic 
m oiety. The bioisosteres of the carboxylic acid m oiety are shown in  F ig. 8.2.
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Presently there is no data as to the re la tive  potencies of these bioisosteres in 
inducing peroxisome p ro life ra tion .
From these studies, i t  can now be seen that a ll peroxisome pro life ra tors 
contain a carboxylic acid m oie ty, or a bioisostere o f th is m oie ty, supported by a 
hydrophobic backbone. This, coupled w ith  the other structura l requirements 
previously mentioned, may make i t  possible to  predict potentia l peroxisome 
pro life ra to rs  from  th e ir chemical structures.
Further S.A.R. analysis may help us define which parameters are im portant 
fo r peroxisome p ro life ra tion  and which parameters are im portant fo r  hypolipidaem ic 
a c tiv ity . I t  has been proposed that a ll peroxisome pro life ra tors are hypolipidaem ic 
agents (Cohen and Grasso, 1981) although the converse is not true (see Table 1.2.). 
The mechanism of the hypolidaemic action of the peroxisome p ro life ra to rs  is as 
equally obscure as the mechanisms of induction of peroxisome p ro life ra tion . 
Proposed mechanisms of the hypolipidaem ic action of the xenobiotic peroxisome 
p ro life ra to rs  include increased oxidation o f fa tty  acids, inh ib ition  o f trig lyce ride  
synthesis, and the displacement of thyroxine from  its serum-binding proteins 
(Hawkins et al., 1987). The hypolipidaem ic e ffe c t of c lo fib ra te  has been shown to be 
dissociated from  the induction of peroxisomal 8-oxidation and la u ric  acid&J - 
hydroxylase (Harrison, 1984; Reich and O rtiz  de M ontellano, 1986). Vast numbers o f 
chemicals have been screened fo r th e ir hypolipidaem ic potency such as the 
a lkyloxyarylcarboxylic acids, 2-3-dihydrophthalazine-l,4-d ione derivatives and 
aminimides (Hall 1985; Murthy et aL, 1986; Tomisawa et al., 1985; Parker et
al., 1977). Analysis o f the peroxisome p ro life ra tive  potencies of these series o f 
compounds may give a great insight in to  the s truc tu ra l requirements fo r peroxisome 
pro life ra tion  and hypolipidaem ic a c tiv ity , and the link between these two 
phenomena.
Recently, i t  has been shown that the (S)-(+)- and (R)-(-) enantiomers of 2- 
phenylpropionic acid have d iffe ring  potencies in the induction of ra t  liv e r b ilirub in  
UDP-glucuronyltransferase and lauric  acid U) -hydroxylase (Fournel et al., 1986),
w ith  the (S)-(+) enantiomer being more potent in both cases. S im ila rly  the two 
stereoisomers of (£J-1) keto MEHP have been shown to possess d iffe re n t potencies 
fo r the induction of peroxisome p ro life ra tion  (Lhuguenot, 1988). M yotonia, or 
muscle weakness, has been reported to be a side e ffe c t of the adm in istra tion of 
c lo fib ra te  to humans (Rush et al., 1986). Sim ilar observations have been made in 
rats (Kwiecinski, 1978; Behrens et al., 1983; Paul and Adib i, 1979). The myotonia 
has been shown to be caused by the blockage of the chloride ion channel (Conte- 
Camerino e t ah, 1984, 1986). Recently, using enantiomers of c lo fib ric  acid 
analogues, i t  has been possible to show stereospecific ity  in  the in te rac tion  of these 
compounds w ith  the chloride ion channel (Betton i e t al., 1987; F e lle r e t al., 1987;
Conte-Camerino et al., 1988). I t  was also observed tha t the hypolipidaem ic and
an ti-p la te le t actions, and the m yotonic e ffec ts  o f the c lo fib r ic  acid re lated
enantiomers can be dissociated (Feller et ah, 1987). The use of stereoisomers of
xenobiotic proxisome p ro life ra to rs  w ill give insight in to  prote in-ligand in teractions 
involved in  the induction of peroxisome p ro life ra tion .
8.2 REGULATION OF CYTOCHROME P-450
The genes coding fo r the cytochrome P-450 isozymes can be regulated in 
several d iffe ren t ways which have recently  been reviewed (Nebert and Gonzalez, 
1985; Adesnik and Atchison, 1985; W hitlock, 1986, Gonzalez, 1989). The genes fo r 
cytochromes P "^^^c+cj 31,6 regulated by the Ah (arom atic hydrocarbon) receptor, a 
soluble in trace llu la r prote in which binds specific  halogenated arom atic compounds 
such as TCDD (Okey et al., 1979; Durrin et al., 1987) and ce rta in  po lycyclic  
arom atic hydrocarbons such as 3-methylcholanthrene (Okey and Vella, 1982). The 
transcrip tion of the genes fo r these isozymes may also be regulated by a d is tinc t 4S 
trans-regu latory protein (Houser et al., 1985; Bresnick et al., 1988). There is 
evidence that these isozymes may also be regulated post-transcrip tiona lly  (Pasco et 
al., 1988; S ilver and K rau te r, 1988). The mechanism of induction o f the 
phenobarbital inducible isozymes, P-450^ and P-450e> is unknown. No cytosolic 
receptor has been found fo r phenobarbital type inducers (Fonne and Meyer, 1987). I t
has been suggested that protein kinase c regulates the induction of these la tte r  
isozymes (Steele and Virgo, 1988) and th e ir  induction is protein synthesis dependent 
(Chianale et al., 1988).
The transcrip tion of cytochrome P“^ - ^ scc cultured bovine adrenocortical 
cells has been shown to be stim ulated by ACTH, mediated by cAMP (John e t al.,
1986). The mechanism of induction involves the action of a " lab ile '1 prote in termed 
steroid hormone inducible protein (SHIP) (Zuber e t ah, 1986), Cytochrom e P- 
4 5 0 ^ ^ ^ ^  is induced by fo llic le  stim u la ting  hormone, again by a cAMP -dependent 
mechanism (Steinkam pf e t ah, 1987). The induction of gene expression by cAMP is a 
w e ll documented phenomenon). I t  has been proposed that cAMP regulates gene 
transcrip tion through its  in te raction  w ith  the C subunit of protein kinase, which 
phosphorylates CRE binding prote in thereby increasing the ra te  of fo rm ation , and 
s ta b ility , of transcrip tion  fa c to r complexes (Roesler e t ah, 1988).
The s tab iliza tion  of mRNA by the inducer, ra the r than an increased ra te  of 
transcrip tion, has been im plicated in the regulation of cytochrome P-45CK (Song at 
ah, 1987). Ligand-dependent enzyme s tab iliza tion  has been shown as yet another 
mechanism of regulation fo r cytochrome P-450 (Watkins e t al., 1986; Eliasson e t al., 
1988; Voorman and Aust, 1988). W ith th is  type of regulation the cytochrom e P-450 
ca ta ly tic  ac tiv itie s  do not corre la te  w ith  the corresponding P-450 mRNA 
concentrations (Tuteja et ah, 1986). I t  has been postulated tha t the induction of 
certa in  isozymes of cytochrome P-450 may be due to  the inducer inh ib iting  
cytochrome P-450 and thereby a lte ring  the disposition of an endogenous compound 
which is m odified by the enzyme. This endogenous compound, or a m etabo lite  o f i t ,  
may act as an inducer or de-repressor (Burnet et ah, 1986). However, doubt has 
been cast on the involvement of th is  mechanism in the induction of cytochrom e P- 
450^ and by phenobarbital (O rtiz  de M ontellano and Costa, 1986).
Enzyme induction does not necessarily occur by a d irect mechanism, such as 
the regulation of cytochrome P-450c+cj by the Ah receptor. Ind irect mechanisms of 
induction can occur as has been shown in the  induction of hepatic m et a llo t hi onein by
alcohols, in  which the mechanism of induction is believed to  be due to  an a lte ra tion  
in zinc and glucocortico id homeostasis (Bracken and Klassen, 1987).
Another mechanism of enzyme regulation that does not involve increased 
gene transcrip tion is post-translationa l m od ifica tion , which may resu lt in  increased 
enzyme s ta b ility . Isozyme-specific phosphorylation of cytochrome P-450 has been 
reported (Pyerin et al., 1987a,b; Bartlom owicz et al., 1989). Prote in phosphorylation 
has also been observed in  peroxisomes (Skorin et al., 1986).
I t  can be seen th a t there are many ways in which enzymes, and th e ir 
ac tiv itie s , can be induced. It  is possible that cytochrome P-450 isozymes may be 
regulated by more than one of the previously mentioned mechanisms.
8.3 MECHANISM(S) OF INDUCTION OF ENZYMES OF THE
PEROXISOME PROLIFERATOR DOMAIN
8.3.1 Soluble cytosolic receptor
The postulated cytosolic receptor fo r  the xenobiotic peroxisome pro life ra tors  
has been purified and p a rtia lly  characterized (Lalw ani e t al., 1983a, 1987). 
However, I have been unable to detect saturable displaceable specific  binding of 
[ 3h ]  -nafenopin or [ 3h ]  -c ip ro fib ra te  to ra t  liv e r  cytosol (Chapter 4). Siest et 
al. (1988) have also been unable to find  any evidence of such a cytoso lic  receptor. 
This, in  its e lf, is not enough to prove the non-existence of the cytosolic receptor. 
Analysis of the data that has been taken to  show the existence of the cytosolic 
receptor, and other in fo rm ation , w ill shed lig h t on the v ia b ility  o f the receptor 
hypothesis.
Lalwani et al., (1983a) showed that c lo fib ra te  and c ip ro fib ra te  were able to  
compete w ith  P h ]  -nafenopin fo r  cytosolic binding sites. The I^g values fo r 
c lo fib ra te  and c ip ro fib ra te  were 0.57 pM and 1.7 pM respective ly which is 
inconsistent w ith  th e ir respective potencies fo r the induction of peroxisomal 3- 
oxidation (see Table 1.7). Wy-14,643 and BR-931, which are peroxisome
pro life ra to rs  th a t have been classed as being s truc tu ra lly  unrelated to c lo fib ra te , did
not compete w ith  I HI -nafenopin fo r  the specific  binding sites. This has lead to  
the proposal th a t there is e ither more than one receptor or one receptor w ith  more 
than one binding s ite  (Reddy and Rao, 1986). The binding characteristics of 
nafenopin to  ra t  liv e r cytosol (K q  = 0.53 pM , n = 2.73 pmol/mg cytoso lic  protein) do 
not meet the classical requirements of a receptor. C lassically, a receptor has high 
a ff in ity  and low capacity fo r  a ligand, thereby im parting sens itiv ity . The binding 
described by Lalwani et al., (1983a) is low  a ff in ity , high capacity which is more 
ind ica tive  of a binding prote in than a receptor. I t  should also be noted th a t the 
stereospecific binding of nafenopin to  ra t liv e r  cytosol claimed by Lalwani et al., 
(1987) to have been previously determined (Lalwani et a l., 1983a) is not supported by 
the existing data.
The soluble cytosolic receptor was purified by a ff in ity  chromatography and 
termed proxisome p ro life ra to r binding protein (PPbP). The ligands used fo r the 
a ff in ity  columns were nafenopin, c lo fib r ic  acid and c ip ro fib ra te , and were attached 
through th e ir  -COOH group to the -N b ^  groups of the Sepharose beads. Cytosol was 
passed down the column and the bound proteins eluted w ith  bu ffe r containing ligand. 
Several proteins were eluted from  the columns in th is  fashion. The m ajor prote in 
eluted, representing 70-80% o f the to ta l prote in bound, was a 70 KD prote in termed 
PPbP. Proteins of 79, 55 and 31 KD M.W t were also eluted. The amount of prote in 
that binds to an a ff in ity  column is a function  of the a ff in ity  o f the prote in fo r  the 
ligand and the concentration of the prote in th a t was loaded onto the column. 
Therefore i t  is possible that the m ajor prote in eluted from  such a column is not the 
protein w ith  the highest a ff in ity  fo r the ligand.
The native of the PPbP was estim ated to  be in  the range of 140 -160 KD 
by gel f i lt ra t io n  and by electrophoresis under nondenaturing conditions. The PPbP is 
a dimer w ith  a subunit of 70 KD . The pi of th is prote in is 4.2 -5.6., suggesting 
th a t i t  has a strong negative charge which may be im portan t fo r  ligand binding. 
Although p a rtia lly  purified PPbP possessed the a b ility  to  specific  a lly  bind [ 3h ]  - 
nafenopin (Lalwani et al., 1987), the fina l preparation o f PPbP had no such
properties (Lalwani et al., 1986).
Doubt may be cast as to whether PPbP is indeed a cytosolic receptor fo r the 
xenobiotic peroxisome pro life ra tors. As has been previously stated in th is discussion 
one of the common features of the xenobiotic peroxisome pro life ra to rs  is a 
carboxylic acid m oiety. However, by attaching the ligands to the column m ate ria l 
through th is  essential s tructura l group, only the hydrophobic backbone of these 
compound is available fo r binding to protein. This may w e ll in te rfe re  w ith  the 
binding o f the ligand and the protein. The strong negative charge of PPbP is not 
necessarily com patible w ith  the binding o f ligands through th e ir  carboxylic acid 
group.
I t  has been observed that MEDICA 16, nafenopin and bezafibrate can acylate 
membrane and cytoso lic  live r proteins in cultured ra t hepatocytes (H ertz  and Bar- 
Tana, 1988). The acylation patterns were tim e- and dose-dependent, and the 
acylated residue consisted of the orig inal xenobiotic. This binding was unaffected 
under conditions where protein synthesis was com plete ly inh ib ited by cyclohexim ide. 
The acylation patterns generated included common proteins which were acylated by 
the three xenobiotics, as well as unique proteins which were spec ifica lly  acylated by 
the respective xenobiotics. The acylation of proteins by MEDICA16 was extrem ely 
rapid, w ith  proteins of Mr 13, 23, 42 and 66 KD being acylated w ith in  10 m inutes, 
whereas acylation of 32, 36, 52, 56 and 72 KD proteins was negligable during the 
f irs t  60 minutes, but became s ign ifican tly  pronounced la te r. The 13, 32 and 52 KD 
prote in were found to be present in the soluble ce ll fra c tio n , whereas the 56 KD 
prote in was shown to be particu la te . The 32 KD prote in was also acylated by 
m yris ta te  and palm ita te . I t  is in teresting to compare these acylated proteins w ith  
the proteins isolated by a ff in ity  chromatography by Lalwani et aL (1987). This 
is shown in Table 8.1.
Table 8.1.
Comparison of acylated and affin ity  purified proteins
A ff in ity  P u rifica tion  
(Lalwani et al., 1987)
Acyla tion  
(H ertz and Bar-Tana, 1988)
M olecular weight (KD)
79
70
55
31
72
56
52
32
ligands nafenopin
c lo fib ra te
c ip ro fib ra te
MEDICA 16 
bezafibrate
nafenopin
There appears to be a degree of corre la tion between these two sets o f 
proteins. Although the M^ do not match exactly , th is  may be due to  in te r-ind iv idua l 
varia tion in the assessment of the Mr from  a SDS-PAGE gel and they may indeed 
represent identica l proteins.
th a t fa t ty  acids and CJ-hydroxyfatty acids can be covalently attached to ce ll 
macromolecules in the mammalian epidermis (W ertz and Downing, 1986). F a tty  
acylated proteins have been detected in several diverse systems including v ira l coat 
proteins, m yelin proteolip id  and enzymes (Grand, 1989; Schultz a t al., 1988).
The acylation of proteins by xenobiotic peroxisome p ro life ra to rs  may o ffe r a 
common mode action fo r these diverse structures and may be re la ted to the 
induction mechanism in the absence of a soluble cytoso lic  receptor.
I t  is in teresting to  search the lite ra tu re  fo r  other reports of in te ractions 
between the xenobiotic peroxisome p ro life ra to rs  and proteins. This in fo rm ation  may 
enable us to  form ula te  an a lterna tive hypothesis fo r  the mechanism of induction of 
peroxisome p ro life ra tion .
The acylation of proteins is a w ell documented phenomenon. I t  has been shown
8.3.2 Substrate overload
8.3.2.1 Inh ib ition of m itochondrial B-oxidation by peroxisome pro life ra to rs .
Peroxisome pro life ra to rs  have been shown to in h ib it m itochondria l B- 
oxidation. C lo fib ra te  inh ib its ra t liv e r m itochondrial respiration at two sites w ith in  
the respiratory chain (Mackerer and H aettinger, 1974; Krishnakantha et ah, 1973). 
M itochondrial fa tty  acid oxidation was s im ila rly  inh ib ited  (Cederbaum et al., 1976). 
The very long chain fa t ty  acids found in high fa t diets th a t induce peroxisomal 
p ro life ra tion  in h ib it the oxidation of oleate and are themselves poorly oxidized in 
the m itochondria (Bremer and Norum, 1982; Christiansen et al., 1977; Osmundsen 
and Bjornstad, 1983). A m etabolite of DEHP, namely m etabolite  VI, has been shown 
to  in h ib it j^ c jp a lm ita te  oxidation in isolated ra t hepatocytes (Elcombe and 
M itche ll, 1986). This m etabolite, m ono(2-ethyl-5-oxohexyl)phthalate, along w ith  
another m etabolite (M etabolite IX , m ono(2-ethyl-3-hydroxyhexyl)phthaltate have 
been shown to  be the proxim ate peroxisome pro life ra tors  derived from  MEHP 
(M itche ll e t  al., 1985a). The proxim ate p ro life ra to r derived from  DEHA appears to  
be 2-ethylhexanoic acid (K e ith  et al., 1988). M etabo lite  VI se lective ly inh ib ited the 
oxidation of oc tanoy l-L -ca rn itine  but not pa lm itoy l-L -ca rn itine  (Elcombe and 
M itche ll, 1986). S im ila rly , bezafibrate has been shown to in h ib it the oxidation of 
pa lm itoyl-C oA , but not pa lm itoy lcarn itine , in isolated m itochondria (Eacho and 
Foxworthy, 1988). This suggests that the s ite  of inh ib ition  is the fo rm ation  of the 
carn itine derivative. Both bezafibrate and bezafibroyl-CoA in h ib it overt carn itine  
palm itoyltransferase (CPT-I) in  ra t liv e r m itochondria w ith  comparable potency but 
w ith  d is tinct kinetics. The activa tion  of bezafibrate to bezafibroyl-CoA is not 
essential fo r the inh ib ition . The leukotriene antagonist, and peroxisome 
p ro life ra to r, 2-hydroxy-3-propyl-4- [ 6 -(te trazo l-5 -y l)hexy loxy ] acetophenone (4- 
THA) has been shown to in h ib it m itochondrial B-oxidation at the s ite  of carn itine  
palm itoyltransferase I (Foxworthy and Eacho, 1988). POCA and valproic acid, both 
of which are inh ib itors of m itochondrial B-oxidation, have been shown to  include 
peroxisome p ro life ra tion  in the ra t  and mouse (Bone et al., 1982; Draye and Vamecq,
1987; Horie and Suga, 1985). The POCA-CoA ester strongly inh ib its  CPT-I. 
Chlorpromazine also inhib its CPT-I and induces peroxisome p ro life ra tion  (Vamecq et 
al., 1987) but also inh ib its carn itine octanoyltransferase (COT) (Vamecq, 1987).
C arn itine pal m itoyl transfer as e-I, an enzyme bound to  the outer aspect of the 
inner m itochondria l membrane, is the key regulatory enzyme in the hepatic 
m itochondrial B-oxidation of long-chain fa t ty  acids. I t  functions to  transfer the 
acyl group from  acyl-CoA to acylcarn itine  and is inh ib ited by m alonyl-CoA 
(McGarry and Foster, 1980). The role of CPT-I is shown in  F ig. 8.3. The molecular 
weights o f CPT-I and COT are 69,200 and 66,000 D respectively (Miyazawa et al.,
1983). COT possesses a d iffe ren t substrate s p e c ific ity  to  CPT and is found m ain ly in  
the peroxisomes.
In teresting ly i t  can be demonstrated in  v itro  that the induction of peroxisomal 
B-oxidation by bezafibrate or c ip ro fib ra te  can be pa rtia lly  reduced by the co- 
adm in istra tion of an inh ib ito r of CPT-I such as POCA, e to m ix ir or 2-brom opalm itate 
(Gerondaes et al., 1988; H ertz and Bar-Tana, 1987; Hertz et al., 1988). However, in 
vivo, the inh ib itors of CPT-I could only reduce the potency of bezafibra te  in  starved 
rats but not in fed rats (H ertz and Bar-Tana, 1987). This is surprising in lig h t of the 
reports that starvation in fa c t potentiates the e ffe c t of peroxisome pro life ra to rs  
(H ertz  and Bar-Tana, 1987). O vera ll, i t  can be seen tha t there is an apparent 
requirement fo r CPT-I in the induction of peroxisome pro life ra tion  by bezafibra te  or 
MEDICA 16. Whether the acylcarn itine deriva tive  of these compounds is involved in 
the induction mechanism is unknown as the conversion of fibrates to  th e ir carn itine 
derivatives has not been demonstrated (H ertz  and Bar-Tana, 1987). The apparent 
involvement of CPT-I could im p lica te  the sequestration of m itochondrial CoA or a 
novel function of the transferase protein.
There does not appear to be a sim ple, ra tiona l explanation fo r  the observation 
th a t POCA only inh ib its  the induction of peroxisome p ro life ra tion  by bezafibra te  in 
the starved animal. This may im ply tha t although bezafibrate can indeed in h ib it 
CPT-I, i t  may require transport in to  the m itochondrial m a trix  fo r  is fu ll
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p ro life ra tive  e ffe c t. I t  may also be re levant th a t POCA is used as a hypoglycaemic 
agent and is only e ffe c tive  in  th is action in starved animals. Perhaps POCA is more 
e ffe c tive  at inh ib iting  CPT-I in starved, ra th e r than fed rats. I t  is clear th a t there 
is a complex in te rac tion  between POCA, bezafibra te , CPT-I and the nu tritiona l 
status o f the animal. Further analysis of these in te ractions may shed lig h t on the 
processes leading to  the induction of peroxisome p ro life ra tion . I t  should be noted 
th a t CPT-I inh ib ito rs, such as POCA, are weak peroxisome p ro life ra to rs  th a t require 
long term  adm in istration at high dose levels to  induce peroxisome p ro life ra tion . 
There are no reports o f CPT-I inh ib itors being peroxisome p ro life ra to rs  in  v itro . I t  
is not clear why POCA inhibits the in  v itro  induction of peroxisome p ro life ra tion  by 
bezafibrate. This may im ply th a t the hepatocyte cu lture  system is more akin to  the 
starved than the fed ra t. I t  may also be re la ted to  the level of insulin in  the culture 
medium. Although insulin is not required fo r  the induction of peroxisome 
p ro life ra tion  i t  is required fo r the maintenance of the v ia b ility  of the hepatocyte 
(M itche ll £ t  al., 1984).
I t  is ironic tha t the adm in istration of peroxisome pro life ra tors  tha t can in h ib it 
CPT-I, actua lly  induce th is  enzyme. This may be an adaptive response in order to  
overcome the inh ib ited CPT-I. This phenomenon of enzyme inh ib itors also acting as 
enzyme inducers has previously been observed (Rodrigues, 1988; Kaul and Novak,
1987).
8 .3 .2 .2  Inh ib ition of other enzymes by xenobiotic peroxisome p ro life ra to rs
Peroxisomal and m itochondrial 2,4-dienoyl-CoA reductases have been reported 
to be inhib ited by c lo fib roy l-C oA  (Yamazaki and Poosch, 1988). I t  has also been 
indicated th a t acyl-CoA oxidase is inh ib ited by c lo fib roy l-C oA  (Bronfman et aL,
1986). Perfluoro-n-decanoic acid has been shown to  be an in h ib ito r of fa tty  acid 
oxidation, in v itro , and in th is  respect i t  is more potent than its  unfluorinated parent 
compound, decanoic acid (Harrison et al., 1988).
The relevance o f the inh ib ition  o f m itochondria l, and possibly peroxisomal 
n is unknown. The induction of peroxisomal 8 -oxida tion may be an
adaptive response to the inhibjtion of m itochondrial B-oxidation, producing a 
pathway th a t may be able to bypass sites o f inh ib ition .
Peroxisome pro life ra tors have been shown to  in te rac t w ith  other cellu lar 
proteins. C lo fib ra te  and c ip ro fib ra te  have been shown to  irrevers ib ly  in h ib it hepatic 
gl ut at hi one-S-transferase through binding to  the enzyme (Fo lio t et al., 1984; 
Awasthi et al., 1984). S im ilarly 2,4-D has been shown to  in h ib it glutathione-S- 
transferase form s C and A (Vessey and Boyer, 1984). This may contribu te  to a 
change in the lip id  p ro file  of the hepatocyte as glutathione-S-transferase has been 
shown to also possess glutathione peroxidase a c tiv ity , thereby pro tecting the cell 
against lip id  peroxides (Prohaska and Ganther, 1977; Mannervik and Jensson, 1982). 
From the work o f H e rtz  and Bar-Tana (1988) i t  was observed tha t several proteins 
were acylated by xenobiotic peroxisome pro life ra to rs . Their id e n tity  and whether 
the ir ac tiv ities  are altered remains to be ascertained. One of these proteins was a 
13 k Da cytosolic protein which could possibly be FABP which acts as the ce llu la r 
analogue to serum albumin in binding fa t ty  acids and th e ir acyl-CoA derivatives 
(Spener et al_., 1989). C lo fib ra te  has been shown to bind to serum albumin and, by 
analogy, may be expected to  bind to  FABP (Meisner and Neat, 1978).
Many xenobiotics tha t possess a carboxylic acid group form  acyl-CoA esters in 
vivo (Berge et al.? 1987b; Aarsland et al., 1988). Such CoA esters are biochem ically 
active interm ediates and can spec ifica lly  in h ib it enzymes or carriers. Some 
compounds, such as 2-brom opalm itate and POCA, need to  be activa ted to  th e ir  CoA 
esters before they can in h ib it enzymes such as CPT-I (Sherratt, 1983; Huang et al., 
1989). Whether peroxisome pro life ra tors require such activa tion  fo r  the induction of 
peroxisome p ro life ra tion  is uncertain. I t  has been reported th a t the a b ility  o f 
c lo fib ric  acid, nafenopin and c ip ro fib ra te  to be activated to  the ir CoA esters 
correlates w ith  the ir pharmacological potency (Bronfman et al., 1986). However to 
date there have been no reports of the non-carboxylic acid containing peroxisome 
pro life ra tors, LY  171883 and perfluorooctanesulphQuic acid, being ac tiva ted  to  th e ir 
CoA esters (Foxworthy and Eacho, 1988; Ikeda et al., 1987). The im portance of
xenobiotic-CoA esters in the mechanism of induction may be investigated using p- 
chloro- and p-n itro  ben zoic acids which in h ib it the fo rm ation  o f these esters 
(Swartzentruber and H arris, 1987).
I t  has been shown throughout th is chapter that the xenobiotic peroxisome 
p ro life ra to rs  in te rac t w ith  several of the enzymes of hepatic fa t ty  acid metabolism 
and th is  w ill undoubtedly m anifest its e lf  in a perturbation.of the normal lip id  p ro file  
of the hepatocyte.
L ip id  deposition, a fte r  the adm in istra tion of peroxisome p ro life ra to rs , is a well
(JU
documented phenomenon (P rice e t al., 1982). The lip id  accunr^ation is usually 
transient in  nature, reaching a peak a fte r  about 24 hours and subsequently re tu rn ing  
to normal, possibly as a result of the peroxisome pro life ra tion . Several xenobiotic 
peroxisome pro life ra tors have been shown to  cause lip id  accumulation, as shown in 
Table 8.2.
8.3.2.3 Hepatic and lip id  accumulation in  response to  peroxisome p ro life ra to rs
Whether lip id  accumulation is inev itab ly  fo llowed by peroxisome p ro life ra tion  
is uncertain. Chlorpromazine has been shown to  cause lip id  accum ulation but not 
peroxisome p ro life ra tion  in rats (Price e ta l. ,  1983). However, recen tly  i t  has been 
shown that mice fed a d iet containing 0. 1 % (w/w) chlorpromazine fo r 4 days did not 
show peroxisome p ro life ra tion  but did when fed 0.5% (w/w) chlorpromazine fo r 7 
days (Vamecq et al., 1987). L ip id  accumulation, but not an induction of peroxisomal
3 -oxida tion, has been shown to  occur in ra ts fed a choline de fic ien t d ie t and 
m ethotrexate (Berge et al., 1988c). Rats fed on a choline de fic ien t diet alone 
showed both lip id  accumulation and an induction of peroxisomal 3-oxidation. This 
may im p ly  that the stimulus fo r induction of peroxisome p ro life ra tio n  is not a 
quantita tive  lip id  accumulation but a qua lita tive  accumulation of pa rticu la r lip id  
species. Peroxisome p ro life ra tion , and induction of the enzymes of the peroxisome 
p ro life ra to r domain, may represent induction of an a lte rna tive  route o f lip id  
metabolism which becomes necessary when the normal pathway is e ither perturbed 
or inadequate.
Table 8.2.'
Xenobiotic peroxisome proliferators that have been shown 
to cause lipid deposition
Compound
DEHP
5-keto-MEHP
POCA
Valproic acid
Oleate
Fenofibrate
PFDA
C itra l
T rich loroediy lene
4-THA
Chlorpromazine 
C lo fib ra te  
High fa t diet
Reference
M itche ll e t al., 1985c 
Koundakjian et al., 1984 
Olson et al., 1986 
Mann eta l., 1985 
Elcombe and M itche ll, 1986 
Vamecq et al., .1987 
Vamecq et al., 1987 
Vamecq et al., 1987 
Price e t al., 1986 
Harrison et a l„  1988 
Jackson et al., 1987 
Elcombe et al., 1985 
Foxworthy and Eacho, 1988 
Price et al., 1985 
Vamecq et al., 1987 
Barnard et al., 1980 
Price e t al., 1982 
Neat e t al., 1981
In te resting ly, lip id  deposition has been shown to occur in guinea pig and 
monkey hepatocyte cultures w ithout induction of peroxisome p ro life ra tion  
(Lhughenot, 1988). This may re fle c t a species d ifference in the nature of the lipids 
deposited or a d iffe rence in the response of the hepatocytes to  the  lip id  insu lt.
The nature of the lip id  deposit is presently unknown although i t  could 
conceivably consist o f free  fa tty  acids and th e ir  CoA and carn itine esters. F ib ra te  
drugs, diabetes and high fa t diets have been shown to increase the hepatic levels of 
CoA, short and long-chain acyl-CoAs (Nilsson et al., 1984; Bhuiyan e t al., 1988) and 
carn itine, and short and long chain acyl carnitines in the rat (Bhuiyan et al., 1988). 
The ra tio  of carn itine  to  CoA is also s ign ifican tly  increased. I t  is possible th a t the 
change in  the co fac to r p ro file  alters the transcrip tion of the genes of the 
peroxisome p ro life ra to r domain (Nilsson, e t al., 1984; Berge and Aarsland, 1985; 
Fukami et al., 1986).
8.3.2.4 In te raction of peroxisome pro life ra tors  w ith  second messenger systems
I t  is possible th a t the xenobiotics, e ithe r d irec tly  or in d irec tly , in te rfe re  w ith  
the ce llu lar second messenger systems such as phosphatidyl inosito l and 
di acyl glycerol. This may be as a resu lt o f the general perturbation o f lip id  
homeostasis. These lip id  molecules are known to  have a role in  ce ll grow th contro l 
and may therefo re  represent a potentia l link  between the e ffec ts  of the peroxisome 
pro life ra tors on peroxisomal 8 -oxidation and th e ir carcinogenic a c tiv ity . Protein 
kinase c has been shown to be inh ib ited by DEHP (Shukla et ah, 1989), long-chain 
acyl-CoAs (Stasia et al., 1987) and activa ted by unsaturated fa t ty  acids such as 
oleic, lino le ic  and arachidonic acids (McPhail e t ah, 1984; Leach and Blumberg, 
1985). Recently i t  has been reported tha t long-chain acyl-CoAs and hypolip idaem ic- 
CoA esters activa te  protein kinase C (Bronfman et al., 1989). C lo fib ra te  has been 
shown to inh ib it ra t hepatic phosphodiesterase a c tiv ity  (Lehotay et al., 1987), 
although no changes in cAMP or the cytoplasm ic cAMP-dependent prote in kinases, 
types I and II, were seen (Fukami et al., 1986). These observations, coupled w ith  the 
observation th a t the tum or prom otor TPA is a peroxisome p ro life ra to r in ce ll
culture (Lillehaug and Berge, 1986), may ind ica te  a possible role of protein 
phosphorylation in  the induction mechanism or carcinogenic ity.
Free fa tty  acids, and th e ir  CoA and carn itine  derivatives, have been shown to  
a ffe c t the ce llu lar Ca^+ homeostasis (Devilliers and Lochner, 1986; Baydoun et al., 
1988; H a lle-Sm ith e t al., 1988). SaliGylate and plasma from  Reye's syndrome 
patients (which is high in  long-chain d icarboxylic fa t ty  acids) have been shown to  
e ffe c t C a^+ re lease-from  ra t liv e r m itochondria (Martens e t al., 1986). The
2 j
potentia l ro le of Ca in the mechanism of induction of peroxisome p ro life ra tion  is 
highlighted by the obserw ation th a t nicardipine, a calcium antagonist, supresses the 
induction of peroxisomal 6 -oxidation, ca rn itine  acetyl transferase and carn itine 
palm itoyltransferase by 60% (Watanabe and Suga, 1988). However, hepatomegaly 
was potentia ted. Ca^+ has been shown to  act as a ce llu lar messenger and involved 
in many functions including cell p ro life ra tion  and cell growth (Pounds and Rosen, 
1988).
8.3.3 The lipid overload theory
Thus, xenobiotics can severely disturb hepatic lip id  homeostasis by in te rac ting  
w ith  the enzymes of fa tty  acid metabolism, causing a lip id  overload. How th is  lip id  
overload causes the observed increased rates of gene transcrip tion is unknown, 
although i t  is possible tha t ce llu la r second messenger systems are involved. This 
lip id  overload hypothesis can provide an unifying hypothesis fo r the induction of 
peroxisome p ro life ra tion  by the s truc tu ra lly  diverse xenobiotics, high fa t  diets, 
natura lly  occurring fa t ty  acids or analogues, such as phytol and c itra l,  diabetes, 
starvation and cold adaptation (the la tte r  being a condition which show increased 
lipolysis and consequently increased flu x  o f heaptic fa t ty  acids).
The vastly d iffe ren t potencies of the peroxisome p ro life ra to rs  may be as a 
results of the extent, or composition, o f lip id  deposition which in  turn  may re fle c t 
the in te rac tion  of these compounds w ith  ce llu lar proteins, possibly includ ing CPT-I, 
or th e ir activa tion  to  CoA esters. I t  has been reported tha t the continual presence 
of the inducer is required fo r the maintenance o f induction, the potency w ill also be
hydroxylase, in ra t hepatocyte cultures (Elcombe, personal communication). 
Hexadecanedioic and dodecanoic fa t ty  acids, when fed in the diet have been shown 
to  induce peroxisomal B-oxidation in ra t  live r (Nilsson et al-, 1987). I t  has also been 
proposed that the proxim ate peroxisome p ro life ra to r of a tiadenol is the tiadenol 
d icarboxylic acid (Berge et ah, 1988a; Facino e ta l., 1988). Whether th is  compound, 
and other xenobiotic dicarboxylates (see F ig. 7.2) act d irec tly  w ith  the trans acting 
facto rs  of the genes fo r peroxisomal B-oxidation is uncertain. The data presented in 
chapter 7 is not inconsistent w ith  the scheme of Sharma et al., (1988a) and also 
shows th a t there is no protein dependency fo r  the  induction o f P-450 IVA1 mRNA. 
The dissection of th is proposed mechanism of induction by the protocols proposed in 
chapter 7 w ill shed lig h t on the va lid ity  of th is  scheme. I t  may be possible th a t the 
signal fo r the induction of peroxisomal B-oxidation may be generated, a lb e it at low  
levels, by constitu tive  P-450 IV A l. This may mean th a t the induction o f P-450 IV A l 
and peroxisomal B-oxidation, although d is tinc t events, may be closely re la ted 
tem porally. In chapter 5 and 6 the data suggests th a t P-450 IV A l is induced before 
peroxisomal B-oxidation although the events do appear to  be closely re la ted 
tem porally. This has been confirm ed in ra t hepatocyte cell cu lture  systems (B ie ri, 
personal communication). A m odifica tion of th is scheme is shown in  F ig . 8.4.
Species, sex and tissue differences in the response to peroxisome p ro life ra to rs  
may be related to  the manner in which the ce ll handles the lip id  deposit, or by 
differences in the composition of th is deposit.
The exact mechanism of induction s t il l is fa r from  certa in . A fu rthe r 
com plication to the understanding o f the mechanism of induction of peroxisome 
p ro life ra tion  is the observation that hormonal status can modulate ce rta in  aspects 
of the induction both in vivo and in  v itro  (M itche ll, et al., 1984; Kawashima et al., 
1983c; H artl and Just, 1987; Eliassen and Osmundsen, 1984). This serves to 
emphasize the complicated nature o f the mechanism o f induction. The 
characterization of the genetic elements around c lo fib ra te -inducib le  genes would 
aid the id en tifica tio n  of protein binding components associated w ith  the mechanism
a product of the pharmacokinetics of the individual inducer. I t  may be possible fo r 
the xenobiotic to become incorporated in to  lip ids and slowly released over several 
days (Caldwell and Marsh, 1984; Fears, 1985). This may explain the extrem ely 
potent e ffec ts  o f PFDA which, fo llow ing a single dose of 50 m g/kg, causes a 20-40 
fo ld  increase in  peroxisomal B-oxidation that persists fo r approxim ate ly 50 days 
(Harrison et al., 1988). The re la tive ly  low  induction of peroxisomal a c tiv itie s  in 
fasted diabetic or fast-fed  rats, as compared to that exerted by xenobiotic 
peroxisome p ro life ra to rs  may be accounted fo r by the rapid m etabolic e lim ina tion of 
the natural long chain fa t ty  acids, as compared to the sustained prevelance of 
xenobiotic peroxisome pro life ra to rs .
The weak xenobiotic peroxisome pro life ra tors  may in te ra c t poorly w ith  
ce llu lar proteins, or may be activa ted slowly to  th e ir  CoA esters or may produce a 
d iffe ren t degree, o r composition, o f lip id  deposition. For example, the 
hypolipidaem ic drugs n ico tin ic  acid and cholestyramine have been shown to 
m arginally increase peroxisomal B-oxidation (Bakke and Berge, 1984). Whereas fo r 
n ico tin ic  acid the mechanism o f induction may be identica l to  the other xenobiotic 
peroxisome pro life ra to rs , fo r  cholestyramine th is cannot be true . Cholestyram ine is 
an anionic resin which is not absorbed from  the gut and there fo re  any induction of 
peroxisomal B-oxidation must be as a result of the remodelling o f the hepatic lip id  
p ro file  caused by this compound.
This lip id  overload mechanism has recently  been proposed by Sharma et al., 
(1988a). They produced a scheme (see F ig. 1.7) in which the  stim ulus fo r the 
induction of peroxisomal B-oxidation is long-chain d icarboxylic fa t ty  acids, which 
have been form ed by the CJ -hydroxyla tion o f the corresponding m onocarboxylic 
fa tty  acids by cytochrome P-450 IV A l. The induction of cytochrome P-450 IV A l is 
proposed to  occur before the induction of peroxisomal B-oxidation. The stim ulus fo r  
the induction of P-450 IV A l may be medium-chain m onocarboxylic fa t ty  acids or the 
xenobiotic itse lf. This scheme, in part, is based on the observation th a t C16 
d icarboxylic fa t ty  acid induces peroxisomal B-oxidation, but not la u ric  acid CJ -
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of action of this drug (Miskimins et al, 1985; White et al., 1985). I t  is plausible that 
some of the genes o f the peroxisome p ro life ra to r domain may possess s lightly  
d iffe ren t regulatory mechanisms and more than one point of regulation. I t  cannot 
be excluded th a t the xenobiotic peroxisome pro life ra to rs  do not in te rac t w ith  the 
trans acting factors associated w ith  the genes of the peroxisome p ro life ra to r 
domain. This may indeed be the case w ith the perfluorinated fa tty  acids i f  fa tty  
acids or th e ir  derivatives are u ltim a te  peroxisome pro life ra to rs . Several of the rat 
responses to  the adm in istration of xenobiotic peroxisome pro life ra to rs , e.g. 
hepatomegaly, he pat ocarci nogenesis and the induction of the enzymes of the 
peroxisome p ro life ra to r domain, appear to be linked yet have been shown to respond 
d iffe re n tly  to  certa in  inducers or hormonal states. Therefore, i t  can be seen that 
the hepatic response to peroxisome p ro life ra to rs  is a complex process th a t requires 
a great deal of fu rthe r research fo r its  e lucidation.
8.4 RELATIONSHIP BETWEEN P-450 IV A l AND P-450 0p-2
Western b lot analysis o f live r microsomes, from  both control and c lo fib ra te  
treated rats, has shown that the antibody raised to e lectrophore tica lly  pure 
cytochrome P-450 IV A l cross reacts w ith two proteins (F ig. 5.11). These two 
proteins have very s im ila r molecular weights, 51,500 (cytochrom e P-450 IV A l) and 
52,000 daltons (Hardwick e t al., 1987). The id e n tity  o f th is second prote in is 
presently unknown. I t  may be a novel prote in or cytochrome P-450 IV A l th a t has 
been post-translationa lly m odified by, fo r  example, sugar or fa t ty  acid conjugation.
Two d iffe ren t types of cytochrome P-450 w ith  reg iose lec tiv ity  fo r  th e 6J -  
hydroxylation of prostaglandins have been isolated from  rabb it tissues. The f ir s t  
type (designated PG CJ -hydroxylase I) includes cytochrome P-450s purified  from  
kidney cortex (Ogita et ah, 1983), small in testine (Kusunose et al., 1984; Kaku e t al., 
1984), and colon (Kaku, 1984). The molecular weight of these proteins are 
approxim ately 53 k Da. These isozymes p re fe ren tia lly  hydroxylate PGA^ and PG A 2 , 
w ith  a turnover ra te  of about 30 nm ol/m in/nm ol P-450. The a c tiv ity  towards PGEj,
is less than 1/20 o f th a t toward PGA^. They also hydroxylate various saturated 
fa tty  acids at the CJ and (cJ -l) positions, w ith  laura te  and m yris ta te  being the most 
e ffic ie n t substrates. The a ff in ity  fo r fa t ty  acids is higher than th a t fo r 
prostaglandins.
The second type (designated as P G w  -hydroxylase II) includes the cytochrome 
P-450 isolated from  the lung of progesterone-treated rabbits (Yamamoto e t al.,
1984). This isozyme hydoxylates a va rie ty  o f prostaglandins (PGEp PGE2,
PGD2, PGAj and PGA2) w ith  a turnover ra te  of 20-50 nm ol/m in/nm ol P-450 
(Kusunose et al., 1985). I t  is capable of hydroxylating fa t ty  acids at the tJ  and (cJ- 
1) positions w ith  the turnover ra te  fo r pa lm ita te  being 40-fo ld higher than th a t fo r 
laurate. This group o f isozymes also includes those isolated from  rabb it placenta 
(Yamamoto et ah, 1986b) and pregnant rabb it lung (W illiam s et al., 1984).
Prostaglandin A^ and lau ric  acid CJ-hydroxylase ac tiv ities  have been shown to 
be induced in rabb it liv e r  and kidney by c lo fib ra te  and DEHP (Yamamoto e t al., 
1986a). DEHP does not induce PGE^ CJ-hydroxylase a c tiv ity  in  the rabb it lung 
(Matsubara et al., 1987). The dram atic induction o f PG CJ-hydroxylase a c t iv ity  seen 
in the pregnant rabb it lung (W illiam s.et al., 1984) is not seen in  the lungs o f pregnant 
hamsters or rats (Powell, 1978). This may point to basic differences in the 
regulation of this isozyme in  these species.
Recently rabb it pulmonary prostaglandin CJ -hydroxylase (P-450^ 2 or P-450 
IVA4) has been shown to share 74% deduced amino acid sequence homology w ith  ra t 
P-450 IV A l, whereas i t  showed less than 25% homology w ith  other P-450 isozymes 
(Matsubara e t ah, 1987). Once species differences have been taken in to  account, 
the two isozymes are considered to be even more closely re la ted  but are not 
identica l. The iso lation, and sequencing, of a cDNA closely re la ted  to  P-450 IV A l 
has been reported (Gonzalez, 1989). The cDNA shares 75% nucleotide sequence 
homology w ith P-450 IV A l. The CYP4 gene has been assigned to chromosome 1 in 
humans (Nebert et al., 1989).
I t  therefore seems plausible tha t the upper band seen in Western b lo t analysis
is P-450 «, i.e. a class II prostaglandin CO -hydroxylase. P-450 IVA1 may belong to p-z
the type I PG CJ -hydroxylases. P u rifica tion , sequencing, and the determ ination of 
the substrate specific ities  o f this upper band w ill help validate this hypothesis. The 
substrate spec ific ty  of P-450IV A l  also needs to  be evaluated. The role o f this 
second prote in in hepatic fa tty  acid metabolism needs to be determined.
I t  may be possible to resolve whether the upper band is indeed P-450p ^ by 
subjecting lung microsomes derived from  contro l and pregnant rabbits to Western 
b lo t analysis. As P-450^ ^ ls induced in pregnant rabb it lung the upper band should 
be induced i f  indeed this is its  iden tity .
I t  has been proposed tha t ra t liv e r contains 2 or 3 cytochrome P-450 dependent 
lauric  acidw-hydroxylases (O rtiz  de Montellano and Reich, 1984; Hardw ick et al.,
1987). Recently, the naming of the genes fo r the cytochromes P-450 has resulted in 
the division o f the cytochrome P-450 IV fa m ily  o f proteins in to  two subfam ilies, 
namely P-450 IVA and P-450 IVB. (Nebert et al., 1989). Subfam ily IVA proteins, 
coded fo r by CYP4A genes, may number between 2 and 7, w hilst subfam ily IVB 
consists o f 2 or 3 isozymes.
8.5 CHANGES IN FATTY AC ID  OXIDATION IN RESPONSE TO
DIABETES AND STARVATION
Chem ically induced diabetes has been shown to  increase the ra te  o f ra t 
hepatic peroxisomal 8 -oxidation (Horie et al., 1984) and lauric acid CJ-hydroxylase 
(Sharma, 1988) and induce both lauric  acid CJ-hydroxylase and P-450j in ra t kidney 
(Imaoka et al., 1988). Increases in the level of specific isozymes o f cytochrom e P- 
450, namely P-450j and P-450 IV A 1 have been observed (Dong et a l., 1988; Sharma,
1988). Fasting has been shown to increase peroxisomal 8 -oxidation (H ertz  and Bar- 
Tana, 1987), lauric  acid CJ-hydroxylase (Hasumura et al., 1983), cytochrom e P-450 
IVA1 (Hardwick e t al., 1987) and cytochrom e P-450j (Hong et al., 1987). 
Cytochrome P-450j is also induced by acetone, alcohol and pyrazole (Tu e t a l., 1981,
1983; Peng et al., 1982; Tu and Yang, 1983) and appears to be regulated at several 
levels, most im portan tly  by post transcrip tiona l mechanisms. There is evidence of 
transcrip tiona l activa tion  (Johansson et al., 1988), p ro te in  s tab iliza tion  (Dong et ah,
1988), but the m ajor mechanism appears to be mRNA stab iliza tion  (Song et al.,
1987). I t  has been proposed that P-45CL may be responsible fo r  cata lyzing the
oxidation of acetone to acetal (Koop and Casazza, 1985) which can subsequently be 
converted to glucose (Casazza et .al., 1984). This pathway may be an im portant 
source of glucose during starvation (Landau and Brunengraber, 1987; A rgiles, 1986). 
I t  has been suggested that as P-450. is induced by s tarva tion and diabetes, both of 
which are ke to tic  conditions. Acetone, ketone bodies or glucose starvation may be 
im portant to the mechanism of induction (M ille r and Yang, 1984; B arne tt et al.,
1988).
During fasting and diabetes a drastic increase occurs in the plasma 
concentration o f monocarboxylic fa tty  acids which is due to an increased lipo lysis in 
adipose tissue (Newsholme and Leech, 1983). Increased urinary excretion of medium 
and long-chain d icarboxylic fa tty  acids is also observed (Cerdan et al., 1988; 
Mortensen, 1980,1981). The hepatic output of ketone bodies depends not only on the 
ra te  o f fa tty  acid input but also on the capacity of the liv e r  to generate acety l-C oA  
and to dispose of this compound through non-ketogenic pathways (McGarry and
Foster, 1980). Increased plasma ketone levels are observed in both fasted and
diabetic rats but not c lo fib ra te  treated rats (Mannaerts et al., 1978; Peng et al., 
1983). However, the endogenous ra te  of ketone body fo rm ation  was increased in 
hepatocytes isolated form  c lo fib ra te  treated rats (Mannaerts et al., 1978; Bergseth 
et al., 1986). I t  has been suggested th a t the CJ -oxida tion o f fa tty  acids has an 
antiketogenic and gluconeogenic e ffects  by producing succinyl-CoA (Wada et al., 
1971; Wada and Usami, 1977; Mortensen, 1980). The 6 J-oxidation o f fa tty  acids has 
been shown to make a sm all contribu tion to the fo rm ation  of the acety l-C oA  pool 
from  which acetoacetate is derived (Schumann et al., 1978; Bjorkhem, 1978; Kam  et
Considering the observation that both P-450. and P-450 IV A l are induced in 
fasted and diabetic rats, and the nature o f the enzyme a c tiv itie s  involved, i t  is 
possible to propose a mechanism to explain these observations.
An increase in hepatic fa tty  acids, as a results of increased lipo lysis in
starvation and diabetes, and perturbation of lip id  homeostasis fo r xenobiotics,
results in an induction of cytochrome P-450 IV A l.  The monocarboxylic fa t ty  acids
are then metabolised by cytochrome P-450 IV A l to  CJ-OH monocarboxylic fa t ty
acids which are subsequently m etabolized to  d icarboxylic fa tty  acids. These
compounds are the stimulus fo r the induction of peroxisomal 8 -oxida tion. The
dicarboxylic fa tty  acids are metabolized by the peroxisomes to non-ketogenic
m etabolites. However the increased flu x  o f monocarboxylic fa t ty  acids through the
peroxisomal and, subsequently, the m itochondria l 8 -oxidation pathway results in an
increased ra te  of form ation of ketone bodies. The accumulation of ketone bodies
then cause an increase in the level o f P-450.. This scheme is shown in Fiq. 8.5.
J y
Analysis of the tim e course of induction of P-450 IV A l and P-450^. in response
to  starvation and in the diabetic ra t w ill help ascertain whether th is proposal is
feasible. I t  w ill also be in fo rm ative  to determ ine whether P-450. is induced by the
J 7
xenobiotic peroxisome pro life ra tors .
In summary, i t  appears that cytochrome P-450 IV A l may play a p ivota l role in 
hepatic fa tty  acid oxidation.
Figure 8.5.
Postulated relationship o f the induction o f cytochromes
P-450 IV A l, P-450j and peroxisomal 8-oxidation
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8.6 FUTURE EXPERIMENTS
The mechanism o f induction of peroxisome p ro life ra tion , and the 
proteins of the peroxisome p ro life ra to r domain, is far from  clear. Further 
investigation of the postulated mechanism o f induction, shown in  Chapter 8, is 
required. This may be achieved by using some of the specific  inducers and 
inh ib itors suggested in Chapter 7. U ltim a te ly , however, the determ ination o f 
the regulatory elements of the genes of the peroxisomes p ro life ra to r domain 
w ill be in tegra l to the understanding of the induction process.
The observation that the adm in istra tion of c lo fib ra te  p rio r to that of 
cyclohexim ide is tox ic  to ra ts  needs to be fu rth e r investigated to determ ine 
whether this is a species-specific phenomenon and re lated to  the mechanism of 
induction.
The investigation of the in te raction  of the xenobiotic peroxisome 
pro life ra tors  w ith  the enzymes of hepatic fa tty  acid oxidation may provide an 
insight in to  the generation of the lip id  deposit which is a characte ris tic  of the 
hepatic response to peroxisome pro life ra tors . The analysis of th is  lip id  deposit 
may provide an insight in to the id e n tity  of the u ltim a te  peroxisome 
p ro life ra to r.
The id e n tity  o f the second cross reacting band seen in  Western b lot 
analysis needs to be determ ined, as does its  re lationship to  cytochrom e P-450 
IVA1 and the mechanism of induction of peroxisome p ro life ra tion . This may 
be achieved by protein pu rifica tion  and determ ination o f its  substrate 
spec ific ity .
U ltim a te ly , the aim of fu tu re  studies must be to understand the 
mechanism o f induction of peroxisome p ro life ra tion  and to ascertain how th is  
relates to the well defined species differences in response to the xenobiotic 
peroxisome p ro life ra to rs  and the observed rodent hepatocarcinogenesis.
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